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Summary 
The low density lipoprotein (LDL) receptor is a transmembrane glycoprotein that 
mediates the uptake of plasma LDL and thereby provides cholesterol to cells. During 
its synthesis in the endoplasmic reticulum, the LDL receptor folds and forms disulfide 
bonds in multiple cysteine-rich repeats. N- and 0-linked oligosaccharide chains are 
added in the endoplasmic reticulum and processed during passage through the Golgi 
apparatus, en route to the cell surface. The aim of this thesis was to study the 
influence of post-translational events on the synthesis of the LDL receptor. 
Experiments addressed: 1) the necessity of the compartmental organisation of the 
secretory pathway for the glycosylation of the LDL receptor; 2) the requirements for the 
formation of disulfide bonds; 3) the role for the chaperone, calnexin, in the folding of 
the LDL receptor; and 4) the manner in which folding was disrupted by mutations. 
Experiments were performed in cultured cells that were incubated with [35S)methionine. 
Biosynthetically-labelled LDL receptor was immunoprecipitated and was analysed by 
SOS polyacrylamide gel electrophoresis. 
Treatment with brefeldin A fused the compartments necessary for glycosylation, the 
endoplasmic reticulum and the Golgi apparatus, and trapped the LDL receptor in the 
secretory pathway. The glycosylation of the LDL receptor was retarded and a series of 
partially-processed glycosylation intermediates were synthesised. Processing 
continued over 4 hours, but fewer than normal 0-linked oligosaccharide chains were 
added to the LDL receptor. The normal secretory pathway was restored when brefeldin 
A was removed. The abnormal LDL receptors were transported efficiently to the cell 
surface, but their glycosylation remained irreversibly altered. These findings 
demonstrate that normal glycosylation requires the secretory pathway to be organised 
into separate membrane compartments. 
The disulfide bonds of the LDL receptor were assessed with a conformation-specific 
antibody and by electrophoresis under non-reduced conditions. In intact cells, the 
disulfide bonds of the mature, endocytic form of the LDL receptor were resistant to 
dithiothreitol-induced reduction, except in the presence of denaturants, as were the 
solubilised forms of the LDL receptor. In contrast, while in the endoplasmic reticulum, 
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the disulfide bonds of the LDL receptor precursor were reduced by dithiothreitol, 
indicating that they were accessible and were prevented from being buried in the folded 
protein core, despite the precursor having a compact, disulfide-bonded structure that 
resisted reduction in vitro. When dithiothreitol was removed from intact cells, disulfide 
bonds reformed rapidly in the endoplasmic reticulum and the refolded receptors were 
transported to the cell surface. A number of novel findings emerged from these 
studies. Disulfide bonds were essential for the folding of the LDL receptor. Disulfide 
bonds did not have to form co-translationally - normal folding occurred when they 
formed post-translationally. Folding required metabolic energy which implicated a 
requirement for associated chaperone protein(s). Ca
2
+ was required for LDL receptor 
folding in a manner that was different to its role in ligand binding to the mature LDL 
receptor. The glycosylation of the LDL receptor did not influence the formation of 
disulfide bonds. Similarly, reduction of the disulfide bonds of the LDL receptor did not 
irreversibly alter its glycosylation. LDL receptor transport from the endoplasmic 
reticulum was impaired when ATP or Ca
2
+ was depleted, when disulfide bonds were 
reduced and when cysteine residues were mutated in the 5th binding repeat of the 
ligand binding domain. All of these changes were shown to affect the folding of the 
LDL receptor. These findings clearly show the inter-relationship between LDL receptor 
folding and transport. A missense mutation causing the conservative substitution of an 
aspartate residue by a glutamate residue (FH Afrikaner-1, Asp206Glu) was shown to 
impair the disulfide bonding of the mutant LDL receptor in the endoplasmic reticulum. 
The disulfide bonds of the LDL receptor were not affected by all missense mutations 
that are known to retard transport from the endoplasmic reticulum. Similarly, mutations 
(truncations and missense) in the cytoplasmic tail of the LDL receptor retarded 
processing, but did not affect the disulfide bond structure of the LDL receptor. The 
chaperone, calnexin, did not show quantitatively significant association with the LDL 
receptor. Together with other results, this suggested that calnexin was not critical for 
the folding of the wild type LDL receptor. Calnexin also was not involved in the 
retention of reduced or mutant forms of the LDL receptor in the endoplasmic reticulum. 
Mutant LDL receptors were constructed to individually substitute (to alanine) each of 
the six cysteine residues in the 5th binding repeat of the ligand binding domain. 
Expressed in CHO cells, the disulfide bond structures of the mutant LDL receptors were 
altered as assessed by electrophoresis under non-reduced conditions, and the rates of 
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transport from the endoplasmic reticulum were retarded. Differences were observed in 
the rates of processing and stability of the mutants, which, in all instances, resulted in 
an extremely low number of surface molecules. These and other results indicate that 
all 6 cysteine residues are required for the folding of the 5th binding repeat, and are 
involved in disulfide bonds, though they prevent the 5th repeat from achieving the most 
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Introduction 
1.1. Cholesterol and the LDL receptor 
Cholesterol is required by all cells as a constituent of membranes, it is also the 
precursor for the synthesis of bile acids in the liver and the precursor for the synthesis 
of steroid hormones in the adrenal gland. Cholesterol is transported in plasma 
lipoproteins in a form esterified to fatty acids, and delivered to cells by the process of 
receptor-mediated endocytosis. The LDL receptor is a membrane glycoprotein which 
binds the predominant cholesterol-containing lipoprotein, LDL, and transports it from 
the plasma into the cell. This cell-surface receptor performs a key role in cholesterol 
homeostasis and its regulation controls both cellular and plasma cholesterol levels. 
Mutations that disrupt the LDL receptor gene cause familial hypercholesterolaemia, 
where the impaired clearance of intermediate density and low density lipoproteins 
causes the accumulation of cholesterol in the plasma and premature atherosclerosis. 
Many features of the cell biology of the LDL receptor have been identified by Brown 
and Goldstein, in Dallas, who began their studies in 1972 and received the Nobel prize 
in physiology or medicine in 1985 (Brown and Goldstein, 1986). In their studies using 
cultured human fibroblasts, they demonstrated that added sterols stimulated 
cholesterol esterification and suppressed cholesterol synthesis within the cell. The 
regulatory effects involved a selective, high affinity receptor that was characterised 
using 1251-labelled lipoproteins: lipoprotein binding at the surface was followed by 
internalisation and the release of regulatory-cholesterol in the lysosomes. In cells 
obtained from patients with FH, the regulatory effects were not observed, unless the 
cholesterol was added in a form which was able to diffuse directly through the cell 
membrane: the underlying defect in FH was the absence of the surface receptor for 
LDL. 
These elegant studies were extended: the binding activity was used to purify the LDL 
receptor to homogeneity; antibodies were produced and used to track the movement of 
this migrant protein through the cell (the LDL receptor is the prototype for the paradigm 
of receptor-mediated endocytosis); heterogeneous defects causing FH were identified, 
including defects of binding and internalisation. Cloning of the gene outlined the 
structure of the LDL receptor and revealed the molecular basis for mutations causing 
FH. The LDL receptor pathway was confirmed in other cultured cells, in an animal 
model of FH (the Watenabe heritable hyperlipidaemic rabbit) and in transgenic mice. 
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Its discovery has advanced the treatment of hypercholesterolaemia, in particular, 
through the development of the HMGCoA reductase-inhibitor class of drugs, the ability 
to genetically-council FH patients and through the use of gene-therapy based on the 
LDL receptor. 
1.2. Itinerary of the LDL receptor 
The LDL receptor protein is translated by polyribosomes attached to the rough 
endoplasmic reticulum as a polypeptide of 860 amino acids (Yamamoto et al., 1984). 
Synthesis is initiated with a 21 amino acid signal sequence which is co-translationally 
inserted into the ER-lumen and then cleaved from the receptor. In the ER the residual 
protein of 839 amino acids folds and forms disulfide bonds and is glycosylated with 
core 0-linked sugar chains and the high mannose, N-linked chains characteristic of an 
ER protein (Cummings et al., 1983). This form of the LDL receptor appears as a 
protein with an apparent molecular mass of 120 kDa on SDS polyacrylamide gels. The 
normal LDL receptor is transported from the ER to the cell surface within 15 to 30 
minutes (Tolleshaug et al., 1982). En route, the LDL receptor passes through the Golgi 
apparatus where the N- and the 0-linked oligosaccharide chains are processed and 
are terminated by the addition of galactose and sialic acid residues. These changes 
modify the apparent molecular mass of the LDL receptor by 40 kDa, from 120 kDa to 
the 160 kDa of the mature LDL receptor. The transport of the LDL receptor from the 
ER is prevented by certain mutations which alter the structure of the LDL receptor 
(Hobbs et al., 1992). This retention is not mediated by specific retention motifs 
(Pelham, 1991 ); it probably is due to interaction of the partially-folded, exposed, 
hydrophobic domains of the LDL receptor with resident chaperone proteins. 
The LDL receptors are not distributed evenly on the cell surface. They are inserted as 
a dispersed population (Sanan et al., 1989) and migrate laterally to be concentrated 
within clathrin-coated pits: in fibroblasts, about 70% of surface LDL receptors are 
clustered in clathrin-coated pits, through which efficient receptor-mediated endocytosis 
occurs (Anderson et al., 1982). In the hepatocytes of transgenic mice, the LDL 
receptors are confined to the basolateral (sinusoidal) surface of the polarised cell 
membrane, and are not detected on the apical (cannalicular) surface (Yokode et al., 
1992; Pathak et al., 1990). Signals in the cytoplasmic tail of the LDL receptors cause 
this distribution by targeting transport from the trans-Golgi apparatus to the basolateral 
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membrane (Matter et al., 1992; Matter et al., 1993; Matter et al., 1994). LDL receptors 
re-enter the cell when the coated pits invaginate to form coated vesicles with the 
extracellular domain of the LDL receptor oriented within their interior. Endocytosis 
occurs constitutively and does not require ligand to be bound to trigger lateral migration 
to coated pits or internalisation. The LDL receptor and the ligand part company in the 
acidic endosome (Brown et al., 1983): ligand is delivered through late endosomes to 
lysosomes, where the apoprotein is degraded and the cholesterol ester is hydrolysed to 
release free cholesterol for use within the cell; the LDL receptor is concentrated within 
membrane-rich, tubular elements and recycles to the cell surface for further rounds of 
endocytosis. In fibroblasts, the half-time for a round of endocytosis is about 12 minutes 
(Brown et al., 1983), which implies that each receptor performs about 60 rounds, given 
a half-life of about 12 hours (Casciola et al., 1988). At steady-state, about 25 - 50% of 
the population of LDL receptors are within the endosomal pathway and the remainder 
are on the surface (Hare, 1990). It is presumed that all receptors are active and 
recycling; there is no evidence for an inactive or a sequestered population of LDL 
receptors, as has been described for the asialoglycoprotein receptor (Weigel and Oka, 
1993). In polarised cells, the itinerary of LDL receptors is more complex than in 
fibroblasts (Li et al., 1991; Matter et al., 1993). LDL receptors require sorting in 
endosomes, either to recycle back to the surface from where they were internalised, or 
to cross the cell in a transcytosis pathway. The path followed depends on the surface 
from which the LDL receptor entered the cell: from basolateral endosomes LDL 
receptors recycle to the basolateral surface, while delivering ligand to the lysosomes; 
by contrast, apically-derived LDL receptors are directed to transcytose ligand to the 
basolateral surface. Thus, from either source of endosomes, the LDL receptors are 
sorted to the basolateral surface, though via different pathways. Disruption of the 
targeting signals causes missorting in endosomes, with both the basolateral and the 
apical LDL receptors being targeted to the apical surface. These basolateral targeting 
signals are the same as those which direct the sorting of newly-synthesised LDL 
receptors within the trans-Golgi network, indicating that a common sorting mechanism 
probably operates at both sites (Matter et al., 1993). 
1.3. Structure of the LDL receptor gene and protein 
The gene coding for the LDL receptor is located on the distal short arm of chromosome 
19 (p13.1-p13.3) (Hobbs et al., 1990). The locus spans 45 kilobases and includes the 
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known upstream promoter-elements which are found within 200 base pairs 5' of the 
methionine codon for translation initiation. The gene is well conserved (amphibians to 
man) (Mehta et al., 1991) indicating that it encodes an ancient protein utilised in 
diverse animals. 
A striking feature is that the division of the gene into 18 exons corresponds to the 
organisation of the protein into domains and subdomains (Figure 1.1 ). In many 
instances, single exons, or groups of exons, encode distinct domains of the protein. 
These units are found to be repeated within the structure of the LDL receptor, other 
members of the LDL receptor gene family and in the genes encoding other proteins, 
which suggests that the exons were duplicated and exchanged (shuffled) through the 
evolution of these genes (Sudhof et al., 1985). 
The LDL receptor is an 839 amino acids protein which contains 2 N-linked and about 
18 0-linked oligosaccharides (Cummings et al., 1983). The calculated molecular mass 
of the glycosylated receptor is about 115 kDa (Tolleshaug et al., 1982). The protein 
spans the cell membrane once and, at the cell surface, is orientated with its N-terminus 
being extracellular and its C-terminus in the cytoplasm (Schneider et al., 1983b ). In 
total, 768 amino acids are extracellular, 22 amino acids span the cell membrane and 50 
amino acids form the intracellular, cytoplasmic tail (Russell et al., 1984; Yamamoto et 
al., 1984). Overall the LDL receptor is a modular protein composed of distinct domains 
(Figure 1.2). The extracellular portion consists of the ligand binding domain, a domain 
with homology to the epidermal growth factor (EGF) precursor and an 0-linked sugar 
domain (Sudhof et al., 1985). Exon 1 encodes a signal sequence which inserts the 
nascent polypeptide into the membrane of the ER and thus initiates its journey through 
the secretory pathway to the cell surface. The signal sequence is cleaved from the 
LDL receptor in the endoplasmic reticulum. Exons 2-6 encode the ligand binding 
domain of 292 amino acids which is composed of 7 repeats of a single unit of about 40 
amino acids that is homologous to the C9 component of complement. Each repeat 
contains 6 cysteine residues and has a characteristic central hydrophobic region 
flanked by hydrophilic ends (Kyte and Doolittle, 1982). The repeats are not perfectly 
homologous: optimum alignment shows that the spacing of the cysteine residues, and 
19 of the 41 amino acids are conserved, including a carboxy-terminal acidic sequence, 
asp-X-ser-asp-glu, thought to be important for ligand binding (Sudhof et al., 1985). The 
cysteines are thought to be fully disulfide-bonded within their given repeat and crucial 
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for maintaining the folded structure of the domain, especially during rounds of 
endocytosis through the acidic environment of the endosomal pathway. The disulfide 
bond pattern was identical in 2 peptides, corresponding to the 1st (Daly et al., 1995; 
Bieri et al., 1995a) or the 2nd (Bieri et al., 1995b) ligand binding repeats, respectively. 
Within each peptide, cysteine 1 paired with cysteine 3, cysteine 2 paired with cysteine 
5, cysteine 4 paired with cysteine 6. Due to the homology between the repeats, is 
probable that the cysteines in the other binding repeats pair in a similar order. 
The domain with homology to the epidermal growth factor (EGF) precursor extends 
from amino acid 293-692 and is encoded by exons 7-14. The domain contains 3 
growth factor repeats (A-C) which are found in 4 copies in the precursor for EGF. The 
A and B repeats of the LDL receptor are separated from the C repeat by 5 copies of a 
40-60 amino acid repeat, each of which contains a conserved YWTD (tyrosine-
tryptophan-threonine-aspartate) motif. The EGF precursor homology domain is needed 
for the binding of LDL on the cell surface, as well as for the dissociation of ligand from 
the receptor in endosomes. 
The 0-linked sugar domain is encoded by exon 15. This 57 amino acid domain (amino 
acids 693 to 750) contains a cluster of 18 serine or threonine residues which are 
potential sites for the addition of 0-linked oligosaccharide chains. The function of this 
domain has not been clearly defined: FH patients homozygous for a deletion of the 
entire exon 15 and identified in the Japanese and the Finnish populations, express a 
mild form of FH (Kajinami et al., 1988; Koivisto et al., 1993). However, deletion of the 
domain by site-directed mutagenesis did not affect the synthesis, transport, binding, 
recycling, nor the degradation of the receptor when transfected into hamster fibroblasts 
(Davis et al., 1986a). It has been speculated that the extensive 0-linked glycosylation 
of the 0-linked sugar domain may hold the receptor in an extended conformation, so as 
to facilitate ligand binding, but this has not been shown directly (Goldstein et al., 1985). 
The membrane-spanning domain anchors the receptor in the membrane of the various 
compartments of the cell. It consists of a hydrophobic, 22 amino acid sequence which 
is encoded by exon 16 and the 5' part of exon 17. The 50 amino acid cytoplasmic tail 
of the LDL receptor (amino acids 790-739) is encoded by the 3' end of exon 17 and 
exon 18. This domain is well conserved between different species and contains signals 
to direct the receptor to the basolateral domain in the plasma membrane of polarised 
cells, and a separate signal necessary for the efficient internalisation of clustered LDL 
receptors through coated pits (Figure 1.3). This domain also is required for the 
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Figure 1.1 Exon organisation and protein domains in the human LDL receptor. 
The six domains of the LDL receptor are labelled in the lower portion. The cysteine-
rich, 40-amino acid repeats in the binding domain are numbered 1 to 7. The three 
growth factor repeats in the EGF precursor homology domain are lettered A to C. The 
positions at which intrans interrupt the coding region are indicated by arrows. Exon 
numbers are shown between the arrows. 








Figure 1.2 Model of the human LDL receptor 
1. LIGAND BINDING 
DOMAIN 
292 Amino Acids 
2. EGF PRECURSOR 
HOMOLOGY 
400 Amino Acids 
3. 0-LINKED SUGARS 
58 Amino Acids 
4. MEMBRANE - SPANNING 
22 Amino Acids 
5. CYTOPLASMIC 
50 Amino Acids 
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The domains of the LDL receptor are indicated. The 40-amino acid ligand binding 
repeats are numbered 1 to 7, and the growth factor repeats of the EGF precursor 
homology domain are labelled A to C. 
(Figure modified from Esser et al., 1986). 
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Figure 1.3 Localisation of the signals for internalisation and targeting 1n the 
cytoplasmic tail of the LDL receptor. 
The sequence of the LDL receptor cytoplasmic tail is given in single letter code. 
The position of the signal for internalisation through clathrin-coated pits is 
indicated, as are the positions for the proximal and distal signals for basolateral 
targeting in polarised cells. 

29 
self-association of receptors into multimeric structures (van Oriel et al., 1987a). The 
carboxy-terminus of the cytoplasmic tail is conserved almost perfectly between species 
and encodes a polarised targeting signal (Matter et al., 1992; matter et al., 1993). 
1.4. Regulation of LDL receptor expression 
The LDL receptor promoter consists of three imperfect repeats and two TATA boxes. 
Repeats 1 and 3 are binding sites for the transcription factor, Sp1, which constitutively 
promotes transcription (Dawson et al., 1988; Sudhof et al., 1987a; Sudhof et al., 
1987b). The activity of the LDL receptor promoter is regulated by oxysterols derived 
from the intracellular pool of unesterified cholesterol: low intracellular sterols stimulate 
maximal positive transcriptional activity, but its positive effect is lost when intracellular 
sterols accumulate. These effects are mediated through repeat 2, which is a 
conditional-positive, sterol regulatory element (Dawson et al., 1988; Briggs et al., 
1993). Two transcription factors which bind repeat 2, sterol regulatory element binding 
protein-1 (SREBP-1) and SREBP-2, have been isolated (Briggs et al., 1993; Hua et al., 
1993; Wang et al., 1993; Yokoyama et al., 1993) and the mechanism of their regulation 
by sterols has been determined (Wang et al., 1994 ). The SREBPs are transmembrane 
proteins which are attached to the ER membrane. When sterols are depleted from 
cells, a protease cleaves the amino-terminal fragment of each SREBP and releases an 
active leucine-zipper type transcription factor which translocates into the nucleus and 
stimulates transcription by binding to the sterol regulatory element. SREBPs also bind 
to the sterol regulatory element of 3-hydroxy-3-methylglutaryl coenzyme A and 
stimulate its transcription: the combined effect is to increase the intracellular pool of 
cholesterol which prevents the proteolytic release of the SREBPs from the ER This 
feedback mechanism serves to limit the accumulation of cholesterol within cells. 
Recently the model of transcription stimulation has been refined to include an 
interaction between the SREBPs at repeat 2 and the binding of Sp1 to repeat 3: 
SREBPs are weak stimulators of transcription; their binding increases Sp1 binding to 
repeat 3, and together they activate expression from the LDL receptor promoter 
(Sanchez et al., 1995; Yieh et al., 1995). 
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1.4.1 Post-transcriptional control of LDL receptor activity 
The action of many hormones regulate the level of LDL receptor activity expressed in 
different cells (Soutar and Knight, 1990). In general, these effects have been 
characterised poorly in comparison to the sterol effects described above. These 
hormones act through transcription mechanisms: the LDL receptor activity being 
regulated directly through its mRNA levels. Interestingly, insulin, human chorionic 
gonadotropin and calmodulin antagonists are able to exert stimulatory effects which 
override the effects of sterols ( either suppression by sterols or apparent full stimulation 
by sterols). Their mechanisms of action are not known. Convincing evidence for the 
post-translational control of LDL receptor activity has not been apparent (Brown and 
Goldstein, 1986) until recently. This was demonstrated by the sterol-mediated down-
regulation of a retroviral vector-encoded transcript of the normal LDL receptor, in 
receptor-deficient cells (Sharkey et al., 1990). This vector contained a strong, 
constitutive promoter which was unresponsive to sterols and did not alter the mRNA 
levels, indicating that the control was at the level of translation or protein stability. 
1.5. LDL receptor mutations 
The Dallas collection of fibroblast cultures from FH patients probably is the largest 
collection of receptor mutants expressed in animal cell (Hobbs et al., 1992; Hobbs et 
al., 1990). This database has enabled the systematic dissection of structure-function 
relationships of the LDL receptor. More than 150 mutations have been identified in the 
LDL receptor genes of hypercholesterolaemic patients. Together with artificial mutant-
constructs, these alleles have provided a wealth of information on the function of 
membrane proteins. The mutations are classified based on their protein phenotype. 
Class 1 mutants do not have detectable receptor protein. They are caused by 
mutations affecting the promoter and by mutations which produce unstable mRNA 
molecules: many are missense mutations which produce mRNA molecules of the 
correct size; the instability is due to translation stopping prematurely. This class would 
also include those alleles producing protein-products which have an extremely short 
half-life possibly due to rapid degradation in the ER Class 2 mutants are transported 
slowly from the ER to the cell surface and are detected by retarded conversion from the 
precursor to the mature form (typically in biosynthetic pulse-chase experiments). This 
phenotype is probably caused by impaired folding of the LDL receptor and its 
subsequent association with chaperones, which promote folding partly by preventing 
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the aggregation of partially-folded proteins. Other defined catalytic activities promote 
disulfide bond formation and the cis-trans isomerisation of peptidyl-prolyl bonds. Class 
2 has been divided into those alleles having an apparent complete block in processing 
and those where the rate only is retarded. These distinctions are largely facile as other 
effects, such as the stability of either the precursor or the mature LDL receptor, often 
are not considered and complicate the interpretation of pulse-chase experiments. 
Many mutations which are classified in other classes, especially class 3 mutants 
(binding defective), overlap with class 2. Overall, more than 50% of the mutant alleles 
belong to his class. An understanding of the folding of the normal LDL receptor and its 
disruption by class 2 mutations is a major theme of this thesis and is discussed further 
in Section 1.8.2. 
Class 3 mutants have a binding defect and are caused by mutations in the ligand 
binding domain or the domain with homology to the EGF precursor. Study of mutants 
of this class have been particularly useful to define the manner in which a receptor 
single binding domain is able to bind structurally unrelated ligands. The manner in 
which the LDL receptor binds to its ligands is described below under "ligand binding to 
the LDL receptor". All mutants described to date have a reduced number of surface 
binding sites; no mutants with a reduced binding affinity have been described. Class 4 
mutants have internalisation defects due to mutations within the cytoplasmic tail of the 
LDL receptor. These mutants range from point mutations within the internalisation 
motif, to larger deletions which truncate the tail. They are discussed in detail under 
"internalisation of the LDL receptor" (Section 1.7). Class 5 mutants are unable to 
recycle during rounds of endocytosis. These mutants have defects within the domain 
with homology to the EGF precursor which prevents the acid-induced dissociation from 
the ligand within the endosomes. These mutants are trapped within the cell and are 
rapidly degraded. Mutants with defects within the polarised targeting signals of the 
cytoplasmic tail would also be classified in this class, but have not been detected. 
They would be unable to recycle back to the correct surface domain of polarised cells. 
A 6th class has been proposed to group the diverse set of mutants which are unstable 
and have a rapid rate of degradation (Fourie et al., 1988). The normal route of 
degradation of the LDL receptor has not been identified. The site and the mechanism 
of the degradation of normal LDL receptors has not been identified. In fibroblasts, LDL 
receptors are turned over with a half-life of about 12 hours (Casciola et al., 1988). This 
rate is not changed by conditions that alter the number of receptors present within the 
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cell, indicating that the number of receptors is regulated solely by the rate of synthesis, 
and not through degradation. Lysosomes, responsible for the degradation of the LDL 
ligand, appear not to be the primary site of receptor turnover, since their activity can be 
inhibited without affecting the half life of the LDL receptor (Casciola et al., 1989). The 
presence of ligand, though, has no effect on the stability of normal LDL receptors 
(Casciola et al., 1988). These results indicate that the receptor and the ligand follow 
independent routes to their sites of degradation (Casciola et al., 1988). The initial 
degradation events of the LDL receptor may occur on the cell surface, as mutations 
which prevent receptor internalisation do not alter their rate of degradation (Casciola et 
al., 1989). The stability of pre-existing LDL receptors is prolonged when new protein 
synthesis is inhibited by cycloheximide (Casciola et al., 1988). This suggests that the 
turnover of the LDL receptor requires a short-lived protein, though its function is not 
known. In the case of the normal LDL receptor expressed in cells defective in 
glycosylation-ability, rapid receptor degradation occurs with the release of a large 
soluble receptor fragment into the medium (Kozarsky et al., 1988). Sometimes, mutant 
LDL receptors are degraded at an enhanced rate due to their being unable to follow the 
normal LDL receptor itinerary. However, the features which dictate the sites at which 
LDL receptors are rendered unstable, are not always clear. Thus certain LDL 
receptors are retained within the ER, probably due to impaired folding (Hobbs et al., 
1990). Some of these mutant LDL receptors are degraded from this site, but others are 
stable while being retained in the ER. LDL receptors with certain other mutations 
escape from the ER and reach the cell surface, where they exhibit their unstable 
phenotype (Fourie et al., 1988). In all these instances, the mechanisms of degradation 
are not known. LDL receptors with mutations in the EGF precursor homology domain 
are prevented from recycling, as they are unable to dissociate from ligand (van der 
Westhuyzen et al., 1991; Davis et al., 1987a). These intracellularly trapped LDL 
receptors are rendered unstable in the presence of ligand, indicating that it is their 
inability to dissociate from ligand which targets them to degradation. Normal LDL 
receptors can also be prevented from dissociating from ligand by incubation with NH4CI 
which prevents the acidification of endosomes. This too enhances the degradation of 
LDL receptors in a ligand-dependent manner (Grant et al., 1990). NH4CI inhibits the 
function of lysosomes, indicating that they are not involved in this enhanced 
degradation process. 
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1.5.1. Mechanism of mutation in the LDL receptor gene 
FH is one of the commonest autosomal dominant genetic disorders in humans, 
affecting about 1 in 500 individuals, though the frequency is much higher in certain 
populations (see below). The factors that influence the frequency of a genetic change 
in a population are: i) the rate at which new mutations occur at a particular locus (and 
the time-span involved); ii) the reproductive advantage (or disadvantage) experienced; 
iii) the chance events, such as founder effects, that affect sampling. 
The molecular mechanisms that underlie the mutagenicity at this locus involve 
recombination events at Alu repeats and cytosine to thymidine transitions at CpG 
dinucleotides. Alu repeats are the commonest "middle repetitive" sequences in the 
human genome: they consist of a 300 base pair sequence which is repeated to about 
91 O 000 copies (Hwu et al., 1986; Hobbs et al., 1990). In the LDL receptor gene, the 
frequency is about double that of the average for the rest of the genome. Alu repeat 
sequences are present at 9 of the 10 known endpoints of the 45 large deletions or 
insertions reported in the LDL receptor gene (Hobbs et al., 1992). 2 mechanisms 
underlie their effect: first, and commonly, an unequal crossover event may occur during 
homologous recombination at meiosis, between daughter chromatids containing Alu 
repeats oriented in the same direction; and second, the formation of a stem-loop 
structure within the same chromosomal strand may cause a mutagenic event between 
Alu repeats oriented in opposite directions (Lehrman et al., 1985a and 1987a). 
Cytosine to thymidine transitions occur at CpG dinucleotides: deamination of cytosine 
forms uracil, which is corrected back to cytosine by uracil glycosidase; deamination of 
methyl-cytosine forms thymidine which is maintained by replication (Cooper and 
Youssoufian, 1988). These changes are implicated in causing 16 % of the missense 
mutations in the LDL receptor locus, and include the recurrence of the same mutation 
on a separate haplotype, indicating a separate mutagenic event (Hobbs et al., 1992). 
In FH, there is no recognised survival advantage associated with the heterozygous 
state, which also does not overtly compromise gene transmission, as the disease 
usually manifests after the reproductive ages. Disease alleles are excluded from the 
population by homozygous patients who commonly die prior to attaining a reproductive 
age. In the Afrikaner, French Canadian, Finnish, Ashkenazi Jews, and Christian 
Lebanese populations, the frequency of FH is amplified by founder effects. These 
arose when certain mutant FH alleles were over-represented in the initial pool of 
settlers, compared to their frequency in the general population (Hobbs et al., 1992). 
This higher allele frequency was maintained as these populations grew in relative 
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isolation, and furthermore were subjected to the random genetic drift characteristic of 
small populations. Characteristically, the FH individuals in a founder population 
express the same mutation (or few mutations), unlike the general population where 
many different mutations cause FH. This is unlike cystic fibrosis, where a single 
mutation causes about 70% of cases (Lemna et al., 1990). Such a pattern could arisen 
either by an ancient mutation having occurred in the context of a very low mutation 
rate, or by recurrent mutations occurring at a particular site ('hot spot'). Other more 
complex models are also possible, such as those which include a survival advantage 
for patients with this particular mutation. 
Finally, the relative ease of diagnosis of FH has facilitated the identification of patients 
and thus the detection of mutations. The LDL receptor gene and the apoB gene are 
the two candidate genes recognised as having the potential to cause a monogenic 
pattern of hypercholesterolaemia. 
Krieger and colleagues have developed an artificial system to select for cells with 
defects in the LDL receptor pathway (Krieger, 1986). After exposing cell to various 
mutagens, toxins were delivered, within LDL, to kill cells with intact LDL receptors and 
to select for cells with defective LDL receptor activity. In this manner, several different 
classes of mutant cells were identified to affect the LDL receptor, itself, and other 
protein involved in protein secretion (Krieger et al., 1981; Kingsley and Krieger, 1984). 
The ldlA class (defective LDL receptor gene) have been used to determine the effects 
of cloned LDL receptor genes (also used in this thesis) (Sege et al., 1984). The ldlC 
and the ldlF class involve defective peripheral Golgi coat proteins necessary for protein 
secretion (Guo et al., 1994; Podos et al., 1994). The ldlD class have defects in UDP-
galactose and UDP-N-acetylgalactosamine 4-epimerase activity (Kingsley et al., 
1986a), causing reversible defects in N- and 0-linked glycosylation (see Section 
1.8.1,"glycosylation of the LDL receptor")(Kozarsky et al., 1988). LDL receptor 
glycosylation also is affected in the ldlB class, though through undefined mechanisms. 
Recently, several more classes have been identified to affect LDL receptor stability and 
intracellular membrane transport (Hobbie et al., 1994 ). 
1.6. Binding to the LDL receptor 
The binding of lipoproteins to cells may be initiated by an interaction with heparan- and 
dermatan-sulfate proteoglycans (HSPG), prior to the involvement of a specific (high 
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affinity) surface receptor, such as the LDL receptor (Saxena et al., 1993). The HSPGs 
might act as an abundant source of low affinity sites to initially concentrate ligand at the 
cell surface and thus facilitate binding to the LDL receptor. Although the binding of 
lipoproteins directly to HSPGs may be poor, two factors increase this binding by up to 
80 fold (Mulder et al., 1993). First, lipoprotein lipase (LPL) acts as an intermediary in 
associating lipoproteins (LDL, Lp(a) and VLDL) with HSPGs (Mulder et al., 1993; 
Williams et al., 1992; Rumsey et al., 1992; Saxena et al., 1993). Second, apoE-
enriched chylomicron remnants (and VLDL) associate with HSPGs without the 
involvement of LPL (Ji et al., 1993). However, the physiological relevance of these 
findings is unclear as the level of LPL used to demonstrate enhanced binding of 
lipoproteins to HSPGs is 2 orders of magnitude higher than the concentration of LPL in 
the circulation (Goldberg et al., 1986; Mulder et al., 1993; Williams et al., 1992). The 
LPL concentration, though, may be far greater in confined compartments such as the 
site of lipoprotein-clearance in the liver (the space of Disse) (Williams et al., 1992). In 
such a localised environment, the interaction of lipoproteins with HSPGs would be 
influenced not only by the availability of LPL, but also by the availability of apoE, which 
inhibits lipoprotein binding to LPL (Saxena et al., 1993). The role of the LDL receptor 
in mediating the endocytosis of HSPG-associated lipoproteins, is controversial (HSPGs 
themselves do not mediate endocytosis). The internalisation of lipoprotein was not 
affected by the down-regulation of LDL receptor activity (with sterols) (Williams et al., 
1992), nor was it reduced in the fibroblasts from FH patients (lacking functional LDL 
receptors) (Rumsey et al., 1992). However, another study indicated a role for the LDL 
receptor when FH fibroblasts exhibited less than 10% of the HSPG-associated LDL 
uptake of normal fibroblasts, and the internalisation activity was suppressed in parallel 
to the down regulation of LDL receptor activity in normal fibroblasts (Mulder et al., 
1993). 
The LDL receptor binds lipoproteins containing apolipoprotein B-100 (apoB) or 
apolipoprotein E (apoE) with high affinity (Goldstein and Brown, 1977), including LDL, 
VLDL, IDL, chylomicron remnants and the lipoproteins derived from cholesterol-fed 
animals, ~VLDL (rabbits)and HDLc (dogs). Binding occurs by ionic interactions 
between basic residues on the apolipoproteins and acidic residues of the 7 repeats in 
the ligand binding domain of the LDL receptor, and is Ca2+ -dependent (Goldstein and 
Brown, 1977). Mutagenic studies have revealed the manner in which a receptor 
utilises multiple repeats, within a single binding domain, to recognise more than one 
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ligand: different combinations of the repeats are required to bind the different ligands 
(Esser et al., 1988; Russell et al., 1989). In these studies where the binding repeats 
were individually deleted, deletion of repeat 5 reduced apoE binding by 60%, whereas 
any other repeat could be removed without affecting binding. The simplest 
interpretation of these findings is that apoE only binds to repeat 5, though other more 
complex models are possible. Repeat 5 has the unique presence of 4 acidic amino 
acid compared to a triplet cluster of acidic amino acids found in the other repeats 
(serine-aspartate-glutamate-glutamate vs. serine-aspartate-glutamate) which are 
important for ligand binding (Goldstein et al., 1985). Interestingly, the binding of apoE-
containing ligands occurs with a 10-fold higher affinity than apoB-containing ligands. 
This is thought, in part, to be due to the many apoE molecules of a single lipoprotein 
particle being able to interact simultaneously, with several LDL receptors gathered 
together in an oligomeric partnership, with each receptor providing a single apoE 
binding site (the stoichiometry of apoB to LDL receptor binding is 1: 1 ). The binding of 
apoB (LDL) tolerated only the deletion of repeat 1, indicating that repeats 2-7 were all 
required for apoB binding. In addition to the ligand binding domain, repeat A of the 
EGF precursor homology domain also is required for the binding of apoB (Esser et al., 
1988); its deletion reduced LDL binding by 75%. However, repeat A is not required for 
the binding of LDL to receptors which are immobilised on nitrocellulose (ligand blot), 
and thus appears to perform a permissive role in LDL binding at the cell surface. The 
receptor binding domain of apoB is composed of 2 clusters of basic amino acids 
together with a flanking region of about 800 amino acids (Milne et al., 1989): one of the 
clusters is homologous to the receptor binding domain of apoE. Due to the large size 
of apoB (4536 amino acids) and its binding domain, apoB is probably relatively rigid on 
the surface of the lipoprotein particle which might explain its poor tolerance to 
mutations in the binding repeats of the LDL receptor. By contrast apoE is a far smaller 
protein (299 amino acids) (Lalazar et al., 1988) which possibly is more mobile on the 
surface of the lipoprotein particle, and thus more able to adapt to distortions introduced 
into the LDL receptor (with the exception of repeat 5) by mutations (induced fit model). 
1.7. Internalisation and recycling of the LDL receptor 
The first signal directing the internalisation of a surface protein, was identified in the 
LDL receptor (Davis et al., 1986b; Lehrman et al., 1985b): it was localised to the first 22 
amino acid (amino acids 790-812) of the 50 amino acid tail (Figure 1.3) and defined to 
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include amino acids 804-807 (the motif NPXY, where X could be any amino acid) 
(Davis et al., 1987b; Chen et al., 1990). This sequence is conserved in the LDL 
receptor tail across 6 species and is found in the cytoplasmic tail of several other 
proteins which are known to be internalised via coated pits, though it is not the only 
amino acid motif able to direct internalisation through coated pits. These 
internalisation signals are all assumed to interact with the same cytoplasmic 
components, and are assumed to adopt a similar conformation (Collawn et al., 1990): 
structural studies on a nonapeptide containing the NPVY LDL receptor signal show that 
it forms a reverse 11 turn (Bansal and Gierasch, 1991 ). Peptides derived from LDL 
receptors that are defective in internalisation do not form reverse turns. The aromatic 
amino acid (tyrosine 807) is crucial to the structural integrity of the turn, there is a lax 
requirement for the amino acid at position 806, in agreement with the earlier mutagenic 
studies (Davis et al., 1987b; Chen et al., 1990), and the region on the COCH-terminal 
side of the signal does not affect the structure of the turn (Bansal and Gierasch, 1991 ). 
The importance of the turn conformation was emphasised by the correlation of the 
efficiency of internalisation with the propensity of the nonapeptide to assume a reverse 
turn; this also has been determined for other internalisation signals without sequence 
similarity to the signal of the LDL receptor (lysosomal acid phosphatase) (Eberle et al., 
1991 ). Thus the internalisation signal is expressed in the structural context of a tight 
reverse turn conformation, which is presented to a putative cytoplasmic acceptor. The 
adaptor protein complex (adaptors) that are localised to the plasma membrane 
(classified as hydroxyapatite type II) recognise the internalisation signal (Pearse and 
Robinson, 1990). Adaptors bind to the cytoplasmic tail of different receptors including 
the LDL receptor and are also required for receptor inclusion into coated pits (Pearse, 
1988; Smythe et al., 1992). These complexes (molecular mass of 250-300kDa) are 
composed of two adaptin subunits (a,11 adaptins) of 1 OOkDa each, together with one 
50kDa protein and another 20kDa protein. The interaction between the adaptor and 
the LDL receptor tail can be prevented by competition by other receptors which are 
internalised via coated pits, indicating the common role of a single protein complex in 
recognising diverse internalisation signals. Importantly a receptor which is not 
internalised via coated pits, the haemaglutinin receptor, does not compete with the LDL 
receptor for the binding of adaptors (Pearse, 1988; Lazarovits and Roth, 1988). The 
actual binding site for adaptors on the LDL receptor has not been studied; on other 
receptors, adaptors bind to the aromatic internalisation signal (Pearse and Robinson, 
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1990). Adaptors also bind clathrin and promote the assembly of clathrin triskelions. 
Thus they have a central role in receptor mediated endocytosis, both by localising 
specific receptors within coated pits and by promoting the formation of the clathrin coat. 
1.8. Post-translational processing of the LDL receptor 
During their transit through the ER and the Golgi apparatus, secretory proteins are 
covalently modified in many ways: disulfide bonds form, sugar chains are added and 
processed, some proteins are proteolytically cleaved and so on. For the LDL receptor, 
the most prominent changes are its glycosylation and the formation of disulfide bonds. 
These and other less well characterised modifications, including sulfation, 
phosphorylation, oligomerisation and proteolytic cleavage are considered in this 
section. 
1.8.1. Glycosylation 
As has been described under "Biosynthesis of the LDL receptor'', the protein molecule 
is modified by the addition of N- and 0-linked oligosaccharide chains after its insertion 
into the ER. In general, the multistep assembly of N-linked chains has been well 
characterised, though for the LDL receptor, the number of N-linked chains has not been 
determined. Cummings has estimated that 1 or 2 biantennary, N-linked chains are 
added in fibroblasts, though this could vary in different cell-lines as there are 5 
potential sites with the glycosylation motif, asparagine-X-serine/threonine (where X 
could be substituted by any amino acid) (Cummings et al., 1983). Three of the 
potential sites are in the binding domain and two are in the EGF precursor homology 
domain: it has been suggested that the compact folding of the binding domain may 
prevent its glycosylation (Goldstein et al., 1985). N-linked chains are known to be 
assembled while attached to the membrane lipid, dolichol, and then transferred to the 
receptor molecule (Kornfeld and Kornfeld, 1985). Initially, the chain is assembled on 
the cytoplasmic face of the ER and then flipped into the ER-lumen. The chain is 
assembled by the sequential addition of 14 hexose monosaccharides derived from 
nucleotide-and dolichol-P sugars, until it has the structure shown in Figure 1.4. As the 
LDL receptor is translated and translocated through into the ER, the 14-hexose chain is 
transferred to the asparagine of the glycosylation-motif. In total, 9 of the hexose sugars 
are removed by glycosidases: in the ER, glucose residues are removed (glucosidase I 
and II) to form the high mannose chain typical of an ER protein, while mannose 
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Endoplasmic reticulum form 
Ser!Thr 
\ 
Cell surface/endocytic form 
Ser!Thr 
\ 
Figure 1.4 Typical structures of the oligosaccharide chains of the LDL receptor. 
The structures of the oligosaccharide chains of the endoplasmic reticulum and the cell 
surface/endocytic forms of the LDL receptor are shown. The N-linked chains are 
attached to asparagine (Asn) residues, and the 0-linked chain are attached either to 
serine (Ser) or threonine (Thr) residues. 
Abbreviations used: GlcNAc, N-acetyl-glucosamine; Man, mannose; Glc, glucose; 
GalNAc, N-acetyl-galactosamine; Fuc, fucose; Gal, galactose; SA, sialic acid. 
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residues are removed in the cis (mannosidase I) and medial Golgi (mannosidase II). 
The chain structure is completed by the addition of N-acetyl-glucosamine and fucose in 
the medial Golgi, and galactose and sialic acid in the trans Golgi. The incorporation of 
35S-sulfate into the LDL receptor was blocked by treatment with tunicamycin, indicating 
that the N-linked chains are sufated (Cummings et al., 1983). 0-linked chains are 
attached to the LDL receptor mainly at the 18 serine and threonine residues clustered 
in the 0-linked sugar domain which lies adjacent to the cell membrane. Up to one 
quarter of the 0-linked chains are dispersed in other regions of the extracytoplasmic 
domain of the LDL receptor (Davis et al., 1986a). The structure of 0-linked chains 
have not been determined precisely. There is the possibility of considerable 
heterogeneity: N-acetylgalactosamine is added to the serine/threonine residue in the 
ER to initiate the chain, followed by the addition of N-acetylglucosamine to some of the 
chains (Figure 1.4)(Cummings et al., 1983). In the Golgi apparatus, galactose and 
sialic acid residues complete the 0-linked structures, forming tri- and tetrasaccharide 
chains (Pathak et al., 1988). Sialic acids may be added at 2 sites on each chain: to the 
galactose or to the N-acetylgalactosamine. The heterogeneity in composition of the 0-
linked chains also is not limited to variation at different sites on the same LDL receptor 
molecule, but probably also varies between different LDL receptors. A prominent 
feature of the glycosylation, is that it dramatically alters the apparent molecular weight 
of the LDL receptor when electrophoresed on SOS polyacrylamide gels (Cummings et 
al., 1983; Davis et al., 1986a). The precursor has the electrophoretic mobility of a 
protein with a molecular weight of 120 000, while it has a calculated molecular weight 
of 93 102 for the protein component, and about 4 000 for the carbohydrate component. 
The processing in the Golgi apparatus contributes the net addition of sugars with an 
estimated molecular weight of 8 000-16 000 (depending on assumptions about the 
number of N- and 0-linked chains), giving the mature LDL receptor an estimated 
molecular weight of about 115 000 (Goldstein et al., 1985), while its electrophoretic 
mobility indicates a molecular weight of 160 000. The mobility shift is largely due to 
extension of the 0-linked chains: its magnitude is not altered by tunicamycin which 
reduces the apparent molecular weight of both the precursor and the mature LDL 
receptor by about 8 000. The effects of the 0-linked chains was shown in a mutant 
strain of CHO cells, deficient in the ability to add galactose residues, which minimised 
the molecular weight change (Cummings et al., 1983). These chains lacked both 
galactose and terminal sialic acid residues. The removal of sialic acids (using 
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neuraminidase) reduced the apparent molecular weight of the mature LDL receptor by 
only 1 O 000, indicating that the galactose residues were the prime determinant of the 
molecular weight change, despite the presence of only a single galactose residue per 
chain (compared to 2 sialic acid residues). Deletion of the 0-linked sugar glycosylation 
domain also minimised the molecular weight change, localising the main cause of the 
apparent molecular weight change to the addition of galactose residues to the 
clustered 0-linked chains (Davis et al., 1986a). The shift in the electrophoretic mobility 
of the LDL receptor facilitates the identification, in biosynthetic studies, of retarded 
processing from the precursor to the mature forms. 
1.8.1.1 Functional effects of LDL receptor glycosylation 
The role of glycosylation in LDL receptor function is unclear, despite several studies 
that have determined the behaviour of LDL receptors with altered sugars. Treatment of 
the LDL receptor with sialidase, which removes sialic acid residues from both N- and 
0-linked chains, has no effect on ligand binding (Schneider et al., 1982). A role for the 
N-linked chains is indicated by the reduced binding affinity of LDL receptors 
synthesised in the presence of tunicamycin (without N-linked chains), and the 40% 
decrease in LDL binding (without a change in LDL receptor number) caused by 
impaired processing in the presence of castanospermine (Edwards et al., 1989; 
Filipovic, 1989). However, substantial LDL receptor activity is expressed in CHO cells 
with 17 different types of defect predominantly affecting N-linked glycosylation 
(Kingsley et al., 1986b). Similarly, the role of the 0-linked chains are not clear. The 
LDL receptor is unstable and cleaved in the region of the 0-linked sugar domain in 
CHO cells with a reversible defect in 0-linked glycosylation which prevents the 
initiation of the 0-linked chains (Kozarsky et al., 1988). Deletion of the 0-linked sugar 
domain ( site of attachment of the clustered chains) does not alter the behaviour of the 
LDL receptor in fibroblasts (Davis et al., 1986a), though it does cause a mild form of 
familial hypercholesterolaemia through a subtle disturbance of receptor function 
(Koivisto et al., 1993). The dispersed 0-linked sugar chains (not in the clustered 0-
linked domain) are involved in ligand binding; their absence in a monensin-resistant 
cell line reduces the binding affinity for LDL and its internalisation rate (Kuwana et al., 
1991; Seguchi et al., 1991; Shite et al., 1988). 
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1.8.2. LDL receptor folding and retention in the ER 
Disulfide bonds cross-link the folded structure of the cysteine-rich domains (binding 
domain and the EGF precursor-homology domain) of the LDL receptor. 63 cysteines 
are present in the LDL receptor: all but 3 are found in the cysteine-rich repeats of the 
extracellular domain and are thought to be involved in disulfide bonding (Figure 1.5). 
One is present in the EGF domain between repeats B and C, one is present in the 
membrane spanning domain and another is in the cytoplasmic tail: these are not 
involved in disulfide bonds (Lehrman et al., 1987b ). The extensive disulfide bonding is 
confirmed by the inability to alkylate the LDL receptor without first reducing the bonds 
(Lehrman et al., 1987b; Daniel et al., 1983). Overall, 30 disulfide bonds form in the ER 
during the folding of each LDL receptor molecule; folding probably occurs co-
translationally with bonding starting as the nascent chain is translocated into the ER 
Bonds form between cysteines probably situated within the same repeat (see section 
1.6, "Binding to the LDL receptor"). The modular character of the folding, and the 
function, of each binding repeat is emphasised by the finding that point mutations 
within different repeats cause the same disruption to binding as deletion of the 
corresponding entire repeat (Esser et al., 1988; Russell et al., 1989). The effects of 
mutations extend only within their own repeat and do not disrupt the function of 
neighbouring repeats. The effects of all of the numerous mutations characterised 
within the ligand binding domain, all conform to these general principles for the role of 
the different repeats in the binding of ligand (Hobbs et al., 1992). Folding is probably 
aided by chaperone proteins that prevent the aggregation of partially-folded 
intermediates and catalyse the formation of the many disulfide bonds (protein disulfide 
isomerase) (Gathing and Sambrook, 1992). Of particular interest is the manner in 
which putative, gate-keeper proteins (possibly the same chaperones) might prevent the 
passage of mutant LDL receptors from the ER, probably by recognising a small region 
of misfolding in the LDL receptor. The retarded processing of mutant alleles was 
described in the initial report of LDL receptor processing (Tolleshaug et al., 1982): 
overall, 54% of the mutant alleles in the Dallas collection are classified as class 2 
(Hobbs et al., 1992). Of these, two thirds affect the binding domain, and one third 
affect the EGF precursor homology domain. In general, the deletion of domains or 
subdomains do not affect processing; rather it is the small deletions and missense 
mutations which have the greatest effects on the structure of the binding domain. 
Small deletions affect the spacing of the cysteine residues which is conserved in the 
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repeats and is apparently crucial for proper folding. Missense mutations cause the 
substitution of amino acids: these changes are dependent on the structure in the local 
environment of the mutation - certain sites are exquisitely sensitive (space-restricted 
regions) and tolerate substitutions poorly; sometimes, these include even substitutions 
which maintain the character (charge, hydrophobicity) of the substituted amino acid, 
such as the FH-Afrikaner-1 mutation where aspartate is substituted by glutamate 
(Fourie et al., 1988; Leitersdorf et al., 1989). Frequently, changes in the space-
restricted regions involve the substitution of glycine residues by residues with longer 
side-chains which are not able to be packed in the confined interior of the cross-linked 
repeats or in tight turns (Esser and Russell, 1988). These changes also may impair the 
disulfide bonding of cysteine residues. 
The role of cysteine residues in slowed processing was addressed using the Lebanese 
allele, where a missense mutation terminates translation at the third cysteine of repeat 
C in the EGF domain (Lehrman et al., 1987b). The pattern of disulfide bond pairing in 
this repeat has been identified in prothrombin and EGF (Esser and Russell, 1988): 
cysteines 1 and 3, 2 and 4, 5 and 6 pair, suggesting that in the truncated mutant, 
cysteines 1 and 2 probably are not involved in intramolecular bonds, but may bond to 
other proteins and prevent transport from the ER. Substitution of these two cysteines 
(by alanine) does not improve the slow processing of the Lebanese mutant in monkey 
kidney (COS) cells (Esser and Russell, 1988) indicating that retention does not 
necessarily involve inappropriate disulfide bonds cross-linking of the LDL receptor with 
other proteins or with other LDL receptor molecules (Tolleshaug et al., 1983; 
Yamamoto et al., 1986; Lehrman et al., 1987b). Clearly these findings do not imply that 
disulfide bonds are not required for successful folding and processing - they are; these 
results only indicate that free cysteine residues are not essential for retention in the 
ER. Possibly not all of the cysteines are required for successful folding: in a monkey 
kidney (COS) cell system, substitution of cysteines 6 and 18 (by alanine) in the first 
binding repeat does not retard processing, though this system is not optimal for the 
study of processing as the normal LDL receptor takes up to 4.5 hours to be converted 
to the mature form (Esser et al., 1988). 
Chaperone proteins retain malfolded proteins, in the ER, by associating with exposed 
hydrophobic regions (Gething and Sambrook, 1992). The specific chaperones 














Figure 1.5 Positions of the cysteine residues in the LDL receptor. 
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Each black dot indicates the position of a cysteine residue in the LDL receptor. The 40-
amino acid ligand binding repeats are numbered 1 to 7, and the growth factor repeats 
of the EGF precursor homology domain are labelled A to C. 
(Figure modified from Lehrman et al., 1987). 
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with the molecular mass of BiP (a major chaperone for secreted proteins) was co-
immunoprecipitated with LDL receptors containing defects in their binding domain 
(Esser and Russell, 1988), but was not characterised further. By 
immunohistochemistry, retained LDL receptors have been localised to the rough ER 
and irregular extensions of the rough ER, (Pathak et al., 1988): sugar analysis 
indicates that they have not passed through the Golgi apparatus, though the retention 
mechanism may involve recycling through a compartment intermediate between the ER 
and the Golgi apparatus (Pelham, 1991 ). 
The fate of the retained proteins vary: as has been described under 'mutations in the 
LDL receptor ' certain proteins escape the retention and appear at the cell surface, 
while others do not seem to exit the ER; some of the retained proteins are remarkably 
stable, though many are degraded at an enhanced rate. Degradation systems operate 
in the ER (Klausner and Sitia, 1990; Bonifacino and Lippincott-Schwartz, 1991 ), but the 
site and mechanisms of LDL receptor degradation have not been determined. The 
inter-relationship between retention and degradation is crucial to the retention 
mechanism preventing the expression of malfolded proteins at the cell surface. For 
retention to be effective, the number of LDL receptors arriving at the cell surface should 
be reduced. However, without degradation of the precursor LDL receptor, this is not 
the case. In the absence of degradation, retention causes the pool of LDL receptor 
molecules in the ER to increase until the absolute rate of transport is restored. Thus, 
certain transport-impaired mutants (FH-Afrikaner-1) are converted quantitatively 
(without degradation) from the precursor to the mature form - the retarded transport 
does not reduce the number of receptor molecules on the cell surface (Fourie et al., 
1988). It has been proposed that one role of the quality control mechanism is to limit 
the induction of an immune response directed against the abnormal proteins (Gathing 
et al., 1986). This function requires that the malfolded proteins do not reach the cell 
surface - they are retained and degraded. 
1.8.2.1. Transport-defective mutations in human disease 
The processes involved in LDL receptor transport are of general relevance in cell 
biology and medicine. Several different genetic diseases have been identified to 
involve mutations which disrupt the transit of specific membrane or secreted proteins 
through the secretory pathway; these proteins include receptors (both transport-
mediators and signalling), ion channels, adhesion molecules, and secreted enzymes 
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and structural components (Table 1.1) (Hobbs et al., 1992; Hobbs et al., 1990). It is 
anticipated that many more members of this group remain to be identified and that the 
group could include the mutant-forms of most surface molecules. 
Table 1.1 Human diseases causes by defects in the transport of membrane and 
secreted proteins. 
Membrane protein Disease 
LDL receptor FH 
cystic fibrosis transmembrane cystic fibrosis 
conductance regulator 
rhodopsin retinitis pigmentosa 
insulin receptor insulin-resistant diabetes 
sucrase-isomaltase sucrase-isomaltase 
deficiency 
common ~-subunit of LFA-1, Mac-1 and leukocyte adhesion 
p150,95 deficiency 
Secreted protein Disease 
a 1-antitrypsin emphysema 
pro-a 1-collagen and pro-a2-collagen osteogenesis imperfecta 
1.8.3. Oligomerisation 
About 25% of LDL receptors at the cell surface are self-associated into dimers and 
trimers (van Oriel et al., 1987a) which are able to bind ligand and recycle through the 
endocytic pathway (Grant et al., 1990). These oligomers may have a higher avidity for 
ligands containing apoE (see Section 1.6, "binding to the LDL receptor"), but, in 
general, the role of oligomers in LDL receptor function has been poorly characterised 
and the site of assembly has not been determined. Classically, the oligomeric 
assembly of proteins occurs during folding and is required for transport from the ER, 
though, for the LDL receptor, it is possible that it could occur at the cell surface. The 
oligomeric structure of the LDL receptor involves non-covalent interactions (not 
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disulfide bonds) and depends on amino acids 812 to 839 of the cytoplasmic tail (van 
Oriel et al., 1987a). 
1.8.4. Phosphorylation 
The LDL receptor is phosphorylated at a serine residue in the cytoplasmic tail (amino 
acid 833) (Kishimoto et al., 1987a). Although a candidate kinase was identified, its 
physiological location and its function were not determined (Kishimoto et al., 1987b). A 
similar phosphorylation event regulates the distribution of proteins in polarised cells 
(Casanova et al., 1990), but has no discernible effect on the targeting of the LDL 
receptor (Yokode et al., 1992). A phosphorylation-dephosphorylation cycle commonly 
regulates the activity of proteins involved in cell signalling; there is no evidence for a 
similar modulation of LDL receptor activity (Lin et al., 1986). 
1.8.5. Proteolytic cleavage 
Apart from cleavage of the signal sequence, the LDL receptor does not normally 
undergo proteolytic processing during its biosynthesis. The cleavage of the LDL 
receptor is induced at a site in the 0-linked sugar domain, by preventing the normal C-
linked glycosylation of the LDL receptor (Kozarsky et al., 1988), or by treatment with 
interferon A, which releases a soluble product consisting of most of the extracellular 
domain of the LDL receptor and mediates part of interferon A's antiviral activity (Fischer 
et al., 1994; Fischer et al., 1993). In both these cases, the cellular site of release has 
not been determined. 
1.8.6. Hydroxylation 
The LDL receptor undergoes a low degree of 13,-hydroxylation at 2 sites in the EGF 
precursor-homology domain (aspartic acid-310 in repeat A and asparagine-349 in 
repeat B) which contain a motif found in other hydroxylated proteins (Stenflo et al., 
1988). Substitution of these residues by alanine suggest that the aspartic acid 310 
may be hydroxylated and influence LDL binding, while asparagine 349 is dispensable 
(Esser et al., 1988). Hydroxylated residues are involved in calcium binding in other 
proteins which may account for the effect on LDL binding (Schneider, 1989). A 
hydroxylase (not identified) may maintain and regulate the low degree of hydroxylation 
of the LDL receptor. 
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1. 9. Research objectives 
The broad aim of this thesis was to study the influence of post-translational alterations 
on the synthesis of the LDL receptor. The revelation of the LDL receptor pathway and 
the recognition of numerous mutations that disturb its function, together have offered a 
means to probe the folding of the LDL receptor. Interest was focused on the 
glycosylation and the folding of the LDL receptor, its transport from the ER and the 
manner in which these processes are disrupted by mutations. 
Experiments were performed to determine: 
1. The influence of the disruption of the compartmental organisation of the secretory 
pathway, with brefeldin A, on the glycosylation of the LDL receptor. 
2. The requirements for the folding of the LDL receptor in the ER. 
3. The effect of mutation of cysteine residues on the folding of the 5th repeat of the 
binding domain of the LDL receptor. 
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2.1. Materials 
The anti-LDL receptor monoclonal antibody, lgG-C7, was prepared from hybridoma 
cells obtained from ATCC (CRL/691) and iodinated using lodogen (Pierce Chemical 
Co.) according to the method of Beiseigel et al. (Beisiegel et al., 1981 ). The anti-LDL 
receptor monoclonal antibody, lgG-HL 1, was a gift from Ors Brown and Goldstein 
(Dallas, Texas). The polyclonal antibodies (rabbit serum) directed at either of 2 
epitopes in the cytoplasmic tail of calnexin (amino acids 487-505 or amino acids 555-
573) were a gift from Dr JJM Bergeron (Montreal, Canada). The polyclonal antibodies 
(rabbit serum) directed against a1-antitrypsin and transferrin were purchased from 
Dako. Goat anti-mouse lgG was purchased from Cappel Laboratories (Malvern, PA, 
USA). Ham's F-12, Dulbecco's modified Eagle's minimum essential medium (DMEM) 
and foetal calf serum (FCS) were purchased from Highveld Biologicals (Kelvin, South 
Africa). LDL and lipoprotein-deficient serum (LPDS) were prepared from human 
plasma (Goldstein et al., 1983), and 11VLDL was prepared from the plasma of 
cholesterol-fed rabbits (Kovanen et al., 1981 ). These lipoproteins were iodinated by 
the iodine-monochloride method (Goldstein et al., 1983). Ca2+-free DMEM was 
purchased from Gibco (Life Technologies). Methionine-free and cysteine-free medium 
and TRAN[35S]methionine were obtained from ICN (Irvine, CA). Na[1
251] and the 
enhanced chemiluminescence immunoblotting kit were obtained from Amersham 
(Buckinghamshire, England). M13BM21, OTT, Endo-a-N-acetyl-galactosaminidase (0-
Glycanase, a trademark of Genzyme Corporation, Cambridge, MA, USA) (from 
Diplococcus pneumoniae), endoglycosidase H, as well as pronase (from Streptomyces 
griseus) was obtained from Boehringer Mannheim. Geneticin, N-ethyl maleimide 
(NEM), 2-deoxy-D-glucose, neuraminidase (from Clostridium perfringens), protein A-
sepharose and brefeldin A were obtained from Sigma. Brefeldin A was stored at -20°C 
as a 10 mg/ml stock solution in methanol. Ca2+ ionophore, A23187, was purchased 
from Calbiochem. 
2.1. Methods 
2.2.1. Cell culture 
Human skin fibroblasts were seeded (day 0) at 20000 cells per 35mm dish and 
incubated at 37°C in 2 ml of full medium (DMEM + 10% foetal calf serum + penicillin 
(60µg/ml) + streptomycin (100 µg/ml)). The medium was changed on day 2 and day 4. 
On day 6 the cells were washed once with Dulbecco's phosphate buffered saline and 
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then incubated for 24 hours in medium (DMEM + penicillin + streptomycin) containing 
5% LPDS, in order to up-regulate LDL receptor activity. Experiments were performed 
on day 7. 
The Chinese hamster ovary cell (CHO) line, TR-715, was a gift from Brown and 
Goldstein (Dallas, Texas). It is a stable line of ldlA7 cells (a mutant cell line lacking 
endogenous, functional LDL receptors) ((Kingsley and Krieger, 1984), which was 
transfected with a plasmid (pLDLR2) encoding the gene for the human LDL receptor 
under the control of a constitutive SV40 promoter (Davis et al., 1986a). Similar ldlA7 
CHO cell lines transfected with the FH Afrikaner-1 (Leitersdorf et al., 1989), FH 
Afrikaner-2 (Leitersdorf et al., 1989) and the FH Afrikaner-3 mutant LDL receptors 
(Graadt van Roggen et al., 1995) were constructed in the Van der Westhuyzen 
laboratory (Cape Town). LdlA7 CHO cells expressing mutant LDL receptors with 
cytoplasmic tail mutations (Stop792, Stop812 and Phe807Ala) were constructed by Ors 
Graadt van Roggen and Davies, also in the Van der Westhuyzen laboratory. Cells 
were seeded ( day 0) at 60 000 cells per 35mm dish (for pulse-chase experiments) or at 
160 000 cells per 60mm dish (for binding experiments) in full medium (Ham's F-12 + 
5% FCS + penicillin (60µg/ml) + streptomycin (100µg/ml)). The medium was changed 
on day 2 and experiments usually were performed on day 3. 
HepG2 cells were seeded (day 0) in 35mm dishes and incubated at 37°C in 2 ml of full 
medium (DMEM + 10% foetal calf serum). The medium was changed every second 
day and experiments were performed when cells were arranged in sinusoids which 
were not yet coalesced. The cells were washed once with Dulbecco's phosphate 
buffered saline and then incubated for 12 hours in DMEM containing 5% LPDS in order 
to up-regulate LDL receptor activity. 
2.2.2. Pulse-chase experiments 
The cell layers were washed once with phosphate-buffered saline and then incubated 
in methionine- and cysteine-free medium for 30 minutes, prior to being pulsed with 50-
1 OOµCi/ml TRAN[
35S]methionine for the indicated time periods. For the chase-
incubation, the cell layers were washed once with chase medium (DMEM containing 
5% LPDS and supplemented with 1 OOµM cycloheximide to ensure an abrupt 
termination of protein translation), and then incubated at 37°C for the indicated times in 
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fresh chase medium. OTT (SmM), BFA (O.OSµg/ml or Sµg/ml), A23187 (SµM), EDTA 
(10mM) or 2-deoxy-D-glucose (20mM) and sodium azide (10mM) were included either 
in the pulse- and/or chase-incubations, as indicated in the figure legends. To enable 
oxidative conditions to be re-established after OTT treatment, cells were washed twice 
with chase medium and then incubated for the indicated times in fresh chase medium. 
2.2.3. lmmunoprecipitation of TRAN[35S]methionine-labelled LDL receptors 
After the pulse or chase period, dishes were cooled to 4°C by washing twice with buffer 
A (150mM NaCL, 2mM CaCb, 10mM Hepes), and then lysed in buffer B (10mM Hepes, 
200mM NaCl, 2mM CaCb, 2.SmM MgCI, 1 mM PMSF, 0.1 mM leupeptin, 1 % Triton X-
100). 20mM NEM was included in both these solutions to alkyl ate reduced cysteine 
residues in order to prevent disulfide bond shuffling. All subsequent steps were carried 
out at 4°C. LDL receptor was immunoprecipitated from the post-nuclear supernatants 
(12 OOOg for 10 minutes) using a preformed immune complex as described by 
Tolleshaug et al. (Tolleshaug et al., 1982), or precipitated using protein A-sepharose. 
After incubating the post-nuclear supernatant with 6µg of lgG-C7 or lgG-HL 1 for 1 hour, 
15µ1 of protein A-sepharose was added for 1 hour. lmmunoprecipitates were washed 
three times with 1 OmM Tris pH 8.0: wash 1 contained 0.5% Chaps; wash 2 contained 
0.2% Nonidet P40 and SOOmM NaCl; wash 3 contained 0.2% Nonidet P40 and 0.1 % 
SOS. Detergents were removed in a single wash with buffer A lmmunoprecipitates 
were then solubilised in gel-loading buffer (10% glycerol, 2.4% SOS, 75mM Tris, 
1 OOmM OTT and 5% 2-mercaptoethanol), boiled for 3 minutes and then separated on 
7% SOS polyacrylamide gel electrophoresis with a 5% stack (Laemmli, 1970). For 
electrophoresis under non-reduced conditions, OTT and 2-mercaptoethanol were 
omitted from the gel-loading buffer. After fixing (10% methanol and 10% acetic acid), 
the gels were enhanced using sodium salicylate ((Chamberlain, 1979), dried and 
subjected to fluorography at -70°C using Kodak BioMax MR-1 or XAR-5 film. Typical 
exposure times ranged from 16-48 hours. 
2.2.4. Analysis of LDL receptor glycosylation 
2.2.4.1. Neuraminidase and 0-Glycanase treatment of the LDL receptor 
For treatment with neuraminidase, TRAN[35S]labelled, immunoprecipitated LDL 
receptor was resuspended in 50µ1 of a buffer containing 20mM sodium citrate, 20mM 
Tris-maleate (pH 6.0) and incubated for 18 hours at 20°C, in the absence or presence 
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of neuraminidase (50milliunits) (Davis et al., 1986a). Certain neuraminidase-treated 
samples were then treated with 4milliunits of 0-Glycanase for 24 hours at 20°C. After 
neuraminidase or 0-Glycanase treatment, 50µ1 of buffer containing 20% glycerol, 
125mM Tris-HCI (pH 6.8), 4.6% SOS and 0.2M dithiothreitol was added to each 
sample, followed by analysis by SOS polyacrylamide gel electrophoresis, as described 
above. 
2.2.4.2. Endoglycosidase H treatment of the LDL receptor 
lmmunoprecipitated [35S]methionine-labelled LDL receptor was resuspended in 50µ1 of 
a buffer containing 30mM sodium citrate(pH 5.5), 0.75mM SOS, 1 mM 
phenylmethylsulfonylfluoride and 1 mM OTT, and incubated for 18 hours at 20°C, in the 
absence or presence of Endoglycosidase H (10milliunits) (Lehrman et al., 1987b). 
After the incubation, 50µ1 of buffer containing 20% glycerol, 125mM Tris-HCI (pH 6.8), 
4.6% SOS and 0.2M dithiothreitol was added to each sample, followed by analysis by 
SOS polyacrylamide gel electrophoresis, as described above. 
2.2.5. Pronase treatment 
Pronase treatment of intact cells was performed as described previously (Tolleshaug et 
al., 1983). Cells were incubated at 37°C in the presence of pronase (1 Oµg/ml) for 20 
minutes. Cells were washed, the LDL receptors were solubilised and analysed as 
described above. 
2.2.6. Binding of 1251-labelled lipoproteins or 1251-labelled lgG-C7 at 4°C 
Semi-confluent 60mm dishes of Chinese hamster ovary cells were incubated in Ham's 
F-12/LPOS for 1 hour at 37°C to clear lipoproteins from LDL receptors at the cell 
surface. OTT (5mM or 50mM) was added for 5 minutes at 37°C and the dishes were 
cooled to 4°C by washing twice with phosphate-buffered saline containing 50mM NEM 
in order to quench the OTT and alkylate reduced cysteine residues. All subsequent 
steps were performed at 4°C. Surface binding assays with 1251-ligands (Fourie et al., 
1992) or 1251-lgG-C? antibody (Tolleshaug et al., 1982) were performed for 2 hours at 
the concentrations indicated in Table 1. Incubations were done in OMEM/LPOS 
buffered at pH 7.4 with 20mM Hepes. After the incubation the cells were washed 4 
times with phosphate-buffered saline containing 0.2% bovine serum albumin, followed 
by 3 washes with phosphate-buffered saline. Total surface-bound radioactivity was 
56 
measured after the cells were dissolved in 1 N NaOH. Specific values were determined 
by subtracting from the total activity the non-specific value obtained in the presence of 
an excess of unlabeled LDL (200µg/ml}, or lgG-C7 (50µg/ml) or r.iVLDL (1 OOµg/ml). 
2.2. 7 Lipoprotein and immunoblotting of LDL receptors 
Semi-confluent fibroblasts or CHO cells were cooled to 4°C by washing (50mM Hepes 
and 1 OOmM NaCl) and then scraped from 10cm dishes in buffer A (50mM Hepes, 
1 OOmM NaCl, 0.5mM leupeptin, 1 OmM NEM, 1 mM PMSF). Cells were collected by 
centrifugation (2min at 10 OOOg) and lysed over 20 min in 100µ1 buffer A containing 1 % 
Triton X-100. The post-nuclear supernatant (1 Omin at 10 OOOg) was adjusted to 1 % 
SOS and 10% glycerol, and subject to SOS polyacrylamide gel electrophoresis (5% 
stack and 7% separating gel) without boiling or the addition of reducing agents. 
Electrophoresed proteins were transferred onto a nitrocellulose membrane in a 
sandwich transfer apparatus submerged in 20mM Tris, 150mM glycine and 20% 
methanol (v/v). Transfer was performed overnight at 1 OOmA at 4°C. Immobilised 
protein was detected either with enhanced chemiluminescence using horseradish 
peroxidase-labelled antibodies (Amersham) or 
1251-labelled r.iVLDL or 1251-labelled 
antibodies. 
2.2.7.1. Detection using 1251-labelled antibodies 
The membrane was blocked by incubation in buffer B (50mM Tris, 80mM NaCl, 2mM 
CaCb and 0.05% Tween 20) containing 3% BSA for 1 hour at 37°C. After incubation 
with primary antibody, 5µg/ml lgG-C7 for the LDL receptor, or a 1 :2000 dilution of 
polyclonal rabbit serum against calnexin, in buffer B containing 3% BSA for 1 hour at 
20°C, the membrane was washed 3 times (15min each) with buffer B. The membrane 
was incubated in buffer B containing 3% BSA and 3x10
6cpm/ml 1251-labelled goat anti-
mouse antibody (LDL receptor) or 3x106cpm/ml 1251-labelled goat anti-rabbit antibody 
(calnexin) for 1 hour, and then washed 3 times (15min each) with buffer B. The dried 
membrane was exposed to Kodak Biomax film at -70°C and the position of the LDL 
receptor or calnexin was confirmed in relation to molecular weight markers. 
2.2.7.2. Detection of the LDL receptor using 
1251-labelled r.iVLDL 
The membrane was blocked in buffer B (50mM Tris, 80mM NaCl, 2mM CaCb and 
0.05% Tween 20) containing 3% BSA and 3% dried milk powder for 1 hour at 37°C. 
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The membrane was incubated in buffer B (with 3% BSA and 3% dried milk powder) 
containing 5µg/ml 1251-r!,VLDL for 1 hour, and then washed 4 times (1 rapid wash, 2 
washes of 15min and a final rapid wash) with buffer B containing 0.3% BSA and 0.3% 
dried milk powder. The dried membrane was exposed to Kodak Biomax film at -70°C 
and the position of the LDL receptor was confirmed in relation to molecular weight 
markers. 
2.2. 7.3. Detection of the LDL receptor using enhanced chemiluminescence 
The membrane (pure nitrocellulose, Amersham) was blocked in buffer C (20mM Tris, 
pH7.6, 137mM NaCl, 2mM CaC!i and 0.05% Tween 20) containing 5% dried milk 
powder for 1 hour at 20°C. The membrane was washed 5 times with buffer C 
containing 0.3% dried milk powder and then incubated with primary antibody (2µg/ml) 
for 1 hour at 20°C. The membrane was washed as before, and incubated with 
horseradish peroxidase-labelled sheep anti-mouse antibody at a 1: 1000 dilution for 1 
hour at 20°C. The membrane was washed as above, dried and then the horseradish 
peroxidase substrate was added as described in the protocol accompanying the 
enhanced chemiluminescence (ECL) immunoblotting kit. Light emission was detected 
with Kodak Biomax film after typical exposes ranging from 5 seconds to 15 minutes. 
2.2.8. lmmunoprecipitation of TRAN[35S]methionine-labelled calnexin 
This procedure was performed as described by Bergeron (Ou et al., 1993). After the 
pulse or chase period, dishes were cooled to 4°C by washing twice with buffer A 
(150mM NaCL, 2mM CaC!i, 1 OmM Hepes pH7.4), and then lysed in buffer B (50mM 
Hepes pH 7.5, 200mM NaCl, 2mM CaC!i, 2.5mM MgCI, 1 mM PMSF, 5µg/ml leupeptin, 
5µg/ml aprotinin and 2% chelate). 20mM NEM was included in both these solutions to 
alkylate reduced cysteine residues in order to prevent inappropriate disulfide bond 
linkage between calnexin and the LDL receptor. Lysates were centrifuged (12 OOOg for 
10 minutes) and the supernatants were retained. For immunoprecipitation under non-
denaturing conditions the supernatants were diluted by the addition of an equal volume 
of buffer B (without chelate) and were mixed (rotary shaker) with 3µ1 of anti-calnexin 
polyclonal antibody for 2 hours at 4°C. 20µ1 protein A-sepharose beads were added 
and mixed for 1 hour at 4°C. Protein A-sepharose beads were collected by 
centrifugation (12 OOOg for 30 seconds) and washed 4 times with 800µ1 of buffer B 
containing 0.5% chelate. For immunoprecipitation under denaturing conditions, lysates 
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were adjusted to 1 % SOS and heated at 90°C for 3 minutes. They were diluted by the 
addition of 20-volumes of buffer B containing 1 % Triton X-100 and immunoprecipitated 
with calnexin as described above. Sequential immunoprecipitations were initially done 
under non-denaturing conditions as described above. 100µ1 of buffer B with 1 % SOS 
(without cholate) was added to the protein A-sepharose beads after the 4th wash, and 
heated at 90°C for 3 minutes. Following centrifugation (12 OOOg for 30 seconds) the 
supernatant was diluted by the addition of 2ml of buffer B (without cholate) containing 
1 % Triton X-100. The second immunoprecipitation was performed using specific 
antibodies to proteins possibly associated to calnexin. The immunoprecipitated 
proteins were analysed by electrophoresis and fluorography. 
2.2.9. lmmunoblotting of calnexin 
CHO and HepG2 cells were collected, electrophoresed and transferred to a 
nitrocellulose membrane as described in section 2.2.7. The membrane was washed 
with buffer A (1 OmM Tris pH 8.5, 300mM NaCl and 0.05% Tween-20) for 30 minutes at 
20°C and then blocked in buffer A with 5% skim milk for 1 hour at 37°C. The membrane 
was incubated with the primary antibody (1:1500 dilution) in buffer A with 5% skim milk 
for 2 hours at 20°c. The membrane was washed 3 times (each for 10 minutes) in buffer 
A with 0.3% skim milk. 1251-labelled goat anti-rabbit lgG (1.5x10
6cpm/ml) was incubated 
with the membrane in buffer A with 5% skim milk for 1 hour at 20°C. 3 washes, each of 
30 minutes were performed with buffer A containing 0.3% skim milk. The dried 
membrane was exposed to Kodak Biomax film at -70°C. 
2.2.10. Construction of LDL receptors with cysteine residues substituted in the 5th 
binding repeat 
Standard molecular biology techniques were used to prepare and manipulate DNA for 
cloning (Ausubel et al., 1994 ). The mutagenesis reactions were performed in the 
bacteriophage, M13BM21, and required subcloning of cDNA fragments from the 
plasmid, pLDLR2, the vector containing the entire cDNA of the human LDL receptor. 2 
overlapping DNA fragments were used to construct the 6 mutants, each corresponding 
to the substitution of a single cysteine residue of the 5th binding repeat by alanine. 
The mutant LDL receptors were designated mutant 1-6, dependent on the cysteine 
residue mutated: mutant 1, Cys176Ala; mutant 2, Cys183Ala; mutant 3, Cys188Ala; 
mutant 4, Cys195Ala; mutant 5, Cys201Ala; mutant 6, Cys21 OAla. The substitution of 
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cysteine residues in mutants 1 and 2 were performed on a Hincll-EcoRI fragment 
(483bp) that was released from pLDLR2 and cloned directly into the polylinker of 
M13BM21. The substitutions of the cysteine residues in the other 4 mutants were 
performed on a Taql-EcoRI fragment (119bp) that was initially released as a 758bp 
Xbal-EcoRI fragment from pLDLR2, and then cleaved with Taql. The residual 639bp 
Xbal-Taql fragment was preserved for later re-assembly of pLDLR2 (see below). The 
restriction enzymes, Accl and EcoRI, were used to generate the cloning site for the 
Taql-EcoRI fragment in M13BM21; Taql could not be used as it has multiple cleavage 
sites in M13BM21. Oligonucleotide-directed mutagenesis was performed without 
phenotypic selection according to the method of Kunkel (Kunkel et al., 1987). A single 
strand bacteriophage template containing uracil was prepared from the culture 
supernatant of the CJ236 strain of Esherichia coli. Unlike the wild type bacteria (strain 
JM109) used in the transformation reactions, these bacteria tolerate the presence of 
uracil in DNA due to the absence of the enzymes uracil N-glycosylase and dUTPase 
(E. coli duf ungl An oligonucleotide 26 nucleotides in length was used to mutate 2 
nucleotides of the codon for cysteine to code for alanine. The entire cloned fragment 
was sequenced (dideoxy method) to confirm that mutagenesis was successful and that 
no other mutations were introduced. In order to reassemble the cDNA for mutants 1 
and 2, the mutated Hincll-EcoRI fragment (483bp) was released from M13BM21 and 
cloned directly into pLDLR2. For the other 4 mutants, the mutated Taql-EcoRI 
fragment (119bp) was introduced into pLDLR2 in a single-step ligation reaction 
together with the corresponding 639bp Xbal-Taql fragment (see above) in order to 
restore the 758bp Xbal-EcoRI fragment. For all 6 mutant constructs, the presence of 
the mutation in pLDLR2 was confirmed by subsequent subcloning of the 758bp Xbal-
EcoRI fragments into M13BM21 and resequencing. Concatamers were excluded by 
the demonstration that each of the enzymes used for the cloning steps successfully 
linearised pLDLR2 without the release of DNA fragments. 
2.2.11. Stable transfection of CHO cells 
The LDL receptor-deficient CHO line, ldlA7, was transfected with the mutant forms of 
the plasmid, pLDLR2 using the calcium phosphate precipitation method (Davis et al., 
1986a). The plasmid, pSV3-Neo, which contains the neomycin-resistance gene was 
co-transfected (1: 10) with the mutants forms of pLDLR2, and the antibiotic, geneticin 
(G418), was used to select for transfected cells. Geneticin was included in the medium 
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(?OOµg/ml) for approximately 3 weeks, during which time clones of surviving cells were 
isolated with cloning rings and expanded into cell lines. Subsequently, cells were 
further cloned by limiting dilution and LDL receptor expression was confirmed by 
immunoprecipitation. The established CHO cell lines expressing the mutant forms of 
the LDL receptor were maintained in cell culture in the same manner as TR-715, the 
cell line expressing the wild type LDL receptor, as described above. All experiments 
were repeated in mutant cell lines obtained from at least 2 independent transfection 
reactions. 
2.2.12. Scanning and printing of fluorograms and autoradiograms 
After fluorography or autoradiography using either Kodak XAR-5 or BioMax MR-1 film, 
the fluorograms and autoradiograms were scanned with a hand-held, 256 grey scale 
scanner (Logitech ScanMan 256) at a resolution of 100 dots per inch. The scanned 
image was edited using FotoTouch (Logitech) software: undesired regions were 
cropped from the scanned image and in certain instances, the order of the lanes was 
rearranged. The brightness, contrast and tonal curve (linearity of response) of the 
scanned image were not altered. The image was exported in tagged image file format 
to a word processor (Microsoft Word, version 6) and labelled. The final image was 
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3.1. Introduction 
The movement of proteins from one membrane compartment to another in the secretory 
pathway is mediated by the budding (formation) and fusion of transport vesicles. 
These processes are regulated by proteins which coat the cytoplasmic face of the 
membranes: budding involves the assembly of the protein coat from cytoplasmic 
components, and fusion requires the coat to be detached from the membranes of the 
transport vesicles (3155, 3019). Assembly of the coat is initiated when the small 
guanine nucleotide-binding protein, ADP-ribosylation factor (ARF), is triggered to bind 
the membrane by binding GTP in exchange for GDP (Donaldson et al., 1992; Palmer et 
al., 1993). The GDP-form is unable to bind the membrane: indeed, the cycle is further 
regulated as GTP-hydrolysis triggers uncoating (Tanigawa et al., 1993). The 
mechanism of regulation of the coat was identified through the effects of brefeldin A, an 
isoprenoid antibiotic derived from fungi, which prevents nucleotide exchange by ARF 
and thus prevents the attachment of the coat proteins onto the membrane (3046, 3011 ). 
In the presence of brefeldin A, vesicles do not form; instead, tubules form and extend 
from the Golgi, along microtubules, to fuse with the ER and redistributes the contents of 
the Golgi into the ER (Klausner et al., 1992; Lippincott-Schwartz et al. , 1990; 
Lippincott-Schwartz et al., 1989). In addition, protein transport from this hybrid 
compartment is prevented. 
The effects of brefeldin A are not limited to the secretory pathway. The clathrin coat of 
vesicles involved in endocytosis and in transport from the trans-Golgi network (TGN), 
are also displaced from the membranes by brefeldin A; an elaborate tubular network 
forms and fuses the early endosomes with the TGN (Lippincott-Schwartz et al. , 1991 ; 
Hunziker et al., 1992). Brefeldin A-treatment thus results in the formation of 2 separate 
hybrid organelles, the ER/Golgi and the TGN/endosomal pathway. 
Protein glycosylation in the secretory pathway is catalysed by multiple enzymes in the 
various compartments of the endoplasmic reticulum and the Golgi apparatus(Kornfeld 
and Kornfeld, 1985; Dunphy and Rothman, 1985). The step-wise processing of sugar 
chains also has been implicated in the quality control mechanism that retains partially-
folded proteins within the ER (Hammond et al., 1994 ): for example, proteins associate 
with calnexin (an ER chaperone) depending on the extent of processing of their N-
linked chains, while the processing enzyme, UDP-glucose:glycoprotein 
glucosyltransferase, is specific for denatured or unfolded substrates (Sousa et al. , 
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1992). Thus, folding, glycosylation and retention/transport are inter-related. While 
ordered glycosylation generally has been thought to be dependent on the vectorial 
movement of proteins through the compartments of the pathway, the role of 
compartmentalisation in these events has not been defined clearly (Mellman and 
Simons, 1992). In fact, recent evidence suggests that due to vesicular traffic and 
tubular connections, the compartments of the Golgi may not be as functionally, nor 
structurally distinct as previously thought (Mellman and Simons, 1992; Orci et al., 
1991 ). The finding that brefeldin A causes the appearance of active, Golgi-derived 
glycosylation enzymes in the ER (Fujiwara et al., 1988; Lippincott-Schwartz et al., 
1989; Ulmer and Palade, 1989), provides a tool to question the role of compartments in 
glycosylation, and the influence of glycosylation on the folding and transport of the LDL 
receptor. 
The influence brefeldin A on the processing of the LDL receptor is described in this 
section. 
3.2. Results 
3.2.1 . LDL receptor glycosylation in the presence of brefeldin A 
After the addition of [35S]methionine, biosynthetically-labelled LDL receptors are 
processed through glycosylation, from an ER precursor form (apparent molecular mass 
of 120 kDa) to a cell-surface, mature form (apparent molecular mass 160 kDa) 
(Tolleshaug et al. , 1983; Beisiegel et al. , 1981) (Figure 3.1 , lane 9). The absence of 
processing-intermediates between the precursor and the mature forms of the LDL 
receptor is in line with rapid transport to the cell surface, once the LDL receptors had 
exited from the ER. The absence of these intermediates also indicated that the Golgi 
apparatus contained a small pool of LDL receptors. 
The effect of brefeldin A on the processing of LDL receptors was determined (Figure 
3.1 ). Cells were treated with Brefeldin A (O.OSµg/ml or Sµg/ml) during the labelling 
period, and processing was monitored for 7 hours in the continued presence of 
brefeldin A. Under these circumstances, neither the 120 kDa precursor, nor the 160 
kDa mature receptor were detected (Figure 3.1, lanes 1 and 2). Instead, a range of 
heterogeneous intermediates were observed (lanes 1-6), which were reproducibly 
distinct, at the earliest (lanes 1 and 2) or latest time-points (lanes 7 and 8), from the 
normal precursor and mature bands, respectively (lane 9). The observation of the 
range of processing-intermediates indicated a general slowing of all stages of 
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processing in the fused ER/Golgi compartment. The effects of the different doses of 
brefeldin A was noted: at each time of chase (less than 7 hours), processing at the high 
brefeldin A dose (Sµg/ml)(lanes 2, 4 and 6) was more extensive than at the lower one 
(O.OSµg/ml)(lanes 1, 3 and 5). At the lower dose, LDL receptors were apparently 
processed through the same intermediates as at the higher dose, but at a reduced rate. 
This somewhat surprising result suggests that the rate of brefeldin A-induced 
redistribution of Golgi enzymes to the ER was dose-dependent in the concentration 
range tested, while the block in secretion from the ER was not. However, we were not 
able to find a dose of brefeldin A which dissociated these separate pathways - no 
doses was identified which gave an unmodified precursor form alone, which would 
have indicated a block to transport without redistribution of the Golgi enzymes into the 
ER. 
The nature of the sugars added to the LDL receptor in the presence of brefeldin A were 
assessed using glycosidase enzymes. Much of the difference in apparent molecular 
mass between the precursor and mature forms of the LDL receptor is accounted for by 
the addition (in the trans-Golgi) of galactose and sialic acid sugars to the 0-linked 
chains (Cummings et al., 1983). As expected, the precursor was not affected by 
neuraminidase-treatment which removed sialic acids from the mature LDL receptor and 
altered its molecular mass (Figure 3.2, lanes 1 and 2). By contrast, all the 
intermediates synthesised in the presence of brefeldin A were sialylated, as assessed 
by neuraminidase, even at the earliest time-points after the addition of brefeldin A. 
(lanes 3-8). Neuraminidase-treatment also indicated that LDL receptors were 
sialylated heterogeneously shortly after the addition of brefeldin A (lanes 3 to 6) - the 
heterogeneity in gel-mobility was largely abolished when the sialic acids were removed. 
During the chase in brefeldin A, sugars other than sialic acids were added to the LDL 
receptor and progressively retarded the gel-mobility of the desialylated forms at the 
different chase times (lanes 4, 6 and 8). Much of this chain extension probably is due 
to the addition of galactose residues to the 0-linked chains, because the overall 
contribution of the N-linked chains to the mobility-shifts were small (assessed by 
treatment with tunicamycin) and similar in the presence or absence of brefeldin A 
(Figure 3.3). The N-linked chains were processed in the presence of brefeldin A, and 
changed from sensitivity to resistance to endoglycosidase H within a chase period of 1 
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-120 kDa 
BFA(1,1g/ml) .06 I 6 .06 I 6 .06 I 6 .06 I 6 0 
Chaae(h) 0 1 2 .6 7 0 
Figure 3.1 The effect of brefeldin A on the post-translational processing of the LDL 
receptor. 
Fibroblasts were labelled with [35S]methionine for 45 minutes, and chased in the 
presence of unlabelled methionine for the indicated times. Brefeldin A (0,05 µg/ml or 5 
µg/ml) was present at the indicated concentrations during both the pulse and chase 
periods. LDL receptors were immunoprecipitated using a preformed immune-complex 
with lgG-C7, followed by analysis by 7% SOS polyacrylamide gel electrophoresis and 
fluorography. The positions of the 120 kDa precursor and the 160 kDa mature forms of 
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Figure 3.2 The effect of neuraminidase on LDL receptors synthesised and processed 
in the presence of brefeldin A. 
Fibroblasts were labelled with [35S]methionine for 45 minutes and chased, where 
indicated, in the presence of unlabelled methionine. Brefeldin A (5µg/ml) was present, 
where indicated, during the pulse and chase periods. LDL receptors were 
immunoprecipitated with lgG-C7, treated with or without neuramfnidase (NMD) for 18 
hours at room temperature, followed by analysis by 7% SOS polyacrylamide gel 
electrophoresis and fluorography. The positions of the 120 kDa precursor and the 160 
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Figure 3.3 Effects of tunicamycin on the LDL receptor synthesised in the presence of 
brefeldin A. 
Fibroblasts were preincubated in the presence of 5µg/ml tunicamycin (lanes 2 and 4) 
for 3 hours prior to being labelled with [35S]methionine for 45 minutes and chased for 5 
hours (lanes 3 and 4). Tunicamycin (5µg/ml) and brefeldin A (5µg/ml) were present in 
the pulse and chase medium, as indicated. LDL receptors were immunoprecipitated 
with lgG-C7 and analysed by SOS polyacrylamide gel electrophoresis and fluorography. 
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hour (results not shown). The maximal extent of processing in the presence of 
brefeldin A was observed after a chase of about 4 hours; this form of the LDL receptor, 
designated the pseudomature form, was slightly, but reproducibly smaller than the 
mature form of 160 kDa, and did not attain that expected molecular mass even after 9 
hours within the ER-Golgi compartment (see Figure 3.1, compare lanes 8 and 9, or 
Figure 3.4, lanes 1 and 2). This interesting finding suggested that the oligosaccharide 
chains formed in the presence of brefeldin A were either shorter than normal or fewer in 
number. An altered protein conformation (in an SOS micelle) was considered less 
likely to be the cause of the altered gel-mobility, since the LDL receptor was boiled and 
reduced prior to electrophoresis. Sialic acids also did not seem to be involved as the 
cause of the altered mobility, as the desialylated form of the brefeldin A-treated LDL 
receptors (Figure 3.4, lane 4) were smaller than the desialylated, normal LDL receptors 
(lane 3). N-linked glycosylation also did not seem to be involved, because, as 
described above, the effect of tunicamycin was similar in the presence or absence of 
brefeldin A 0-linked glycosylation was assessed further with 0-Glycanase: once the 
sialic acids have been removed with neuraminidase, 0-Glycanase is known to cleave 
sugars with the disaccharide structure (Umemoto et al., 1977): 
serine/threonine-N-acetyl-galactosamine--galactose 
0-Glycanase treatment caused substantial band-shifts to the desialylated LDL 
receptors and abolished the difference between the normal and the brefeldin A-treated 
LDL receptors (Figure 3.4, lanes 3-6). The most likely explanation was that fewer 0-
linked carbohydrate chains were added to the LDL receptors synthesised in the 
presence of brefeldin A This finding confirmed that a glycosylation defect, and not a 
proteolytic or other post-translational processing event, accounted for their enhanced 
mobility. In summary, the effect of brefeldin A was to retard the overall rate of 
glycosylation of the LDL receptor which made apparent the processing intermediates. 
Sialic acid residues were added to the 0-linked chains of the LDL receptor shortly after 
its synthesis and may have contributed to the addition of fewer than normal 0-linked 
chains. The N-linked glycosylation was relatively unaffected. 
3.2.2. Reversibility of the effects of brefeldin A 
The effects of brefeldin A on the morphology of the cell are reversible. Therefore, the 
processing of the LDL receptor was assessed after cells were labelled in the presence 
of brefeldin A, washed and then chased for a 4 hour period without brefeldin A (Figure 
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3.5). During this period in the absence of brefeldin A, the LDL receptor failed to attain 
the apparent molecular mass of the normal mature 160 kDa form (lane 2), and did not 
process beyond the pseudomature form seen in the continued presence of brefeldin A 
(lane 3). The same result was obtained when the chase period in the absence of 
brefeldin A was extended to 12 hours (data not shown). In these experiments, the 
washout of brefeldin A was complete, since the synthesis, as well as the glycosylation 
and the transport of newly-synthesised LDL receptors, resumed within 30 minutes after 
brefeldin A removal (data not shown). The lack of reversibil ity of the glycosylation 
-defect of the LDL receptor in the presence of brefeldin A was unexpected: previous 
studies have shown that brefeldin A does not redistribute the TGN to the ER and thus 
causes incomplete chain processing (Chege and Pfeffer, 1990) with the absence of N-
linked sialylation (Sampath et al. , 1992; Spiro et al., 1991; Chege and Pfeffer, 1990; 
Shite et al., 1990; Doms et al., 1989). In these instances, processing was completed 
when brefeldin A was removed (Sampath et al., 1992; Ulmer and Palade, 1989; Spiro 
et al., 1991) and transport through the TGN was restored. By contrast, for the LDL 
receptor, the glycosylation in the presence of brefeldin A was not simply interrupted, 
rather, together with the 0-Glycanase result, it was demonstrated that the 0-linked 
glycosylation was irreversibly altered. 
3.2.3. The effect of brefeldin A on the function of the LDL receptor 
The nature of the glycosylation defect was not assessed more definitively. The 
following functional properties of the brefeldin A-treated LDL receptors were 
investigated: 1) LDL receptor transport to the cell surface; 2) LDL receptor stability and 
3) ligand binding by the LDL receptor. 
3.2.3.1. LDL receptor transport to the cell surface 
After the LDL receptors were synthesised in the presence of brefeldin A, brefeldin A 
was removed and the LDL receptors' ability to be transported to the cell surface was 
assessed. The assay used was the ability of pronase (added to the medium) to cleave 
the molecules on the cell surface. The rationale was that in the continued presence of 
brefeldin A, protein transport through the secretory pathway would be blocked, and the 
LDL receptors would be resistant to pronase. Once brefeldin A was removed, transport 
through the secretory pathway would be restored and pronase would cleave the LDL 























Figure 3.4 The effect of 0-glycanase on LDL receptors synthesised and 
processed in the presence of brefeldin A. 
Fibroblasts were labelled with [35S]methionine for 45 minutes and chased (lanes 2, 
4 and 6) in the presence of unlabelled methionine. Brefeldin A (5µg/ml) was 
present during the pulse and chase periods in lanes 2, 4 and 6. LDL receptors 
were immunoprecipitated with lgG-C7, treated with neuraminidase (NMD) for 18 
hours at 20°C (lanes 3-6) , followed by treatment with 0-Glycanase (lanes 5 and 6) 
for 24 hours at 20°C. Samples were then analysed by 7% SOS polyacrylamide gel 
electrophoresis and fluorography. The positions of the 120 kDa precursor and the 
160 kDa mature forms of the LDL receptor are shown. The 120 kDa precursor, 
detected in the absence of brefeldin A, facilitates a comparison of band positions 
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Figure 3.5 The effect of removal of brefeldin A on the post-translational processing of 
LDL receptors. 
Fibroblasts were labelled with [35S]methionine for 45 minutes and chased in the 
presence of unlabeled methionine for 60 minutes (labelled as pulse). Brefeldin A 
(0,05µg/ml) was present where indicated. The cells were then washed four times and 
chased for a further 4 hours (lanes 2 and 3) in the continued presence (lane 3) or 
absence of brefeldin A (lane 2). LDL receptors were immunoprecipitated with lgG-C7 
and analysed by 7% SOS polyacrylamide gel electrophoresis and fluorography. The 




pronase would enter the cell by fluid phase endocytosis as the treatment was 
performed over 20 minutes at 37°C. In intact cells, the LDL receptors synthesised in 
the continued presence of brefeldin A were unaffected by pronase (Figure 3.6, lanes 1-
4 ), indicating that they were located intracellularly. As expected, the endocytosed 
pronase was unable to access the ER-Golgi (Lippincott-Schwartz et al., 1991; Hunziker 
et al., 1992). In contrast, the LDL receptors became progressively more sensitive to 
pronase during the chase following removal of brefeldin A (Figure 3.6, lanes 3-10.) . 
Within one hour of the removal of brefeldin A, more than half of the labelled receptors 
were accessible to pronase which indicated their transport to the cell surface or into the 
endocytic pathway (Figure 3.6, lanes 5 and 6); by 2 hours, virtually all the labelled LDL 
receptors were degraded. Thus, removal of brefeldin A did affect the transport of LDL 
receptors and enabled them to reach the cell surface (Figure 3.6), though without 
correcting their aberrant glycosylation (Figure 3.5). 
3.2.3.2 LDL receptor stability 
Abnormal protein structure is often associated with enhanced protein breakdown 
[3414]. In the case of secretory proteins such as LDL receptors, certain mutant 
proteins are retained and degraded in the ER, while others reach the cell surface but 
are unstable (Hobbs et al., 1992; Hobbs et al., 1990) . LDL receptors lacking 0-linked 
sugars were previously shown to be rapidly degraded on the cell surface (Davis et al., 
1986a). As shown in Figure 3.5, the abnormally glycosylated LDL receptors 
synthesised in the presence of brefeldin A, appeared to be stable in the brefeldin A-
fused ER/Golgi compartment and were efficiently transported to the cell surface 
following brefeldin A removal. Thus, no obvious instability was apparent, though these 
results should be interpreted with caution as it is difficult to know what the "normal" rate 
of turnover would be in the ER: the apparent turnover of the precursor is due to 
processing to the mature form of the LDL receptor which seems to be quantitative 
(without degradation). It also probably is not appropriate to compare the stability of the 
LDL receptor in the ER/Golgi (in the presence of brefeldin A) to that of the mature, 
endocytic LDL receptor (in the absence of brefeldin A) as they are in different locations 
within the cell. A better assessment of the protein stability of the brefeldin A-altered 
LDL receptors was made once brefeldin A was removed and transport to the cell 
surface was restored. During the early phase (less than 2 hours) after removal of 
brefeldin A, the brefeldin A-altered LDL receptors were not unstable while en route to 
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the cell surface (Figure 3. 7 A). Similarly, once on the cell surface (Figure 3. 78), the 
brefeldin A-altered LDL receptors were not more unstable than the receptors which had 
. 
not been treated with BFA. Thus, the subtle structural changes in the brefeldin A-
affected LDL receptors did not appear to cause the protein to be unstable. 
3.2.3.3. Ligand binding by the LDL receptor 
In order to determine the ligand binding ability of the LDL receptor synthesised in the 
presence of brefeldin A, it was necessary to exclude the binding activity of the pre-
existing, normal LDL receptor population. When cells were pre-incubated for 12 hours 
in the presence of brefeldin A, LDL receptor synthesis was severely impaired (results 
not shown). Thus it was not possible to use a long pre-incubation to replace the total 
LDL receptor pool with brefeldin A-modified LDL receptors, given that normal LDL 
receptors are removed with a half-time of about 12 hours (Casciola et al. , 1988). 
Similarly, the alternative strategy of first removing the pre-existing LDL receptors 
population with a protease, prior to re-populating the cell with brefeldin A-modified LDL 
receptors, was doomed by the limited period during which cells tolerated brefeldin A-
treatment. 
Ligand binding to LDL receptors immobilised on nitrocellulose membranes (ligand blot) 
also was assessed (Figure 3.8). After a 12 hour incubation in the presence of brefeldin 
A, pronase was added which could not access the intracellular, brefeldin A-modified 
LDL receptors, while the pre-existing, normal LDL receptors were cleaved at the cell 
surface (and in endosomes). The use of pronase was similar to the use described 
above to assay for LDL receptor transport to the cell surface (section 3.2.3.1.) After 
electrophoresis and protein transfer to nitrocellulose membranes, lgG-C7 and BVLDL 
was used to detect the LDL receptor. As expected, the pronase treatment abolished 
the signal corresponding to the normal, mature LDL receptor at the cell 
surface/endocytic pathway (compare lanes 1 and 2; or lanes 5 and 6). Unexpectedly, 
after pronase treatment, 11VLDL did detect a heterogeneous population of LDL 
receptors (lane 6) with a mobility faster than the mature LDL receptor (lane 5). These 
possibly represented partially-degraded LDL receptor, though they were not detected 
by lgG-C7 (lane 2), (blot was exposed longer -not shown). This difference in detection 
by BVLDL and lgG-C7 possibly was explained by pronase having cleaved the lgG-C7 
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Figure 3.6 The effect of brefeldin A and its removal on the transport of the LDL 
receptor to the cell surface. 
Fibroblasts were labelled with [35S]methionine for 45 minutes and chased in the 
presence of unlabelled methionine for 60 minutes (labelled as pulse), in the presence 
of brefeldin A (0,05 µg/ml). The cells were then washed four times and chased, for the 
indicated time periods, in the continued presence or absence of brefeldin A. Cells were 
then incubated at 37°C for 20 minutes in the presence or absence of pronase. LDL 
receptors were immunoprecipitated with lgG-C? and analysed by 7% SOS 
polyacrylamide gel electrophoresis and fluorography. The positions of the 120 kDa 
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Figure 3.7 Stability of the LOL receptor after removal of brefeldin A. 
Panel A: Fibroblasts were labelled with [35S]methionine for 1 hour and chased for 45 
minutes in the presence of 0.05µg/ml brefeldin A. Cells were washed 4 times and 
chased for the indicated times in medium without brefeldin A. LOL receptors were 
immunoprecipitated with lgG-C7 and analysed by SOS polyacrylamide gel 
electrophoresis and fluorography. The results of duplicate dishes from a single 
experiment are shown. 
Panel B: Fibroblasts were labelled with [35S]methionine for 1 hour and chased for 45 
minutes in the presence (lanes 4-8) or absence (lanes 1-3) of 0.05µg/ml brefeldin A. 
Cells were washed 4 times and chased for a further 2 hours without brefeldin A to 
enable the labelled LOL receptors to reach the cell surface and equilibrate in the 
recycling endocytic pathway. Cells were then chased for the indicated times in medium 
without brefeldin A. LOL receptors were immunoprecipitated with lgG-C7 and analysed 
by SOS polyacrylamide gel electrophoresis and fluorography. 
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Figure 3.8 lgG-C7 and r.iVLDL blotting of brefeldin A-treated LDL receptors 
immobilised on nitrocellulose membranes 
Fibroblasts were preincubated with brefeldin A (5µg/ml) for 12 hours and then 
treated with pronase at 37°C for 20 minutes, as described in section 2.2.5. Cells 
were lysed, proteins were subject to SOS polyacrylamide gel electrophoresis under 
non-reduced conditions and transferred to nitrocellulose membranes, as described 
in section 2.2.7. The LDL receptor was detected with either lgG-C7 (5µg/ml) and 
1251-labelled goat anti-mouse (3x10
6cpm/ml) (lanes 1-4) or 1251-labelled r.iVLDL 
(5µg/ml) (lanes 5-8) (described in sections 2.2.7.1 and 2.2.7.2). The specific 




receptor able to bind BVLDL. 
Disappointingly, after brefeldin A preincubation, pronase removed the total signal 
corresponding to the mature LDL receptor (detected by lgG-C?) (lanes 3 and 4). The 
expected intracellular pool of LDL receptors that were synthesised in the presence of 
brefeldin A were not detected after pronase treatment. This could be accounted for by 
impaired LDL receptor synthesis during the preincubation with brefeldin A (see above). 
This, together with the pronase-induced heterogeneous LDL receptor forms (lanes 6 
and 8) prevented an interpretation of the BVLDL blot of the brefeldin A-treated LDL 
receptor. 
An indirect assay to determine LDL receptor binding activity took advantage of the 
observation that NH4CI prevents the recycling of LDL receptors in a ligand-dependent 
manner (Grant et al., 1990). In the endosome, the acid-induced dissociation of the LDL 
receptor from ligand is neutralised by NH4CI, which traps the LDL receptor within the 
cell and causes its rapid degradation. Those LDL receptors which were internalised 
while unoccupied by ligand, were not trapped and recycled normally: trapping (and 
degradation) was ligand-dependent (Figure 3.9, lanes 1 and 2). The ability of NH4CI 
and ligand to trap and degrade LDL receptors that were synthesised in the presence or 
the absence of brefeldin A, was determined (Figure 3.9). The hypothesis being that 
brefeldin A-treated LDL receptors would have an enhanced rate of degradation only if 
able to bind ligand. The results indicated that as for the normal LDL receptors (lanes 
2-4), ligand did enhance the rate of degradation of brefeldin A-treated LDL receptors in 
the presence of NH4CI, suggesting that they were able to bind ligand (lanes 6-8). 
However, a major weakness in this experiment was the realisation that ligand bound to 
a normal LDL receptor possibly could trap other LDL receptors of an oligomeric 
partnership, which could include brefeldin A-treated LDL receptors which were 
unoccupied by ligand. Thus trapping (and degradation) of brefeldin A-treated LDL 
receptors might not necessarily indicate their ability to bind ligand. This limitation 
assumes the formation of mixed oligomers composed of normal and brefeldin A-
modified LDL receptors, which has not been verified. Such mixed oligomers would 
have to have been assembled at the cell surface or within the endocytic pathway, since 
the monomers would have been synthesised (in the ER) at different times. It is not 
known whether the members of an oligomeric group are able to be shuffled at the cell 
surface or within the endocytic pathway. 
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As a result of these difficulties in assessing the functional consequence(s) to the LDL 
receptor of the glycosylation defects induced by brefeldin A-treatment, more extensive 
sugar analysis was not performed to precisely characterise the altered sugar chain 
structure. 
The partially processed sugar chains generated in the presence of brefeldin A were 
used in section 4.2.8 to assess the influence of glycosylation on the folding and the 
disulphide bond formation of the LDL receptor. 
3.3. Discussion 
There are several potential causes of the altered glycosylation of LDL receptors in the 
presence of brefeldin A First, the TGN does not redistribute to the ER/Golgi 
compartment in the presence of brefeldin A, and therefore not all glycosyltransferases 
would be present in the fused ER/Golgi compartment (Lippincott-Schwartz et al., 1989; 
Chege and Pfeffer, 1990; Lippincott-Schwartz et al., 1991; Wood et al., 1991; Bosshart 
et al., 1991 ). Brefeldin A has been shown to give rise to incomplete N-linked 
oligosaccharide chains in other proteins, an effect that is reported to be reversible 
(Sampath et al., 1992). In the case of LDL receptors, abnormal processing involves 0-
linked carbohydrates. In contrast to N-linked glycosylation, all steps of normal, 0-
linked processing are thought to be possible in the fused ER/Golgi compartment found 
in the presence of brefeldin A (Chege and Pfeffer, 1990; Shite et al., 1990; Cummings 
et al., 1983; Lippincott-Schwartz et al., 1990). Indeed, the presence of N-
acetylgalactosamine, galactose and sialic acid residues in the 0-linked sugars of the 
LDL receptor indicated that the relevant glycosyltransferases were present in the fused 
ER/Golgi. Despite this, the 0-linked glycosylation of the LDL receptor is here shown to 
be abnormal under such conditions. 
A second general cause for abnormal glycosylation might be that altered conditions 
within the fused ER/Golgi compartment may affect enzyme specificities or substrate 
availability in such a way as to change the structure or numbers of oligosaccharide 
chains. Competition between processing enzymes normally found in separate 
compartments might also be a factor. Altered conditions such as pH, ionic strength and 
possibly geometric differences might influence enzyme specificities (Griffiths et al., 
1984; Zizi et al., 1991 ). The same conditions might affect the folding and conformation 
of LDL receptor processing-intermediates. Another feature, the prolonged residence 
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Figure 3.9 Incubation of the brefeldin A-treated LDL receptor with LDL and NH4CI 
Fibroblasts were labelled with [35S]methionine for 90 minutes in the presence (lanes 5-
8) or absence of 5µg/ml brefeldin A (lanes 1-4). Cells were washed 4 times and chased 
for 3 hours to enable the labelled LDL receptors to reach the cell surface and 
equilibrate in the recycling endocytic pathway. Cells were incubated at 37°C for a 
further 4 hours in the presence of 5µg/ml (lanes 3 and 7) or 40 µg/ml LDL (lanes 4 and 
8) and 1 OmM NH4CI (lanes 2-4 and 6-8). LDL receptors were immunoprecipitated with 
lgG-C7 and analysed by SOS polyacrylamide gel electrophoresis and fluorography. 
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time of LDL receptors within the fused ER/Golgi compartment might also influence their 
folding and, in turn, their glycosylation. In this regard, ribophorins, which normally do 
not contain 0-linked chains, are 0-glycosylated in the presence of brefeldin A (lvessa 
et al., 1992). Interestingly, the ribophorins are transiently accessible to the 
glycosyltransferases in the presence of brefeldin A, possibly as a consequence of a 
conformational change during their maturation. In the presence of brefeldin A, even 
the earliest LDL receptor intermediates were found to be sialylated, and such early 
sialylation may have affected subsequent folding and processing. One hypothesis is 
that in the presence of brefeldin A, premature sialylation prevents (by conformational 
hindrance) certain serine or threonine residues of the LDL receptor from serving as 
substrates for N-acetylgalactosamine-transferase. This could result in the addition of 
fewer 0-linked oligosaccharide chains to the LDL receptor than in the absence of 
brefeldin A. 
In summary, fusion of the ER and Golgi compartments, by brefeldin A, caused the 
slowed and the abnormal glycosylation of the LDL receptor. These results indicate that 
one of the most compelling structural features of the secretory pathway - the presence 
of discrete compartments - may indeed have a functional role. 
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4.1 . Introduction 
In the cell, secretory and membrane proteins fold and form disulfide bonds in the 
endoplasmic reticulum (ER). In this compartment many factors have the potential to 
influence the folding process. Topologically, the ER is equivalent to the extracellular 
space with which it shares millimolar levels of Ca2+ compared to the micromolar levels 
found in the cytosol. The redox enzymes and the oxidising milieu of the ER promote 
the formation of disulfide bonds (Hwang et al., 1992). Post-translational modifications 
such as glycosylation are initiated in the ER and influence the folding of certain 
proteins (Helenius, 1994). Proteins may begin to fold as they enter the ER and before 
translation completes the elongation of the nascent chain (Chen et al., 1995). 
Chaperone proteins are present at high concentrations and facilitate productive folding 
reactions while preventing the transport of partially folded and malfolded proteins from 
the ER (Gething and Sambrook, 1992). The regulated transport ensures that migrant 
proteins are retained in this specialised folding environment until their folding is 
complete. 
In the present chapter, requirements for the folding of the wild type LDL receptor are 
examined. The folding of the LDL receptor has been reviewed in the introductory 
chapter (section 1.8.2). The LDL receptor contains 63 cysteine residues and forms 30 
disulfide bonds during its folding in the ER. Disulfide bonds cross-link the 7 cysteine-
rich repeats of the ligand binding domain and the 3 cysteine-rich repeats in the EGF 
precursor homology domain. The reducing agent, OTT, has been used to study protein 
folding in living cells (Alberini et al., 1990; Braakman et al., 1992a). OTT-treatment 
reduces the disulfide bonds of newly synthesised proteins without disrupting other 
critical actions of the secretory pathway (Lodish and Kong, 1993; Tatu et al., 1993; 
Opstelten et al., 1993; Jamsa et al., 1994; Losch and Koch-Brandt, 1995). After DTT-
treatment, proteins reform disulfide bonds as oxidising conditions are re-established in 
the ER. 
The ability of OTT to reduce the disulfide bonds of the precursor and the mature forms 
of the LDL receptor were compared both in intact cells and in vitro. This assay 
(sensitivity to reduction by OTT) was used to assess the folding of the precursor form of 
the LDL receptor. The relationship between the formation of disulfide bonds and LDL 
receptor translocation into the ER was determined. Ca2+ and ATP were depleted in the 
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ER of intact cells, and their effects on the structure of the LDL receptor were 
determined. The effect of LDL receptor glycosylation of the formation of disulfide 
bonds was determined. The relationship between the folding of the LDL receptor and 
its transport from the ER was assessed. 
4.2. Results 
4.2.1. LDL receptor precursor was sensitive to OTT in the ER 
The disulfide bonds of the human LDL receptor were studied in Chinese hamster ovary 
cells. Cells were biosynthetically-labelled with [35S]methionine, LDL receptors were 
isolated by immunoprecipitation and then analysed by electrophoresis under reduced 
and non-reduced conditions (Figure 4.1 ). The difference in the electrophoretic 
mobilities of the LDL receptor under reducing or non-reducing conditions demonstrates, 
as previously shown (Tolleshaug et al., 1982; Beisiegel et al., 1982; Schneider et al., 
1982; Daniel et al. , 1983; Yamamoto et al., 1984), that both the precursor and mature 
forms are extensively disulfide-bonded and that this bonding contributes to their folding 
into a compact structure which migrated further into the gel (Figure 4.1, compare lanes 
1 and 4). The earliest precursor form that was identified (5 to 15 minutes after the 
addition of [35S]methionine) had formed extensive disulfide bonds (results not shown). 
OTT treatment of cells (5mM for 5 minutes) caused extensive reduction of disulfide 
bonds of the precursor LDL receptor as witnessed by the mobility shifts. The precursor 
from OTT-treated cells exhibited a mobility on non-reducing gels (lane 3, arrow) that 
was similar to the fully-reduced precursor (lane 1 ). The precursor from treated cells 
had a slightly altered mobility on reducing gels (Figure 4.1, lanes 1 and 2; Figure 4.2, 
lanes 1 and 3). This altered mobility (detected under reducing electrophoretic 
conditions) was apparent after EndoH-treatment, indicating that N-linked sugar chains 
were not involved (Figure 4.2, lanes 3 and 4). This altered mobility also was induced 
by OTT treatment at 4°C and was not altered by the inclusion of 4M urea in the gel 
application buffer (results not shown). When OTT was removed, and the cells were 
incubated in the presence of fresh medium for 10 minutes, the OTT-treated LDL 
receptor regained the wild type LDL receptor mobility (see below, section 4.2.5). 
Together, these results indicate an additional OTT-induced covalent alteration (apart 




on (mM) o 
R NR 
2 3 4 





5 6 7 





Figure 4.1 Reduction of the disulfide bonds of the LOL receptor in intact cells and 
in vitro. 
Dishes were pulsed for 1 hour with 50µCi/ml Tran[35S]methionine and then were 
treated with the indicated concentration of on for 5 minutes. LOL receptor was 
immunoprecipitated with lgG-HL 1 (lanes 1-4) or lgG-C7 (lanes 5-7) and was 
analysed by electrophoresis under reduced (R) (lanes 1, 2 and 5-7) or non-
reduced conditions (NR) (lanes 3 and 4). The positions of the precursor (p, P) 
and the mature (m, M) LOL receptor are indicated under non-reduced (p, m) and 
reduced (P, M) conditions. The arrow identifies the precursor LOL receptor which 











Figure 4.2 Effects of Endoglycosidase H and on on the LOL receptor. 
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CHO cells were pulsed for 45 minutes with 50µCi/ml [
35S]methionine. 0.5mM OTT 
was included in the pulse medium of dishes 1 and 2. The LOL receptor was 
immunoprecipitated with lgG-C7 and treated in the presence (lanes 2 and 4) or 
absence (lanes 1, 3 and 5) of 10 milliunits Endoglycosidase H (Endo H) for 18 
hours. The LOL receptor then was analysed by SOS polyacrylamide gel 
electrophoresis and fluorography. The positions of the mature and the precursor 
forms of the LOL receptor are indicated. 
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The unfolding of the precursor LDL receptor was further monitored using the 
conformation-specific antibody, lgG-C7, which binds the first repeat of the ligand 
binding domain of the LDL receptor only if properly folded. on (added to cells) 
reduced the precursor and caused the loss of its immune-reactivity. Therefore there 
was a marked decrease in precursor signal detected in the gel (Figure 4.1, lanes 5-7). 
Unexpectedly, on treatment of cells did not result in the complete reduction of the 
mature LDL receptor, assessed either by electrophoretic mobility (Figure 4.1, lane 3) or 
immune-reactivity (Figure 4.1, lanes 6 and 7). This indicated that the mature receptor 
was more resistant to unfolding caused by disulfide bond reduction, than the precursor 
form. 
To determine whether on had any detectable structural effect on the mature LDL 
receptor in intact cells, the ability of the LDL receptor to bind antibody and lipoprotein 
ligands was measured. After treatment with on (5 minutes at 37°C), cells were cooled 
to 4°C, washed with alkylating agent and then incubated for 2 hours in the presence of 
1251-labelled ligands. (Table 4.1 ). At a saturating ligand concentration, the binding of 
the antibody, lgG-C7, to on-treated cells was between 40% (at 50mM on) and 60% 
(at SmM on) of control cells. The binding of lipoproteins to on-treated cells varied 
in three experiments, but was always more severely impaired than the binding of lgG-
C7. At the higher concentrations of OTT (50mM), LDL binding was reduced to about 
20% or less compared with normal cells, while the effect of 5mM on was less marked. 
The binding of ~VLDL was reduced to an intermediate degree compared to that of lgG-
C7 or LDL (experiment 2). These results indicate that some, but not all of the disulfide 
bonds of the mature LDL receptor, were reduced by on. Different combinations of the 
repeats are required to bind the different ligands ((Russell et al., 1989). Thus sensitive 
disulfide bonds were detected in repeat 1 (lgG-C7 binding), and in repeat 5 (~VLDL 
binding), and among repeats 2 to 7 (LDL binding). In all of the experiments, except for 
the use of LDL in experiment 1, a saturating concentration of ligand was used to 
determine the effects of OTT on LDL receptor binding. It was not possible from this 
data to determine an effect on binding affinity, as binding studies at a range of ligand 
concentrations (binding curves) were not performed. The loss of lgG-C7 
immunoreactivity detected by the binding experiment (Table 4.1) was not matched by a 
similar loss of mature LDL receptor in the immunoprecipitation experiments (Figure 
4.1 ). The cause of this difference in sensitivity between the 2 assays is not known. 
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Table 4.1: Binding of 1251-labelled lgG-C7, 1251-labelled LOL and 1251-labelled BVLOL to 









































Binding studies were performed as described in Methods. 1.25µg/ml 1251-labelled LOL 
was used in experiment 1, and 1 Oµg/ml 1251-labelled LOL was used in experiments 2 
and 3. 1 µg/ml 1251-labelled lgG-C7 was used in each experiment, and 5µg/ml 1251-
labelled BVLOL was used in experiment 2. Binding values obtained after OTT-
treatment are expressed as a percentage of the value obtained (ng/mg cell protein) 
when OTT was not added. Each value is the average of duplicate dishes. 
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4.2.2. Reduction of solubilised LOL receptor by OTT 
The OTT sensitivity of the solubilised LOL receptor was tested. lmmunopurified LOL 
receptor was boiled in SOS polyacrylamide gel electrophoresis sample buffer, in the 
presence of increasing doses of OTT and then electrophoresed on a non-reducing gel 
(Figure 4.3). Addition of O.SmM OTT increased the mobilities of both the precursor and 
the mature receptor compared with the mobilities of the non-reduced forms, suggesting 
the formation of more compact structures. Higher doses of OTT progressively retarded 
the mobility of both the precursor and mature LOL receptor, indicative of an increasing 
degree of reduction. Importantly, the effect of increasing doses of OTT appeared to be 
identical for the precursor and the mature receptor forms. The resistance of the mature 
receptor to reduction as observed in intact cells was therefore abolished under these in 
vitro conditions. 
4.2.3. LOL receptor must be denatured to be reduced in vitro 
The effect of denaturants (boiling and the detergent, SOS) on the OTT-induced 
reduction of the LOL receptor was assessed (Figure 4.4) OTT was added to 
immunopurified LOL receptor for 5 minutes at 37°C, in the presence of either Triton X-
100 or SOS. Samples were alkylated with N-ethyl maleimide (NEM), in order to quench 
the OTT and to prevent shuffling of disulfide bonds. Samples were then boiled, and 
electrophoresed without the addition of further reducing agents. The non-reduced, 
folded LOL receptor is seen in lanes 1 and 6 and the fully-reduced LOL receptor is 
seen in lane 4. Compared to the non-reduced forms, the mobility of the precursor and 
the mature LOL receptor were slightly slower in the OTT-treated samples, alone (lane 
5) or together with either 1 % Triton X-100 (lane 3) or 1 % SOS (lane 2). Receptors 
were fully-reduced only when the alkylating agent was not added, causing active OTT 
to be present when the sample was boiled (lane 4). Under these conditions, there was 
no difference between the sensitivity to OTT of the precursor and the mature LOL 
receptor. These results show that it was necessary to denature (boil) the LOL receptor 
to allow complete reduction by OTT. The sensitivity of the precursor LOL receptor, in 
the ER of living cells, was dependent on it being maintained in a partially folded or 
denatured state. Its sensitivity was dependent on its localisation within the ER; in 
contrast, fully-folded mature receptors in the endocytic pathway, were relatively 
resistant to unfolding caused by addition of a reducing agent. 
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4.2.4. LDL receptor folding and processing in the presence of OTT 
When cells are labelled in the presence of OTT, protein synthesis continues and the 
secretory pathway remains functional (Braakman et al., 1992b; Tatu et al. , 1993; 
Opstelten et al., 1993; Jamsa et al., 1994; Losch and Koch-Brandt, 1995). However, in 
the ER, the folding of certain proteins is prevented since they are unable to form 
disulfide bonds. The effect of OTT on LDL receptor folding and transport was 
assessed in Figure 4.5. In the presence of OTT, LDL receptor precursor was 
synthesised; at doses greater than 0.15mM, LDL receptor transport out of the ER was 
impaired and less mature form was detected (compare lanes 2 and 3). Increasing 
doses of OTT had further effects: 0.5mM OTT (lane 4) caused the covalent change 
described in section 4.2.1; 1.5mM OTT destroyed the lgG-C7 epitope (lane 5). Thus 
LDL receptor transport from the ER was retarded at a lower dose of OTT (0.15mM 
OTT) than the unfolding of the lgG-C7 epitope (1 .5mM OTT). The mobility of the LDL 
receptor precursor was altered on non-reduced gels at 0.5mM OTT (not shown), which 
correlated with the complete block to processing from the ER (lane 4). Similar results 
were obtained in a repeat experiment (and see Figure 4.1 ). These experiments show 
that the formation of disulfide bonds was required for the folding of the LDL receptor 
and its transport out of the ER. 
4.2.5. Post-translational folding of the LDL receptor. 
Next, OTT was removed, and the post-translational folding and disulfide bond formation 
of the unfolded LDL receptor was assessed in living cells. Cells were labelled in the 
presence of OTT and then chased in fresh medium without DTT, for varying times, to 
enable oxidative conditions to be re-established in the ER (Figure 4.6). Cycloheximide 
was included during the chase period to prevent protein translation from continuing 
after the pulse period. In this manner, the folding of the LDL receptor molecules 
labelled during the pulse-period were monitored during the chase period. After 1 
minute of chase, a disulfide-bonded, folded form of the precursor LDL receptor was 
detected (Figure 4.68, lane 4). After longer chase times (30 minutes) a mature form of 
the receptor was observed (lanes 7-9). Thus, the LDL receptor formed disulfide bonds 
post-translationally with sufficient fidelity to escape the quality control mechanism that 
normally retains malfolded proteins in the ER. A mutant LDL receptor (FH Afrikaner-1) 
that is known to be slowly-processed under normal conditions (F ourie et al., 1988) was 
retained when OTT was reversed, confirming that the normal quality-control mechanism 
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Figure 4.3 Reduction of solubilised LDL receptor. 
Dishes were pulsed for 1 hour with 50µCi/ml Tran[3
5S]methionine and LDL 
receptor was immunoprecipitated with lgG-C7. lmmunoprecipitates were boiled 
for 3 minutes in SOS-containing gel loading buffer containing on at the 
concentrations indicated , and then analysed by electrophoresis. The positions of 
the non-reduced forms of the precursor (p) and the mature (m) LDL receptor are 
indicated. In each lane, the "upper" band corresponds to the mature LDL 
receptor and the "lower" band corresponds to the precursor LDL receptor. 

1 2 3 
OTT + + 
sos + + 
Tx-100 + 








Figure 4.4 Effect of denaturation on the reduction of solubilised LDL receptor 
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Dishes were pulsed for 1 hour with 50µCi/ml Tran[35S]methionine and LDL 
receptor was immunoprecipitated with lgG-C7. lmmunoprecipitates were treated 
with 5mM OTT (lanes 2-5) for 5 minutes at 37°C in the presence of 1 % SOS 
(lanes 1, 2, 4 and 6) or 1 % Triton X-100 (lane 3) . NEM (20mM) was added (lanes 
2, 3 and 5) and immunoprecipitates were boiled for 3 minutes in gel loading buffer 
without the addition of further reducing agents. They were then analysed by 
electrophoresis. In each lane, the "upper" band corresponds to the mature LDL 
receptor and the "lower" band corresponds to the precursor LDL receptor. 
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mature-
precursor-
OTT (mM) 0 0.05 0.15 0.5 1.5 5 
Figure 4.5 LOL receptor synthesis in the presence of OTT. 
CHO cells were pulsed for 45 minutes with 50µCi/ml Tran[3
5S]methionine in the 
presence of the indicated concentrations of OTT. The LOL receptor was 
immunoprecipitated with lgG-C7 and analysed by SOS polyacrylamide gel 
electrophoresis under reducing conditions. lmmunoprecipitated protein was detected 
by fluorography. The positions of the mature and the precursor forms of the LOL 
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Dishes were pulsed for 1 hour with 1 OOµCi/ml Tran[
35S]methionine. OTT (5mM) was 
included in the pulse-period of dishes 2-7 (panel A) and of dishes 3-8 (panel B). Dishes 
were washed and then chased for the times indicated in fresh medium containing 
cycloheximide. Dishes were cooled to 4°C, alkylated and lysed in detergent. LDL 
receptor was immunoprecipitated with lgG-HL 1 and then divided for electrophoresis 
under reduced (panel A, all lanes and panel B, lane 1) and non-reduced conditions 
(panel B, lanes 2-9). As described in Figure 5.1, the positions of the precursor (p, P) 
and the mature (m, M) LDL receptor are indicated under non-reduced (p, m) and 
reduced (P, M) conditions. 

109 
increase in the amount of LOL receptor detected (Figure 4.6A), indicating that some of 
the labelled LOL receptors were not detected at the beginning of the chase (Figure 
4.6A, lane 2). This was due, in part, to the epitope for the antibody, lgG-HL 1, being 
partially sensitive to OTT. Protein aggregates were not detected during the folding 
process, but possibly did contribute to the loss of signal observed. In this experiment, 
refolded LOL receptor was poorly recovered when compared with the untreated 
controls. In experiments where OTT was added after the LOL receptor had been 
synthesised, instead of during the pulse period, the post-translational folding-efficiency 
was close to 100% (see Figure 4.9A, lanes 1-3). These results thus demonstrated that 
the translation or the translocation of the LOL receptor was impeded when OTT was 
present during LOL receptor synthesis and that the post-translational folding-process 
was efficient. In summary, these results demonstrated that precursor LOL receptors 
were able to form disulfide bonds post-translationally, and, therefore, that co-
translational folding was not required for normal LOL receptor synthesis. 
4.2.6. Folding of the LOL receptor required Ca2+ 
The ionophore, A23187, was used to deplete the ER of Ca
2
+ to determine whether the 
LOL receptor required Ca2+ to fold and form disulfide bonds. In the presence of 
A23187, precursor LOL receptor was synthesised with a relatively normal mobility on 
reducing gels (Figure 4. 7 A, lanes 1 and 2). However, transport of the precursor from 
the ER was prevented and mature LOL receptor was not detected during the 45 minute 
labelling period. A23187 reportedly does not have a general effect on protein transport 
from the ER; only malfolded proteins are retained (Lodish and Kong, 1990; Lodish et 
al., 1992). In the absence of Ca2+ the LOL receptor did form disulfide bonds as non-
reduced electrophoresis indicated that the mobility of the precursor was enhanced 
when compared with that of the reduced precursor (Figure 4. 7 A, lane 2 versus lane 5). 
However, in the presence of A23187 the mobility of the precursor population was 
heterogeneous and, in general, was faster than the mobility of the normally-folded 
precursor, indicating that the folding of the precursor was altered (Figure 4. 7 A, lane 5 
versus lanes 3 and 6). It is not known whether this abnormal mobility reflects 
incomplete disulfide bonding, or abnormal disulfide bond positioning, or both. 
Supplementing the medium with Ca2+ (up to 1 OmM), either during or after treating the 
cells with A23187, did not correct folding of the precursor (data not shown). These 
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results indicate that precursor LDL receptor requires Ca2+ for folding and transport from 
the ER. 
Since the mature LDL receptor requires Ca2+ to bind lipoprotein ligands (Goldstein and 
Brown, 1977) and the conformation-specific, monoclonal antibody, lgG-C7 (van Oriel et 
al., 1987b), its disulfide bond structure was examined after depleting Ca2+. Pulse-
labelled cells were washed with Ca2+-free medium containing A23187 and EDTA to 
remove free Ca2+. This did not alter the electrophoretic mobility of the mature LDL 
receptor either on reduced (Figure 4. 78, lane 2) or non-reduced gels (Figure 4. 7 A, lane 
4). Thus Ca2+ was not needed to maintain the disulfide bonds of the mature LDL 
receptor. In contrast, the conformation of the precursor LDL receptor was altered by 
depleting Ca2+. On non-reducing gels, the mobility of the precursor was enhanced and 
heterogeneous (Figure 4.7A, lane 4), and similar to the mobility of the precursor 
synthesised in the absence of Ca2+ (Figure 4. 7 A, lane 5). An altered conformation was 
also evident from the inability of the conformation-specific antibody, lgG-C7, to 
precipitate the precursor from treated cells (Figure 4. 78, lane 3). Thus depletion of cell 
Ca2+ affected the disulfide bonding of pre-existing, folded precursor LDL receptor, but 
not that of mature LDL receptor. 
To test whether the LDL receptor was able to rebind Ca2+, we replaced Ca2+ in the cell 
lysate in order to be certain that the Ca2+ gained access to both the precursor and the 
mature LDL receptor. lgG-C7 was used to detect whether the LDL receptor had 
rebound Ca2+. In the absence of Ca2+, lgG-C7 was severely impaired in its ability to 
immunoprecipitate both the precursor and the mature receptor (Figure 4.78, lane 3), in 
comparison with lgG-HL 1 which was less affected (Figure 4. 78, lane 2). When Ca2+ 
was replaced in the lysate, the lgG-C7 epitope of the mature receptor was restored 
(Figure 4.78, compare lanes 3 and 4), while the precursor remained immunologically 
undetectable. Ca2+ depletion had disrupted the structure of the normal precursor such 
that replacing Ca2+ was not sufficient for the antigenic epitope to reform. In contrast, 
mature LDL receptor was able to bind Ca2+ reversibly (Figure 4.78, lanes 3 and 4), 
supporting the finding that its disulfide bonds were not disrupted by Ca
2
+ -removal. 
Thus, Ca2+ was required for the formation of the normal disulfide bonds of the precursor 







Ca2+ removed + 
non-reduced 
3 4 5 6 
+ + 
reduced 
1 2 3 4 
M-
P-








Figure 4. 7 Effects of A23187 and Ca2+ on the disulfide bonds of the LDL receptor. 
Panel A: Dishes were pulsed for 45 minutes with 50µCi/ml TRAN[35S]methionine and the LDL 
receptor was immunoprecipitated with lgG-HL 1. Ca2+ was depleted bl including A23187 (5µM) 
during the pulse (lanes 1 and 5) or during a chase (5 minutes) in Ca + -free medium containing 
5mM EDTA and 5µM A23187 (dish 4). Lanes 1, 4 and 5 were lysed in the presence of 150µM 
EDTA, and lanes 2, 3 and 6 were lysed in the presence of 2mM Ca2+. lmmunoprecipitates 
were analysed by electrophoresis under reduced (lanes 1 and 2) or non-reduced conditions 
(lanes 3-6). 
Panel 8: Dishes were pulsed for 45 minutes with 50µCi/ml TRAN[35S]methionine. Ca2+ was 
depleted during a chase (5 minutes) in Ca2+-free medium containing 5mM EDTA and 5µM 
A23187 (lanes 2-4). Cells were lysed in the presence (lanes 1 and 4) or absence of 2mM Ca2+ 
(lanes 2 and 7). LDL receptor was immunoprecipitated with lgG-C7 (lanes 1, 3 and 4) or lgG-
HL 1 (lane 2) and analysed by electrophoresis under reduced conditions. 
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although the mature LDL receptor required Ca
2
+ for ligand binding, it was able to bind 
Ca2+ reversibly without an alteration of its disulfide bonds. 
4.2.7. Folding of the LDL receptor requires ATP 
The metabolic energy requirement for the formation of disulfide bonds in the precursor 
LDL receptor was investigated. Metabolic energy is required for protein translation, 
and thus its role in disulfide bond formation cannot be assessed in normal biosynthetic 
pulse-labelling experiments. The use of DTT enabled the folding of the LDL receptor to 
be studied as an isolated, post-translational process, independent of translation or the 
translocation of the protein into the ER Newly-synthesised LDL receptor was labelled, 
treated with DTT to reduce the disulfide bonds and then chased for 20 minutes in 
medium without DTT either in the presence or absence of ATP (Figure 4.8). ATP was 
depleted by using glucose-free medium supplemented with 1 OmM azide and 20mM 2-
deoxy-D-glucose (8raakman et al., 1992a). In control cells that were not treated with 
DTT, about 50% of the pre-existing precursor was converted to mature form during a 
20 min chase in the presence of ATP (Figure 4.8A, lanes 1 and 2). In cells that were 
reduced with DTT (lane 3) and then chased in the absence of ATP, the precursor LDL 
receptor was almost undetected by lgG-HL 1 (lane 4) and lgG-C7 (lane 6). In contrast, 
significantly more precursor receptor was detected by both antibodies after chasing in 
the presence of ATP (lanes 5 and 7). Thus, precursor receptor required metabolic 
energy for refolding after reduction. It was unexpected that after a short chase in the 
absence of ATP, the precursor was immunoprecipitated poorly by the monoclonal 
antibody, lgG-HL 1, (Figure 4.8A, lane 4), as lgG-HL 1 was able to detect the fully-
reduced form of the precursor LDL receptor (lane 3). One possibility was that in the 
absence of ATP, the reduced precursor formed disulfide-bonded aggregates with other 
proteins which were not detected by the monoclonal antibodies. A prolonged exposure 
of the non-reduced gel did show that after being reduced (Figure 4.88, lane 3), the 
precursor was able to form disulfide bonds in the absence of ATP (Figure 4.88, lanes 4 
and 6). However, these precursors exhibited a heterogeneous and largely abnormal 
mobility compared to normal precursors (lanes 5 and 7). Together with the poor 
immuno-reactivity of the ATP-depleted LDL receptor, these results indicated that the 
correct folding of the LDL receptor was not spontaneous, but required metabolic 
energy. 
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4.2.8. Glycosylation does not affect LDL receptor reduction or oxidation 
The influence of glycosylation on the folding of the LDL receptor was examined. 
Brefeldin A, known to fuse the ER with the Golgi apparatus and to prevent protein 
transport to the cell surface (Klausner et al., 1992), was used to manipulate the 
glycosylation of the LDL receptor (see Chapter 3). BFA-treatment caused the 
glycosyltransferases of both the ER and Golgi apparatus to modify the newly-
synthesised LDL receptor, resulting in a heterogeneous population of precursors with 
an electrophoretic-mobility intermediate between the normal precursor and mature 
forms of the LDL receptor (Figure 4.9A, lane 4 versus lane 1 ). The processing of the 
oligosaccharide chains continued during a 4 hour chase-period (Figure 4.9A, lane 8). 
The OTT-sensitivity of the extensively-glycosylated, intermediate forms of LDL receptor 
were examined. OTT-treatment prevented lgG-C7 from immunoprecipitating all these 
intermediate forms of the LDL receptor, including those that were chased for 4 hours in 
BFA, and that had extensive processing of their oligosaccharide chains (Figure 4.9A, 
lanes 5 and 9). Thus, the extent of the post-translational modification of the LDL 
receptor did not influence the sensitivity of the disulfide bonds to OTT. Next, the 
location of the precursor LDL receptor in the cell was varied with brefeldin A and its 
sensitivity to OTT was examined. In the presence of brefeldin A, the LDL receptor was 
trapped in an abnormal, fused ER/Golgi compartment; transport to the cell surface was 
re-established when cells were incubated in fresh medium without BFA (see section 
3.2.3.1.). The OTT-sensitivity of the LDL receptor either in the ER/Golgi or in the cell 
surface/endocytic pathway was compared. Despite their different locations, these LDL 
receptors were glycosylated to a similar extent (Figure 4.9A, compare lanes 8 and 12). 
Importantly, unlike the intracellular form (lanes 8 and 9), the surface/endocytic LDL 
receptor was resistant to OTT (lanes 12 and 13). Thus, the location of the LDL 
receptor in the cell determined its sensitivity to OTT, independent of the extent of its 
glycosylation. 
The effect of glycosylation on the formation of disulfide bonds by the LDL receptor was 
examined. The approach used was to examine the ability of the partially-glycosylated 
forms of the LDL receptor to refold and reform disulfide bonds after having been 
reduced with OTT. Brefeldin A was used to manipulate the extent of glycosylation of 
the LDL receptor. The extensively-glycosylated, intermediate-forms of the LDL 
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Figure 4.8 Formation of disulfide bonds by the LDL receptor in the absence of ATP. 
Dishes were pulsed for 35 minutes with 1 OOµCi/ml Tran[35S]methionine, after which 
OTT (5mM) was added to dishes 3-7 for 5 minutes. Dishes 2, 4, 5, 6 and 7 were 
chased for 20 minutes in the presence (lanes 2, 5 an 7) or absence of ATP (lanes 4 
and 6). Dishes were cooled to 4°C, alkylated with NEM, lysed and LDL receptor was 
immunoprecipitated using lgG-C7 (lanes 1, 2, 6 and 7) or lgG-HL 1 (lanes 3, 4 and 5). 
Samples were split and analysed by electrophoresis under reduced (panel A) or non-
reduced conditions (panel B). During the chase, ATP was depleted using azide (10mM) 
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Figure 4.9 Formation of disulfide bonds by the LDL receptor in the presence of 
brefeldin A. 
Panel A: Dishes were pulsed for 45 minutes with 50µCi/ml Tran[
35S]methionine. BFA 
(5µg/ml) was included in the pulse in dishes 4, 5, 6, 8, 9, 10, 12, 13 and 14. After the 
pulse, dishes 8-10 and 12-14 were chased in the continued presence of BFA. After 2 
hours, dishes 12-14 were washed and chased in the absence of BFA for a further 2 
hours. OTT (5mM) was added for the final 5 minutes of the pulse (dishes 2, 3, 5 and 6) 
or the chase period (dishes 9, 10, 13 and 14). Dishes 3, 6, 10 and 14 were washed to 
remove the OTT and incubated at 37°C in fresh chase medium for a further 1 O minutes. 
Dishes were cooled to 4°C, alkylated and lysed in detergent. LDL receptor was 
immunoprecipitated with lgG-C7 and immunoprecipitates were split for analysis by 
electrophoresis under reduced (panel A) or non-reduced conditions (panel B). 
Panel B: OTT+ dishes correspond to lanes 3, 6, 10 and 14 of panel A which were 
chased for 1 O minutes after OTT-treatment. Samples corresponding to lanes 2, 5, 9 
and 13 of panel A were not included in panel B. 
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(Figure 4.9A, lanes 2, 5 and 9), were washed and chased in fresh medium. Within 10 
minutes, all the glycosylation-intermediates reformed disulfide bonds and were 
recognised by lgG-C7 (Figure 4. 9A, lanes 3, 6 and 10). The structures of the refolded 
glycosylation-intermediates also were examined by electrophoresis under non-reduced 
conditions (Figure 4.9B). This showed that the refolded forms of the LDL receptor 
(lanes 2, 4 and 7) achieved their expected electrophoretic mobility as was obtained 
prior to reduction by OTT (lanes 1, 3 and 6). Thus the extent of LDL receptor 
glycosylation had no detectable influence on the formation of disulfide bonds. 
4.3. Discussion 
The major findings of these experiments are as follows: 1) folding of the LDL receptor 
involves disulfide bond formation and requires metabolic energy; 2) the disulfide bonds 
of the folded precursor LDL receptor remain sensitive to reduction by OTT and are not 
irreversibly hidden in the hydrophobic core during folding in the ER; 3) the LDL 
receptor is able to fold and form disulfide bonds post-translationally in the ER; 4) Ca2+ 
is required for the folding of the precursor LDL receptor in a manner different to its role 
in ligand and antibody binding to the mature LDL receptor; 5) folding and disulfide bond 
formation are not affected by the glycosylation of the LDL receptor. 
The disulfide bonds of the LDL receptor cross-link the cysteine-rich domains into 
compact, robust structures which are able to endure repeated, acid-induced 
conformational changes during endocytosis and recycling (Goldstein et al. , 1985). In 
the studies presented in this thesis it was shown that the mobility of the OTT-treated 
mature form of the LDL receptor was not altered under non-reduced electrophoretic 
conditions. Thus, most of the mature LDL receptor's disulfide bonds are evidently 
within the folded structure of the LDL receptor and are largely inaccessible to on. 
Some of the disulfide bonds were reduced by on, which impaired the ability of the 
LDL receptor to bind several different ligands, to varying degrees, with LDL binding 
being more severely impaired than r.,vLDL binding, and with C7 binding being the least 
impaired. This indicated that some of the disulfide bonds in several of the ligand 
binding repeats were reduced, and correlates with the different number of repeats (and 
thus the number of disulfide bonds) normally required to bind each ligand (Russell et 
al., 1989). 
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Analysis of the reduction of the LOL receptor precursor in vitro showed that its disulfide 
bonds were not inherently accessible to OTT. The reduction of the disulfide bonds of 
influenza virus haemagglutinin and vesicular stomatitis virus G protein also were 
promoted in the ER, and were dependent on ATP (Tatu et al., 1993). One hypothesis 
is that a chaperone is contributing to the reduction of the hidden disulfides of partially 
folded protein in the ER This action would facilitate the shuffling of disulfide bonds 
during the folding of a complex protein such as the LOL receptor. A candidate 
chaperone is protein disulfide isomerase which facilitates disulfide bond interchange, 
and which promotes disulfide bond reduction under reducing conditions (Creighton et 
al., 1980; Kaji and Lodish, 1993). One possibility is that the reduction of accessible 
disulfide bonds of the LOL receptor promotes its association with protein disulfide 
isomerase and which, in turn, facilitates extensive reduction and unfolding. 
The specific chaperone protein(s) necessary for LOL receptor folding has not yet been 
identified. Calnexin is a major chaperone associated with the folding of membrane 
glycoproteins, associating with partially folded proteins and contributing to their 
retention in the ER (Rajagopalan et al., 1994; Jackson et al., 1994). As described in 
chapter 5, less than a few percent of the ER-pool of LOL receptor was detected in 
association with calnexin, which may imply that other chaperone proteins are needed 
for LOL receptor folding. Calnexin is unlikely also to be the chaperone responsible for 
mediating the OTT-induced reduction of the precursor LOL receptor in the ER 
Proteins associate with calnexin through their N-linked oligosaccharide chains, but the 
binding is limited to proteins that have monoglucosylated core chains (Hammond et al. , 
1994; Ou et al., 1993; Hebert et al., 1995; Helenius, 1994, Ware et al., 1995). Thus the 
extent of chain-trimming regulates protein interaction with this chaperone. After a 
prolonged exposure to brefeldin A, the LOL receptor was processed beyond this form 
(was resistant to endoglycosidase H), and yet it was reduced by OTT. The interaction 
of the LOL receptor with calnexin is considered in detail in chapter 5. 
The results showed that the reduction of the LOL receptor and its consequent 
unfolding, were reversed following OTT removal. Translation of the peptide chain 
occurred while cysteines remained reduced. When OTT was removed, disulfide bonds 
formed within minutes, and the refolded LOL receptor was transported rapidly from the 
ER Disulfide bond formation was normal despite having been delayed by the 
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presence of the reducing agent. The folding machinery thus is able to prevent 
inappropriate disulfide bond formation or to facilitate recovery from inappropriate 
bonding. These findings indicate that the normal folding of the cysteine-rich repeats of 
the LDL receptor does not necessarily proceed vectorally from the N- to the C-
terminus. Folding is dictated by the sequence of amino acids and is not constrained by 
limitations imposed by a co-translational folding process. Such mechanisms could add 
enormously to the repertoire of possible folded-conformations for a given protein. Post-
translational protein folding is not always successful , or equivalent to the co-
translational formation of disulfide bonds. A beta-lactamase fusion protein did not 
regain enzymatic activity when it refolded after reduction, though it was transported 
from the ER (Simonen et al. , 1994). Similarly, reduced plasminogen activator was 
over-glycosylated when the disulfide bonds were formed post-translationally (Allen et 
al., 1995). 
The formation of new disulfide bonds was impeded when cellular energy was depleted, 
resulting in the formation of partially folded LDL receptor. This was in contrast to the 
ability of the first and the second repeats of the ligand binding domain to fold 
spontaneously, as isolated peptides, in vitro (Bieri et al. , 1995b; Bieri et al., 1995a; 
Daly et al., 1995). These findings point to the need for chaperone proteins in LDL 
receptor folding in vivo: energy is required by chaperones during the association-
dissociation cycle with their folding-substrates (Gething and Sambrook, 1992; 
Hendershot et al. , 1995). When energy was depleted, for example, influenza virus 
haemagglutinin protein and the vesicular stomatitis virus G protein were trapped as 
large protein aggregates containing abnormal , intermolecular disulfide bonds 
(Braakman et al., 1992a; de Silva et al., 1993). When energy was restored, monomeric 
influenza haemagglutinin was rescued and proceeded to fold normally (Braakman et 
al., 1992a). Transient aggregates were also detected during the folding of vesicular 
stomatitis virus G protein under energy-rich conditions (de Silva et al. , 1993). In this 
thesis, neither protein aggregates, nor intermediates with partially formed disulfide 
bonds, were detected during normal LDL receptor folding or following recovery from 
OTT-treatment. Possibly this was due to the antibodies used not being able to 
quantitatively detect partially-folded or reduced LDL receptor. Thus, the poor recovery 
of immunoprecipitable LDL receptor obtained might be accounted for by the trapping of 
misfolded LDL receptor into aggregates during the initial phase of folding after OTT 
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was removed, and oxidising conditions were being re-established in the ER, particularly 
when metabolic energy was limiting. Aggregation might also have occurred when 
disulfide bonds were formed in the absence of Ca2+, which also led to a poor recovery 
of immunoprecipitable LDL receptor (see below). The disulfide bonds of pre-existing, 
folded, precursor LDL receptor were not affected by depleting metabolic energy, in 
contrast to the altered structure reported for the influenza virus haemagglutinin protein 
and the vesicular stomatitis virus G protein when energy was depleted in the ER 
(Braakman et al. , 1992a; de Silva et al., 1993). The transport of the LDL receptor from 
the ER was impaired, but this was not an suitable index of LDL receptor folding as 
energy-depletion prevents both the formation of coated transport vesicles and their 
mechanism of fusion with a subsequent acceptor compartment (Balch et al., 1986). 
Energy-depletion may have affected other mechanisms, apart from chaperone activity, 
which were necessary for LDL receptor folding. In this regard, energy was required for 
the assembly of MHC class 1 antigens in vitro (Levy et al., 1991 ). Interestingly, protein 
disulfide isomerase does not require ATP to promote disulfide bond formation in vitro 
(Wetterau et al., 1991 ). The re-establishment of an oxidative redox potential in the ER 
also did not appear to be critically energy-dependent, as disulfide bonds did form, 
albeit abnormally, when energy was depleted (Braakman et al. , 1992a). 
Ca2+ was shown to be essential for the formation of the correct disulfide bonds of the 
LDL receptor in the ER. This may be due to Ca2+ binding either to the LDL receptor 
itself, or to another protein required for receptor folding, such as one of the Ca2+ -
binding chaperones, protein disulfide isomerase, calnexin, calreticulin, immunoglobulin 
heavy chain binding protein (BiP) and GRP94. In the LDL receptor, Ca2+ probably 
binds to the cysteine-rich repeats of the ligand-binding domain and possibly also to the 
cysteine-rich repeats of the EGF precursor-homology domain (Schneider, 1989; Stenflo 
et al., 1988). Ca2+ has been shown to bind to the first repeat of the ligand binding 
domain which contains the epitope for the Ca2+ -dependent antibody, lgG-C7 (van Oriel 
et al. , 1987b; Daly et al. , 1995), and Ca2+ is required for the LDL receptor to bind 
lipoprotein ligands (Goldstein and Brown, 1977). Ca2+ manipulation enabled reversible 
binding of lgG-C7 to the mature LDL receptor, whereas antibody binding to the Ca2+ -
depleted precursor LDL receptor was not restored by Ca2+ replacement. This indicates 
that the Ca2+ -requirements for the structure of the precursor LDL receptor were different 
to those of the mature LDL receptor. As shown by non-reduced electrophoresis, Ca2+ -
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depletion disturbed the disulfide bond structure of the precursor but not of the mature 
LDL receptor. The precursor LDL receptor did remain partially folded and thus only 
some of the disulfide bonds were dependent on Ca
2
+. The disulfide bonds of the first 
repeat of the ligand binding domain were not altered by Ca
2
+ -depletion when studied as 
an isolated peptide (Daly et al., 1995). However, the present data showed a clear 
Ca2+ -requirement for LDL receptor folding in vivo. 
Precursor LDL receptor was not transported from the ER when Ca
2
+ was depleted. 
Ca2+ levels may affect several different processes involved in regulating the transport of 
protein from the ER. Initially it was reported that high levels of ER-Ca
2
+ were 
necessary to retain proteins in the ER (Sambrook, 1990). Ca
2
+ depletion had caused 
secretion of resident proteins from the ER (Booth and Koch, 1989) and a yeast mutant 
with low levels of ER-Ca2+ was unable to retain misfolded proteins within the ER 
(Rudolph et al., 1989). Subsequently it was recognised that the effects of Ca
2
+ -
depletion were selective, with certain secretory proteins exiting the ER while others 
were retained. Ca2+ -depletion caused resident proteins to accumulate in the ER, partly 
due to their synthesis being induced (Dorner et al., 1990; Lodi sh and Kong, 1990; 
Kozutsumi et al., 1988). Thus, depletion of Ca2+ caused the T-cell receptor-alpha chain 
to dissociate from BiP and be secreted, while BiP remained in the ER (Suzuki et al., 
1991 ). By contrast, the addition of Ca2+ stimulates the dissociation of proteins from 
other ER-chaperones, including GRP94, protein disulfide isomerase, ERp72, 
calreticulin and pSO (Nigam et al., 1994). These effects are consistent with a role for 
Ca2+ in aiding certain proteins to fold and to associate with chaperones, with 
incompletely-folded protein being retained and possibly degraded, in the ER (Wikstrom 
and Lodish, 1993; Lodish et al., 1992; Wileman et al. , 1991 ). The fate of the LDL 
receptor has not been explored during prolonged Ca2+ -depletion. 
Since both N- and 0-linked sugar chains are added to the LDL receptor in the ER 
(Cummings et al. , 1983), the influence of glycosylation on disulfide bond formation was 
determined in this protein. It has been suggested that the complex, multi-step 
processing of sugar chains may regulate aspects of protein folding within the ER, 
having effects which are transient and different to the function of mature sugar chains 
on folded protein at the cell surface (Helenius, 1994). There are also indications that 
the presence of abnormal sugars might be more disruptive to protein function than the 
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complete absence of the sugar chains (Helenius, 1994). Preventing N-linked 
glycosylation with tunicamycin did not impede LDL receptor transport from the ER, or 
presumably protein folding (Filipovic, 1989, Fourie, Coetzee and Van der Westhuyzen, 
unpublished results), whereas interruption of the trimming of N-linked chains with 
castanospermine, possibly did reduce receptor transport to the cell surface (Edwards et 
al., 1989). Similarly, deletion of the clustered 0-linked sugar domain did not impair 
receptor function in fibroblasts (Davis et al., 1986a), though it does cause a mild form 
of familial hypercholesterolaemia through a subtle disturbance of receptor function 
(Koivisto et al., 1993). Thus, the finding that unfolded LDL receptors with mature 
oligosaccharide chains were able to reform disulfide bonds normally is important, as it 
shows that (i) these large, negatively-charged chains do not interfere with disulfide 
bond formation and (ii) precursor oligosaccharide chains are not necessary for LDL 
receptor folding, for example neither directly by affecting conformation nor by acting as 
a tag for association with chaperones such as calnexin (discussed above). These 
findings also suggest that altered disulfide bonds are not likely to be the cause of the 
reduced binding affinity reported for both mature LDL receptor lacking dispersed 0-
linked chains (Yoshimura et al. , 1987) and mature LDL receptor without N-linked chains 
(Filipovic, 1989). 
In summary, in the ER, the disulfide bonds of the LDL receptor were unstable and 
remained sensitive to the redox potential and the concentration of Ca2+, but not to 
metabolic energy. Reduced disulfide bonds were able to reform reversibly in an 
energy-dependent manner following redox changes, but not following Ca2+ depletion. 
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5.1. Introduction 
Chaperone proteins are present at high concentrations in the ER and contribute to the 
folding of membrane and secreted proteins. Chaperones function either through 
catalytic effects, such as the isomerisation of disulfide bonds by POI, or they bind 
partially-folded proteins and promote their efficient folding by stabilising folding 
intermediates and by preventing their aggregation (Gething and Sambrook, 1992; Hartl 
and Martin, 1995; Hartl , 1995; Hartl et al. , 1994). Chaperone-binding also serves to 
retain malfolded proteins in the ER. In this section, the role of the chaperone, calnexin, 
is considered in relation to the folding of the LDL receptor. 
Calnexin was originally identified as one of several phosphoproteins radiolabelled by 
[y32P]GTP in canine pancreatic rough microsomes (Wada et al. , 1991 ). It was later 
recognised to be identical to an 88 kDa protein which associated with class 1 major 
histocompatibility (MHC) molecules during their assembly in the ER, and a 90 kDa 
protein that associated with incompletely assembled forms of the T-cell receptor, class 
1 MHC molecules and the B-cell antigen receptor (Degen and Williams, 1991 ; 
Ahluwalia et al. , 1992; Galvin et al., 1992; Hochstenbach et al. , 1992). Calnexin is a 
type 1 transmembrane protein of 573 amino acids (Bergeron et al., 1994). Its luminal 
domain has sequence homology with calreticulin, the major calcium binding protein in 
the ER (Michalak et al. , 1992), and does not contain motifs for N-linked glycosylation 
(in mammals). The cytoplasmic domain contains an ER-retention motif (RKPRRE) and 
a phosphorylated serine residue (function unknown). 
Three lines of evidence indicate calnexin's role in protein folding and transport 
(Bergeron et al. , 1994). First, pulse-chase experiments show that many newly-
synthesised proteins associate transiently with calnexin and that the kinetics of 
association correlate with protein folding, and in many cases, the rate of transport from 
the ER (Ou et al., 1993; Kim and Arvan, 1995; David et al. , 1993; Galvin et al. , 1992; 
Hammond and Helenius, 1994; Hammond et al., 1994; Tatu et al. , 1995). Transferrin 
folding-intermediates bind to calnexin during disulfide bonds formation, while the more 
mature ER-forms are not bound (Kim and Arvan, 1995). Second, incompletely 
assembled and unfolded proteins associate with calnexin for prolonged periods (Kim 
and Arvan, 1995; Degen et al. , 1992; David et al. , 1993; Loo and Clarke, 1994; Pind et 
al. , 1994; Gelman et al. , 1995; Le et al. , 1994; Schreiber et al. , 1994; Lenter and 
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Vestweber, 1994; Ou et al., 1993; Wada et al., 1994). This is illustrated by the 
assembly of class 1 MHC molecules, where calnexin shows prolonged binding to 
incompletely assembled subunits and the duration of binding correlates with the 
different rates of secretion of allotypes from the ER (Degen et al., 1992). Both the wild 
type and mutant forms of the cystic fibrosis conductance transmembrane regulator and 
a1 -antitrypsin interact transiently with calnexin, but the common mutant form of cystic 
fibrosis conductance transmembrane regulator (~F508) is unable to dissociate from 
calnexin and is trapped in the ER apparently until it is degraded (Pind et al., 1994). 
Similarly, malfolding induced by the proline analogue, azetidine-2-carboxylic acid, 
prolongs association with calnexin (Ou et al., 1993). Third, the involvement of calnexin 
in the quality control mechanism which retains malfolded proteins in the ER, is 
demonstrated by the finding that truncated forms of calnexin that are unable to be 
retained in the ER, redistribute associated proteins to the Golgi and the cell surface 
(Rajagopalan et al. , 1994). Conversely, in cells from Drosophila melanogaster, the 
rapid transport of class 1 molecules from the ER, is retarded by the co-expression of 
calnexin, again clearly indicating its critical role in modulating transport from the ER 
(Jackson et al. , 1994). 
Calnexin substrates includes soluble and membrane proteins, but are restricted, with 
few exeptions, to glycoproteins (Ou et al., 1993; Ware et al., 1995). For glycoproteins, 
the binding is specific for N-linked oligosaccharide chains that are partially trimmed to 
contain core monoglucosylated chains (incomplete folding alone is not sufficient for 
binding) (Hammond et al., 1994; Hebert et al., 1995; Helenius, 1994). Further 
processing of the N-linked chains prevents binding to calnexin. The conformation of 
the folding protein determines its suitability as a substrate for the interplay between 
glucosidase II, UDP-Glc:glycoprotein glucosyltransferase and calnexin, which in turn 
modulates further folding and transport from the ER (Sousa and Parodi , 1995; Labriola 
et al., 1995). The role of the N-linked chains of the target protein is to modulate the 
initial binding of calnexin to its substrate; once bound, the sugar chains are not 
required for continued association (Ware et al. , 1995; Zhang et al. , 1995). Apart from 
the effects of glycosylation, substrate binding requires calcium and ATP, though it is 
not clear whether the ATP requirement is due to direct or indirect effects, as calnexin 
does not contain an obvious nucleotide binding site (Wada et al. , 1994). 
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The specific chaperone protein(s) necessary for LDL receptor folding has not yet been 
identified. A protein with the molecular mass of BiP (a major chaperone for secreted 
proteins) was co-immunoprecipitated with LDL receptors containing defects in their 
binding domain (Esser and Russell, 1988), but was not characterised further. As a 
membrane glycoprotein which contains N-linked oligosaccharides, the LDL receptor 
may be suitable substrate for binding to calnexin. The role of calnexin in the folding of 
the LDL receptor was assessed. In addition, the association between calnexin and 
mutant forms of the LDL receptor was studied. The mutant LDL receptors used were 
the 3 common mutant alleles identified as causing FH in the Afrikaner population in 
South Africa (see chapter 6) (Rubinsztein et al., 1994). These LDL receptors contain 
missense mutations in repeat 4 (FH Afrikaner-3) and repeat 5 (FH Afrikaner-1) of the 
ligand binding domain, and in the domain with homology to the EGF precursor (FH 
Afrikaner-2). The possibility that calnexin might be involved in the retarded transport of 
these mutant LDL receptors from the ER was investigated. 
5.2. Results 
5.2.1. Detection of calnexin in HepG2 and CHO cells by immunoblotting 
Calnexin was identified in cultured cells by western blotting using a polyclonal antibody 
directed at the cytoplasmic domain (residues 555-573) (Figure 5.1 ). In both cell-lines 
tested, CHO cells (lane 1) and HepG2 cells (lanes 2 and 3), a single protein band was 
recognised with the expected molecular weight of calnexin (90k0a) which indicated that 
the polyclonal antibody did not cross-react with other proteins. A subtle difference in 
the electrophoretic mobility of calnexin was noted in the HepG2 cells compared to the 
CHO cells, but was not further characterised. 
5.2.2. lmmunoprecipitation of calnexin and associated proteins 
To detect calnexin either with or without its associated proteins, cells were 
biosynthetically labelled with [35S] methionine and were lysed either under non-
denaturing or denaturing conditions. Under denaturing conditions (boiling in SOS), a 
protein band corresponding to the molecular weight of calnexin was 
immunoprecipitated (Figure 5.2, lane 1 ). The anti-calnexin antibody also detected 
albumin which was used as a conjugate during the production of the polyclonal 
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Figure 5.1 Detection of the calnexin by immunoblotting. 
Proteins derived from CHO (lane 1) and HepG2 (lanes 2 and 3) cells were subject 
to SOS polyacrylamide gel electrophoresis under non-denaturing conditions and 
transferred to nitrocellulose membranes, as described in section 2.2.9. Cell 
protein loaded: lane 1, 43µg; lane 2, 114µg; lane 3, 228µg. Calnexin was 
identified with a rabbit polyclonal antibody directed against residues 555-573 of 
calnexin. The calnexin-antibody complex was detected with 
1251-labelled goat anti-
mouse antibody (1.5x106cpm/ml) and autoradiography. The membrane was 
exposed to Kodak XAR5 film for 17 hours at -70°C. In comparison to molecular 
weight standards, calnexin migrated as a protein of approximately 90kDa, similar 






Figure 5.2 lmmunoprecipitation of calnexin and associated proteins 
After labelling HepG2 cells with TRAN[35S]methionine for 20 minutes, calnexin was 
immunoprecipitated under denaturing (lane 1) or non-denaturing conditions (lane 2). 
Denaturing conditions involved lysing and boiling cells in the presence of SOS in 
order to elute proteins from calnexin . Non-denaturing conditions involved cell lysis 
in the presence of cholate, without boiling, as described under section 2.2.8. 
lmmunoprecipitated proteins were subject to SOS polyacrylamide gel 
electrophoresis and detected by fluorography. 
Albumin was detected since it was used as a conjugate during the production of the 
anti-calnexin antibody in rabbits. 
' 
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antibody in rabbits. Under non-denaturing conditions (lysis in cholate), many newly-
synthesised proteins were co-immunoprecipitated with calnexin (lane 2). These 
proteins were eluted from calnexin by boiling in SOS, but no LOL receptor was 
observed amongst them following immunoprecipitation with the antibody, lgG-C?.(not 
shown). It was subsequently determined that the lgG-C7 epitope, in the 1st cysteine-
rich repeat of the binding domain of the LOL receptor, was destroyed during elution 
from calnexin (by being boiled in SOS). The antibody, lgG-HL 1, which is able to 
recognise the denatured LOL receptor (Figure 5.3), was used in subsequent 
experiments. Its epitope lies in the linker region between the 4th and 5th binding 
repeats of the ligand binding domain. Unexpectedly, despite using lgG-HL 1, less than 
1 % of the LOL receptor in the ER was detected among the proteins eluted from 
calnexin in either HepG2 or CHO cells (results not shown). 
The duration of the labelling-period was varied in order to detect a transient calnexin-
LOL receptor complex. However, using CHO or HepG2 cells, similar results were 
obtained when the labelling-period (using 200µCi/ml [35S]methionine) was varied 
between 1 O and 30 minutes (results not shown). Shorter pulse-periods did not 
adequately label the LOL receptor. 
a1-Antitrypsin was selected as a positive control in order to confirm that the technique 
used to immunoprecipitate calnexin was adequate to retrieve the associated proteins. 
a1-Antitrypsin has been identified previously as a calnexin-substrate in HepG2 cells 
(Ou et al., 1993; Le et al., 1994). In these cells, after 10 minutes of labelling with 
[
35S]methionine, a1-antitrypsin was detected easily which indicated that its expression 
was far greater than the expression of the LOL receptor (Figure 5.4, lane 1 ). However, 
as shown in Figure 5.4 (lanes 1 and 3), less than 1 % of the ER-pool of a1-antitrypsin 
co-immunoprecipitated with calnexin. Similar results were obtained in three separate 
experiments. This was in contrast to the published report that about 25% of a1-
antitrypsin binds to calnexin (Ou et al., 1993). Importantly, although the fraction of a1-
antitrypsin that was bound to calnexin was extremely low, the specificity of this 
interaction was demonstrated by: 1) it was only the ER-form of a1-antitrypsin that 
bound calnexin (as expected, the Golgi-processed form of a1-antitrypsin did not bind 
calnexin)(compare lanes 2 and 4); and 2) the fraction of newly-synthesised a1-
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antitrypsin, that was bound to calnexin, as expected, declined during a 20 minute chase 
(lanes 3 and 4). 
The poor recovery of calnexin-associated protein may have been due to the incomplete 
immunoprecipitation of calnexin. In order to improve the immunoprecipitation of 
calnexin, 2 polyclonal antibodies (raised against different peptides of calnexin) were 
used simultaneously in the same immunoprecipitation reaction. This did improve the 
immunoprecipitation of calnexin under denaturing (Figure 5.5, lane 1) and non-
denaturing conditions (lane 2) (The comparisons to the individual use of the antibodies 
are not shown). However, the enhanced avidity of this interaction did not significantly 
improve the yield of a1-antitrypsin retrieved after elution from calnexin (Figure 5.5, 
lanes 3 and 4). In these experiments controls were performed to confirm that the 
antibody used (against a1-antitrypsin) was not affected by boiling nor by SOS (results 
not shown). 
The extent to which calnexin was recovered in a single round of immunoprecipitation 
was determined. Sequential rounds of calnexin immunoprecipitation were performed 
on the same sample of cell lysate. The second round of immunoprecipitation recovered 
less than 10% of the calnexin recovered in the first round (results not shown). Thus, 
about 90% of the calnexin in the lysate was recovered during the first round of 
immunoprecipitation. 
Cognisant of the low level of expression of both calnexin and the LDL receptor in 
transfected CHO cells (relative to the level of calnexin and a 1-antitrypsin in HepG2 
cells}, the association between calnexin and mutant forms of the LDL receptor was 
studied (Figure 5.6 and Figure 5.7). The mutant LDL receptors used were the 3 
common alleles which cause FH in the Afrikaner population in South Africa (see 
chapter 6). These LDL receptors contain missense mutations in repeat 4 (FH 
Afrikaner-3) and repeat 5 (FH Afrikaner-1) of the ligand binding domain, and in the 
domain with homology to the EGF precursor (FH Afrikaner-2). These mutations 
produce receptor molecules which are transported slowly from the ER The aim was to 
determine whether calnexin was involved in this process. The results of two separate 
experiments are presented (Figure 5.6 and Figure 5. 7). CHO cells expressing the wild 
type (lanes 1 and 2) or the mutant LDL receptors (lanes 3-8) were pulse-labelled with 
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Figure 5.3 The sensitivity of the LOL receptor epitope for lgG-HL 1 to SOS and 
boiling 
After being biosynthetically labelled with TRAN[35S]methionine for 30 minutes, 
CHO cells were lysed in the presence of 1 % Triton X-100. In lane 1, the LOL 
receptor was immunoprecipitated from the post-nuclear supernatant (12 OOOg for 
10 minutes). In lane 2, the post-nuclear supernatant was boiled for 3 minutes in 
the presence of 1 % SOS and then diluted 20-fold by the addition of 1 % Triton X-
100 lysis buffer, prior to the immunoprecipitation of the LOL receptor with 
lgG-HL 1. lmmunoprecipitated protein was analysed by SOS polyacrylamide gel 















Figure 5.4 lmmunoprecipitation of calnexin and a1-antitrypsin. 
+ 
HepG2 cells were biosynthetically labelled with 200µCi/ml TRAN[35S]methionine 
for 10 minutes and chased (lanes 2 and 4) for 20 minutes in the presence of 
unlabelled methionine. Cells were lysed and calnexin was immunoprecipitated 
under non-denaturing conditions, as described in section 2.2.8. a1-Antitrypsin 
then was immunoprecipitated from the proteins which did not bind to calnexin 
(lanes 1 and 2) or amongst the proteins eluted from immunoprecipitated calnexin 
(lanes 3 and 4). lmmunoprecipitated protein was analysed by SOS 
polyacrylamide gel electrophoresis and detected by fluorography. The precursor 
and the mature forms of a1-antitrypsin are indicated. Panel A is a 6 hour 
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Figure 5.5 The immunoprecipitation of calnexin with a mixture of 2 polyclonal 
antibodies. 
After being biosynthetically labelled with 200µCi/ml TRAN[35S]methionine for 30 
minutes, HepG2 cells were lysed and calnexin was immunoprecipitated under 
denaturing (lane 2) or non-denaturing conditions (lane 1, 3 and 4), as described in 
section 2.2.8. A mixture of the polyclonal antibodies directed against 2 different 
epitopes of calnexin were used to enhance the avidity during 
immunoprecipitation. Lanes 3 and 4: a1-Antitrypsin then was immunoprecipitated 
from the proteins which did not bind to calnexin (lanes 3) or amongst the proteins 
eluted from immunoprecipitated calnexin (lanes 4). lmmunoprecipitated protein 








Figure 5.6 lmmunoprecipitation of calnexin and the LDL receptor. 
CHO cells expressing the wild type LDL receptor (wt), FH Afrikaner-1 (FH1), FH 
Afrikaner-2 (FH2) and FH Afrikaner-3 (FH3) mutant LDL receptors were pulsed 
for 30 minutes with 150µCi/ml [35S]methionine. Cells were lysed and calnexin 
was immunoprecipitated under non-reducing conditions, as described in section 
2.2.8. The LDL receptor then was immunoprecipitated, with lgG-HL 1, from the 
proteins which did not bind to calnexin (lanes 2, 4, 6 and 8) or amongst the 
proteins eluted from immunoprecipitated calnexin (lanes 1, 3, 5 and 7). The LDL 
receptor was analysed by SOS polyacrylamide gel electrophoresis and 
fluorography. The positions of the mature and the precursor forms of the LDL 
receptor are indicated . The gel was overexposed (for 48 hours) to Kodak Biomax 
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Figure 5. 7 lmmunoprecipitation of calnexin and the LDL receptor. 
CHO cells expressing the wild type LDL receptor (wt), FH Afrikaner-1 (FH1), FH 
Afrikaner-2 (FH2) and FH Afrikaner-3 (FH3) mutant LDL receptors were pulsed 
for 30 minutes with 1 SOµCi/ml [35S]methionine. Cells were lysed and calnexin 
was immunoprecipitated under non-reducing conditions, as described in section 
2.2.8. The LDL receptor then was immunoprecipitated, with lgG-HL 1, from the 
proteins which did not bind to calnexin (lanes 1, 3, 5 and 7) or amongst the 
proteins eluted from immunoprecipitated calnexin (lanes 2, 4, 6 and 8). The LDL 
receptor was analysed by SOS polyacrylamide gel electrophoresis and 
fluorography. The positions of the mature and the precursor forms of the LDL 
receptor are indicated. Panel A: The gel was exposed for 36 hours to Kodak 
Biomax film. 
Panel B: The gel was overexposed (for 8 days) in order to detect the small 





35S]methionine and calnexin was immunoprecipitated. LDL receptors were recovered 
by immunoprecipitation from the co-immunoprecipitated proteins which were eluted 
from calnexin, and compared to the LDL receptors recovered from the proteins which 
did not bind calnexin. Similar results were obtained in both experiments. The results 
showed that the overall level of association of all these mutant LDL receptors with 
calnexin was very poor - the overwhelming proportion of the LDL receptors recovered 
were in the fractions that were not co-immunoprecipitated with calnexin (Figure 5.6, 
lanes 2, 4, 6 and 8; Figure 5. 7, lanes 1, 3, 5 and 7). Thus, the mutant LDL receptors 
which were slowly transported from the ER, were not retained in the ER in a calnexin-
LDL receptor complex. Total LDL receptor was immunoprecipitated from control dishes 
(without calnexin immunoprecipitation) and found to be quantitatively equivalent to the 
pool that was not bound to calnexin (results not shown). Thus, LDL receptor was not 
lost during the immunoprecipitation procedure. Carryover of signal between adjacent 
lanes during electrophoresis did not occur, as indicated by the absence of mature wild 
type LDL receptor in the calnexin-associated lanes (Figure 5.6, lane 1; Figure 5.7, lane 
2). 
Interestingly, the FH Afrikaner-2 mutant bound calnexin to a greater degree in 
comparison to the other mutants and the wild type LDL receptor (Figure 5.6, lane 5; 
Figure 5. 7, lanes 6). This finding was consistent in the 2 separate experiments. The 
possible role of LDL receptor conformation in determining its association with calnexin 
also was assessed by reducing the disulfide bonds of the wild type LDL receptor by the 
addition of OTT to intact cells (see chapter 4 for a detailed discussion of this 
technique). This unfolding did not enhance LDL receptor binding to calnexin (results 
not shown). 
A limitation of the pulse-labelling technique was that the [
35S]methionine label was used 
in trace quantities and possibly was not incorporated into every protein molecule 
synthesised during the labelling period. The high cost of the [
35S]methionine label also 
limited the size of the dishes (hence the number of cells) and concentration of label 
used. An alternative strategy was to use enhanced chemiluminescence immunoblotting 
(instead of immunoprecipitation) to detect the LDL receptor amongst the proteins eluted 
from immunoprecipitated calnexin. The advantages were that a blotting method would 
detect the entire pool of LDL receptors in the ER (not only the labelled fraction) and 
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could be performed on a larger number of cells. Several methods for the 
immunoblotting of the LDL receptor have been described which have the sensitivity to 
detect the pool of mature LDL receptor in the recycling endocytic pathway (ligand and 
immunoblotting) (Daniel et al., 1983; Beisiegel et al., 1982). However, these methods 
do not have the sensitivity to detect the small pool of LDL receptor present within the 
ER, let alone the fraction possibly bound to calnexin. Once the relative antibody 
concentrations were optimised (not shown), enhanced chemiluminescence 
immunoblotting blotting was able to detect the precursor LDL receptor in the ER of cells 
derived from a 60mm dish (Figure 5.8, compare lanes 1 and 2). The absence of signal 
in cells which were not transfected (lane 3) indicated that the bands detected (lanes 1 
and 2) were derived from the human LDL receptor. Promising preliminary results show 
that the precursor forms of two slowly-processed ( class 2), mutant LDL receptors (lanes 
4 and 5) were detected more readily than the wild type LDL receptor (lanes 1 and 2), 
due to the enlarged pool of these mutant LDL receptors in the ER The absence of 
mature LDL receptor in the mutant with a substitution (to alanine) of the 3rd cysteine in 
the 5th binding repeat (lane 4), contrasts with the FH Afrikaner-1 mutant, where 
significant mature LDL receptor was detected (lane 5). Interestingly, a protein band 
with a molecular weight intermediate between the precursor and the mature LDL 
receptor was detected in those lanes where mature LDL receptor was detected (lanes 
1, 2 and 5) . This form either may be a degradation fragment derived from the mature 
LDL receptor, or else may derive from the incomplete processing of the LDL receptor in 
the Golgi apparatus during transport to the cell surface. 
This immunoblotting technique will allow for a definitive experiment be carried out 
aimed at determining the actual relative amounts of mutant LDL receptor associated 
with calnexin in the ER, independently of pulse-labelling techniques. This experiment 
had yet to be performed at the time of the writing of this thesis. 
mature-
precursor-
1 2 3 4 5 
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Figure 5.8 Detection of the LDL receptor by enhanced chemiluminescence 
western blotting. 
Proteins derived from CHO-ldlA7 cells were subject to SOS polyacrylamide gel 
electrophoresis under non-denaturing conditions and transferred to nitrocellulose 
membranes, as described in section 2.2.7. Protein corresponding to confluent 
60mm dish was loaded in each lane. The LDL receptor was identified with lgG-
HL 1 and detected with ECL immunoblotting using a horseradish peroxidase-
coupled secondary antibody. An exposure of 5 minutes was used in lane 1; an 8 
second exposure was used in lanes 2-5. The CHO cells were transfected with 
the wild type LDL receptor (lanes 1 and 2), the mutant LDL receptor with a 
substitution (to alanine) of the 3rd cysteine of the 5th binding repeat (lane 4), and 
the FH Afrikaner-1 LDL receptor (lane 5). The CHO cells in lane 3 did not 
express the human LDL receptor (were not transfected). 
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5.3. Discussion 
In summary, only a small fraction of the newly-synthesised LDL receptors was found to 
be associated with calnexin in the ER These results were inconclusive in indicating a 
role for calnexin in the folding of the LDL receptor. The interaction between calnexin 
and the LDL receptor was not increased when transport was retarded by the FH 
Afrikaner-1 mutation, or when disulfide bonds were reduced by DTI. Thus the 
retention of all class 2 LDL receptors did not occur in a complex with calnexin. The FH 
Afrikaner-2 mutant demonstrated an increased association with calnexin compared to 
other forms of the LDL receptor studied, but this association could not account directly 
for the large accumulation of LDL receptor in the ER 
Transferrin and a1-antitrypsin were used as positive controls in order to confirm that 
the immunoprecipitation of calnexin was adequate. The apparent poor binding of these 
proteins to calnexin is unexplained, and reason for caution in interpreting the results for 
the involvement of calnexin with the LDL receptor. In other studies, the maximal 
degree of association of newly-synthesised a1-antitrypsin (Ou et al. , 1993; Le et al., 
1994) and transferrin (Ou et al. , 1993) with calnexin was about 30%, which is 
equivalent to the degree of association reported for several other proteins: major 
histocompatibility complex class 1 heavy chain (Jackson et al., 1994; Degen and 
Williams, 1991 ), thyroglobulin (Kim and Arvan, 1995), vesicular stomatitis virus G 
protein (Hammond and Helenius, 1994), C3 (Ou et al., 1993) and cystic fibrosis 
transmembrane conductance regulator (Pind et al., 1994). Glycoprotein80 (Wada et 
al., 1994) and B1 integrin (Lenter and Vestweber, 1994) show an even greater (about 
60%) association with calnexin. These findings might suggest that the methods used in 
this thesis were not adequate to immunoprecipitate calnexin and then detect the 
associated proteins. However, the anti-calnexin antibodies used in this thesis were 
obtained from the same source as in several of these studies (Wada et al. , 1994; Le et 
al., 1994; Ou et al. , 1993; Hammond et al., 1994 ), and were shown to effectively 
immunoblot and immunoprecipitate calnexin. Similarly, immunoprecipitation of the LDL 
receptor (using lgG-HL 1 ), a1-antitrypsin and transferrin were not affected by the 
conditions (boiling in SOS) used to elute proteins from calnexin. During the 
immunoprecipitation of calnexin, neither Ca2+ nor ATP were depleted, both of which are 
reported to dissociate proteins from calnexin (Wada et al. , 1994). Since Ca2+ is 
required for the folding of the LDL receptor (see chapter 4), experiments were 
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performed in the presence and absence of added Ca2+ - this did not affect calnexin-
association (results not shown). 
The finding that the significant accumulation of a LDL receptor-calnexin complex could 
not be demonstrated certainly did not exclude calnexin's possible role in the folding of 
the mutant forms of the LDL receptor. Mutant proteins may fold along independent 
paths compared to their wild type counterparts, and interact with a different set of 
chaperones, although this has not been reported. Certainly, the kinetics of folding of 
mutant proteins (even along the same folding paths) may be sufficiently different to 
reveal transient interactions not detected during rapid wild type folding (Le et al., 1994; 
Ou et al., 1993; Pind et al., 1994; Loo and Clarke, 1994). Similarly, the reduction of 
disulfide bonds by OTT-treatment enhances the association of thyroglobulin with 
calnexin (Kim and Arvan, 1995), though this was not the case for the LDL receptor. 
The manner in which mutations disrupt the folding of the LDL receptor is considered 
further in chapter 6. LDL receptor mutants are described to fold rapidly to an abnormal 
conformation in which they persist until their exit from the ER. Results presented here 
(chapter 5) indicate that despite their abnormal conformation, the retained LDL 
receptors do not persist in a complex with calnexin in the ER. 
The actual role of calnexin in folding has not been determined. Calnexin does not 
possess catalytic activity (such as protein disulfide isomerase) and may promote 
folding by preventing the aggregation of partially-folded proteins. In chapter 4, the 
influence of glycosylation on the folding of the LDL receptor, is discussed. These 
findings show that the extent of processing of the glycosylation chains of the LDL 
receptor, does not affect its folding, as assessed by the formation of disulfide bonds. 
The implication is that calnexin is not critically involved in these processes, as the 
highly-processed sugar chains of the LDL receptor would prevent its interaction with 
calnexin (Helenius, 1994). Similarly, unpublished results (Fourie, Coetzee and Van der 
Westhuyzen) show that tunicamycin-treatment, which prevents N-linked glycosylation 
(and hence protein association with calnexin) (Ou et al., 1993), did not enhance the 
rate of transport of the slowly processed, FH-Afrikaner-2 LDL receptor (Fourie et al., 
1988) from the ER. Thus neither direct evidence (association with calnexin) nor 
indirect evidence (manipulating glycosylation) implicates a role for calnexin in the 
retention of mutant forms of the LDL receptor in the ER. 
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The apparent limited extent of the association between the LDL receptor and calnexin, 
does not preclude that a brief interaction may be critical for the folding of the LDL 
receptor. Indeed, vesicular stomatitis virus G protein associated with BiP and calnexin 
briefly, and in sequence, during its folding (Hammond and Helenius, 1994). Such 
transient binding, especially at an early stage in the folding of the LDL receptor, would 
be difficult to detect without using systems with a much higher level of protein 
expression than used in this thesis. Viral systems have the advantage that viral 
proteins alone are synthesised while the synthesis of endogenous proteins are . 
suppressed (Hammond and Helenius, 1994). Another approach that may be useful in 
the context of brief interactions would be the use of dysfunctional forms of calnexin 
(Rajagopalan et al., 1994). Such experiments require the calnexin-mutants to exert 
dominant negative effects, which may not occur considering that several chaperones 
aid the folding of a given protein (Langer et al., 1992; Kim and Arvan, 1995; Kuznetsov 
et al., 1994; Kahn-Perles et al., 1994; Hammond and Helenius, 1994). It is not known 
whether different chaperones are able to substitute for each other, which could 
complicate interpretation of results. 
The results presented using the enhanced chemiluminescence western blotting 
technique are preliminary. They simply demonstrate that the technique is sensitive 
enough to detect the precursor LDL receptor in the ER, and could be an alternative to 
the sequential immunoprecipitation technique. Unfortunately, use of this technique 
does not bypass the problems, referred to above, concerning the overall poor 
association of protein with calnexin. 
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6.1. Introduction 
In this chapter the folding and the transport of mutant LDL receptors, from the ER, is 
considered. The transport of the LDL receptor from the ER is reviewed in section 1.5 
and the folding of the LDL receptor is reviewed in section 1.8.2. 
The manner in which mutations affect the folding of the LDL receptor molecule has not 
been determined. Presumably mutations alter the folding of the LDL receptor and 
cause its retention to be mediated through a chaperone quality-control mechanism in 
the ER. Structural studies would show definitively how mutations alter the structure of 
the LDL receptor. However, these studies have been prevented by the difficulty of 
crystallising membrane proteins such as the LDL receptor. Insights have been 
obtained by the functional consequences (effects on binding, recycling and stability) of 
the various mutations and have been used to assign functional roles to the various 
domains and subdomains of the LDL receptor (Hobbs et al., 1992; Hobbs et al., 1990). 
Within the binding domain, a myriad of mutations are described to reduce LDL receptor 
transport from the ER and binding activity on the cells surface (Hobbs et al. , 1992). 
Other phenotypes are apparent which vary between the different mutant alleles. 
Differences are observed between the rates of LDL receptor transport from the ER, the 
apparent stability of the LDL receptor in the ER and on the cell surface, and the 
apparent mobility assessed by SOS polyacrylamide gel electrophoresis. The structural 
basis for these phenotypes has not been determined. 
Many questions can be phrased concerning the folding of the different ligand binding 
repeats: are they equivalent?; do they fold in sequence?; are all of the repeats similar 
in structure?; are all the disulfide bonds necessary for folding?; do missense mutations 
affect the disulfide bonds?; are the phenotypes (transport rate, stability and mobility on 
gels) influenced by which disulfide bonds are disrupted by mutations? 
In order to assess the requirements for disulfide bonds in the folding of the 5th binding 
repeat, cysteine residues of that repeat were individually substituted with alanine. Six 
mutant LDL receptors were constructed and the phenotypes of the expressed proteins 
were assessed in transfected CHO cells. The 5th ligand binding repeat was selected 
as it is unique (compared to the other binding repeats) in being required for both LDL 
and ~VLDL binding to the LDL receptor (Esser et al. , 1988; Russell et al., 1989). It is 
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also the repeat affected by the FH Afrikaner-1 mutation (Asp206Glu) which results in 
the intriguing phenomenon of the expression of 2 surface forms of the same mutant 
LDL receptor (Fourie et al., 1992; Fourie et al. , 1988). One form binds lipoproteins with 
normal high affinity while the other does not. The possibility that these alternative 
stable structures involve the formation of different patterns of disulfide bonds was 
assessed by electrophoresis under non-reduced conditions. The disulfide bonds of the 
other 2 common mutant alleles causing FH in the Afrikaner population of South Africa 
(Rubinsztein et al. , 1994) also were examined. These LDL receptors contain missense 
mutations in repeat 4 of the ligand binding domain (FH Afrikaner-3, Asp154Asn) 
(Graadt van Roggen et al., 1995), and in the domain with homology to the EGF 
precursor (FH Afrikaner-2, Val408Met) (Leitersdorf et al. , 1989; Fourie et al. , 1988). 
The use of electrophoresis under non-reduced conditions is discussed in chapter 4 
where the formation of the disulfide bonds in the wild type LDL receptor is considered. 
In the course of studying mutations affecting the oligomerisation of the LDL receptor, it 
was noted that alterations to the cytoplasmic tail retards the LDL receptor's rate of 
processing from the ER (Davies, Graadt van Roggen, van der Westhuyzen, 
unpublished results) . The possibility that these mutations (Phe807 Ala, Stop792 or 
Stop812) affect the formation of disulfide bonds in the LDL receptor was examined. 
6.2. Results 
6.2.1. Phenotypic characterisation of mutant LDL receptors with cysteine substitutions 
in the 5th binding repeat 
Site-directed mutagenesis was performed to individually substitute the cysteine 
residues in the 5th binding repeat by alanine, as described under methods. 6 mutant 
LDL receptors were constructed, and designated mutant 1-6, dependent on the 
cysteine residue mutated: mutant 1, Cys176Ala; mutant 2, Cys183Ala; mutant 3, 
Cys188Ala; mutant 4, Cys195Ala; mutant 5, Cys201Ala; mutant 6, Cys210Ala. Briefly, 
after subcloning a DNA fragment corresponding to the 5th repeat of the LDL receptor 
into bacteriophage M13, oligonucleotide-directed mutagenesis was performed 
according to the method of Kunkel (Kunkel et al., 1987). The plasmid, pLDLR2, was re-
assembled with the mutated DNA fragment and the mutations were confirmed by DNA 
sequencing. The mutants were stably-expressed in CHO cells and selected by 
resistance to the antibiotic, geneticin (G418). Colonies of thriving cells were isolated 
155 
with cloning rings and cloned by limiting dilution. Clones were expanded into cell lines 
and the expression of the LDL receptor was confirmed by immunoprecipitation. The 
results presented for each mutant was representative of experiments performed on at 
least 2 separate clones. 
For each mutant with one altered disulfide bond, a precursor was observed that had an 
apparent molecular weight that was equivalent to the wild type LDL receptor (120 kDa) 
as determined by SOS polyacrylamide gel electrophoresis under reducing conditions 
(Figure 6.1A). Hence the core sugar chains of the precursor were not altered. When 
electophoresed under non-reducing conditions (Figure 6.1 B), the altered disulfide 
bonded structure of the mutant LDL receptors (lanes 2-7) was evident from their 
enhanced mobility compared to the wild type LDL receptor (lane 1 ). Subtle differences 
were noted in the mobilities of the different mutant LDL receptors under non-reduced 
conditions, indicating slight differences in the structure dependent on which disulfide 
bonds were altered (Figure 6.1 C). Resolution was not improved by altering the 
electrophoretic gel density (over a range from 4% to 11 %) in uniform or gradient gels 
(results not show). 
When pulse-labelled or then chased or 3 hours, no significant loss of precursor signal 
was observed (Figure 6.2A). Mature LDL receptors were not detected in any of the 
mutants. This indicated that alterations to any of the disulfide bonds of the 5th ligand 
binding repeat impaired LDL receptor transport from the ER When the chase period 
was extended to 13 hours, each mutant was processed through to mature forms to 
some extent, though the relative yields of precursor and mature LDL receptor were 
quite different after this time for each of the different mutants (Figure 6.28). Mutants 4, 
5 and 6 had more mature than precursor, mutants 1 and 2 equivalent amounts, and 
mutant 3 had more precursor than mature LDL receptor. For each of the mutant LDL 
receptors, the ratio of precursor to mature forms remaining at the end of the 13 hour 
chase period was a function of the rates of LDL receptor processing through the ER 
and LDL receptor stability both in the ER and the post-ER compartments, including 
potentially the recycling endocytic pathway. 
Given that little loss of precursor LDL receptor occurred during a 3 hours chase (Figure 
6.2A), it seemed that there was a time lag of more than 5 hours (2 hours of pulse + 3 
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hours of chase) before transport to the cell surface occurred. Since it was after this 
period that the LDL receptor was unstable (Figure 6.28), the most likely explanation is 
that the mutants were unstable once they had departed from the ER Mutant 3 was 
more stable than the others, possibly due to an extremely slow rate of transport from 
the ER 
Another feature of mutant 3 was that the precursor form did not alter in molecular 
weight during the 3 hour (or 13 hour) chase period (compared to the pulsed forms) 
(Figure 6.2A and B), unlike all the other mutants which had a slightly retarded 
electrophoretic mobility, under reduced conditions, after the chase period. This slight 
change in molecular weight was probably due to enhanced processing of the sugar 
chains. It was not determined whether this resulted from the addition of more chains or 
the extension of existing chains of the precursor LDL receptor. 
Despite mature LDL receptor being noted in all 6 mutants in pulse-chase experiments 
(after a 13 hour chase), in all cases the cell-surface binding of 1251-labelled lgG-C7 
antibody (performed at 4°C) was less than 15% of the binding measured for the wild 
type LDL receptors (results not shown). One caution in the interpretation of this result 
is that it does not take into account the differences in the level of LDL receptor 
expression in the different transfected cell lines. Biosynthetic experiments with 
[
35S]methionine indicated that the level of expression of all of the mutants except 
mutants 1 and 6 were greater than that of the wild type LDL receptor. Lipoprotein 
binding studies were not performed due to the low number of surface LDL receptors, 
and since the disruption of cysteine residues in the 5th binding repeat of the LDL 
receptor would be expected to severely impair lipoprotein binding (Esser and Russell , 
1988; Russell et al. , 1989). 
In summary, disruption of any of the disulfide bonds of the 5th ligand binding repeat of 
the LDL receptor severely retarded its transport from the ER The mutant LDL 
receptors were unstable after having exited from the ER and were reduced in number 
at the cell surface in comparison to the wild type LDL receptors. Differences were 
noted in the stabilities of the different mutants and in the ratio of precursor to mature 
LDL receptors remaining after a 13 hour chase period. The individual mutation of 
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Figure 6.1 Expression of LDL receptors with cysteine substitutions in the 5th 
ligand binding repeat. 
CHO cells expressing mutant LDL receptors with cysteine substitutions in the 5th 
ligand binding repeat were pulse-labelled for 1 hour with 1 OOµCi/ml 
Tran[35S]methionine. The LDL receptor was immunoprecipitated with lgG-C7 and 
analysed by SOS polyacrylamide gel electrophoresis under reducing (panel A) or 
non-reducing conditions (panel B and C). lmmunoprecipitated protein was 
detected by fluorography. The labels indicate the wild type LDL receptor (wt) and 
the cysteine residue which was substituted in the mutant LDL receptors: 1, 






wt 1 2 3 4 5 6 
3 0 3 0 0 3 0 3 chase Io (hours).___--~--~--~---------~---
B. 
1 2 3 4 5 6 
mature-
precursor-
Figure 6.2 Processing of LDL receptors with cysteine substitutions in the 5th 
ligand binding repeat. 
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CHO cells expressing mutant LDL receptors with cysteine substitutions in the 5th 
ligand binding repeat were pulse-labelled for 2 hours with 1 OOµCi/ml 
Tran[35S]methionine and then chased for 3 hours (panel A) or 13 hours in the 
presence of unlabelled methionine. The LDL receptor was immunoprecipitated 
with lgG-C? and analysed by SOS polyacrylamide gel electrophoresis under 
reducing conditions. lmmunoprecipitated protein was detected by fluorography. 
The labels indicate the wild type LDL receptor (wt) and the cysteine residue which 
was substituted in the mutant LDL receptors: 1, Cys176Ala; 2, Cys183Ala; 3, 
Cys188Ala; 4, Cys195Ala; 5, Cys201Ala; 6, Cys210Ala. 
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in the phenotype of the expressed proteins. Paired phenotypes resulting from the 
substitution of cysteine residues involved in the same disulfide bond were not detected. 
6.2.2. Assessment by non-reduced electrophoresis of the disulfide bonds of FH-
Afrikaner LDL receptors 
Three founder mutations cause FH in the South African Afrikaner population 
(Rubinsztein et al., 1994 ). These mutations are located in the 4th binding repeat (FH 
Afrikaner-3, Asp154Asn) (Graadt van Roggen et al., 1995), 5th binding repeat (FH 
Afrikaner-1, Asp206Glu) and in the domain with homology to the EGF precursor (FH 
Afrikaner-2, Val408Met) (Fourie et al., 1992; Leitersdorf et al., 1989; Fourie et al., 
1988). Although none of these missense mutations involve cysteine residues, 
experiments were performed to determine whether they affected the formation of 
disulfide bonds. None of these mutations affected the mobility of the mutant proteins 
when electrophoresed under reduced conditions (Figure 6.3A, lanes 2-4)., indicating 
that their molecular weights were equivalent to the wild type LDL receptor (lane 1 ). 
Under non-reduced conditions, the mobility of the FH Afrikaner-1 mutant was increased 
compared to the wild type LDL receptor, indicating that the disulfide bond structure was 
altered by the amino acid substitution (Figure 6.38, lanes 1 and 2). This enhanced 
mobility was similar to that of the 6 mutants with altered disulfide bonds in the 5th 
repeat (see Figure 6.1 B). The FH Afrikaner-2 and FH Afrikaner-3 LDL receptors had 
mobilities equivalent to the wild type LDL receptor (Figure 6.38, lanes 1, 3 and 4). 
The mature forms of the FH Afrikaner-1 and FH Afrikaner-3 LDL receptors also were 
compared and found to have an electrophoretic mobility equivalent to the wild type 
mature LDL receptor under reduced (results not shown) and non-reduced conditions 
(Figure 6.4, compare lanes 2, 3 and 4). The mature LDL receptor with the FH 
Afrikaner-1 mutation was of particular interest as it reportedly exists in 2 conformations 
at the cell surface (Fourie et al., 1992). However only a single mature form was 
identified (compare lanes 2 and 3). 
6.2.3. Assessment by non-reduced electrophoresis of the disulfide bonds of LDL 
receptors with cytoplasmic tail mutations 
In the course of studying mutations affecting the internalisation of the LDL receptor, it 
was noted that alterations to the cytoplasmic tail retarded their rate of processing from 
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the ER. 3 different mutations were assessed: Phe807 Ala, and mutants with stop 
codons at positions 792 (Stop792) or 812 (Stop812) (van Oriel et al. , 1987a). The 
electrophoretic mobility of the Phe807 Ala was equivalent to that of the wild type LOL 
receptor under either reduced (Figure 6.3A, lanes 1 and 5) or non-reduced conditions 
(Figure 6.38, lanes 5 and 6). The truncated mutants, Stop792 and Stop812, as 
expected, had an enhanced mobility compared to the wild type LOL receptor under 
reduced conditions (Figure 6.3A, lanes 1, 6 and 7). Under non-reduced conditions, it 
was difficult to assess the folding of the truncated mutants from their gel mobility 
(Figure 6.38, lanes 7 and 8) as the truncation directly affected their mobility. The 
relative differences between their mobilities and the wild type LOL receptor obtained 
under reduced conditions (Figure 6.3A, compare lanes 1, 6 and 7) were maintained 
under non-reduced conditions (Figure 6.38, lanes 6, 7 and 8). The diffuseness of the 
bands corresponding to the mutant LOL receptor forms (lanes 5, 7 and 8) were 
equivalent to the wild type LOL receptor (lane 6). Thus alterations to the cytoplasmic 
tail did not affect the disulfide bonded structure of the LOL receptor as assessed by 
electrophoresis under non-reduced conditions. 
6.2.4. The formation of disulfide bonds by mutant LOL receptors 
The ability of the mutant LOL receptors with cysteine substitutions in the 5th binding 
repeat to reform disulfide bonds was assessed after they were reduced with OTT 
(Figure 6.5). The methods used were the same as described for the wild type LOL 
receptor in chapter 4. The on-sensitivities of the cysteine-mutants were not different 
to that of the wild type LOL receptor (results not shown). After washing, the reduced 
LOL receptors were chased in the presence of fresh medium to enable disulfide bonds 
to reform. Within 10 minutes, all of the cysteine-mutants refolded to the conformation, 
on non-reduced gels, that they had prior to reduction (Figure 6.5). These slowly 
processed mutants thus folded rapidly to an altered conformation from which they were 
processed to the mature form at a retarded rate compared to the wild type LOL 
receptor. 
The ability of OTT to reduce the FH Afrikaner-1 mutant LOL receptor was assessed 
(Figure 6.6). When OTT was added after normal protein synthesis, the OTT-sensitivity 
of the FH Afrikaner-1 LOL receptor (panel 8) was equivalent to that of the wild type LOL 
receptor (panel A). OTT (O.SmM) induced a similar covalent change in the FH 
A. reduced 1 2 3 4 5 6 7 
mature-
precursor-
wt FH1 FH2 FH3 807 792 812 
B. non-reduced 1 2 3 4 5 6 7 8 
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wt FH1 FH2 FH3 807 wt 792 812 
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Figure 6.3 Expression of FH Afrikaner mutant LDL receptors and LDL receptors 
with mutations within the cytoplasmic tail. 
CHO cells expressing the wild type LDL receptor (wt), FH Afrikaner mutant LDL 
receptors (FH Afrikaner-1 (FH1), FH Afrikaner-2 (FH2) and FH Afrikaner-3 (FH3)), 
and LDL receptors with mutations within the cytoplasmic tail (Tyr807Cys (807), 
Stop792 (792)and Stop812 (812)) were pulse-labelled for 1 hour with 50µCi/ml 
Tran[35S]methionine and the LDL receptors were immunoprecipitated with lgG-
HL 1. lmmunoprecipitates were analysed by SOS polyacrylamide gel 
electrophoresis under reducing (panel A) or non-reducing conditions (panel B) 
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Figure 6.4 Electrophoretic mobility of the FH Afrikaner-1 and FH Afrikaner-3 LDL 
receptors. 
CHO cells expressing the wild type (wt), FH Afrikaner-1 (FH1) and FH Afrikaner-3 
LDL receptors (FH3) were pulse-labelled with Tran[35S]methionine and 
immunoprecipitated with lgG-C7. lmmunoprecipitates were analysed by 
electrophoresis under reducing (lane 1) or non-reducing conditions (lanes 2-4) and 
fluorography. The positions of the precursor (p, P) and the mature (m, M) LDL 
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Figure 6.5 Post-translational folding of LOL receptors with cysteine substitutions 
in the 5th ligand binding repeat. 
CHO cells expressing mutant LOL receptors with cysteine substitutions in the 5th 
ligand binding repeat were pulse-labelled for 1 hour with 1 OOµCi/ml 
Tran[35S]methionine. The OTT- set was alkylated and lysed at 4°C, while the 
OTT+ set was treated with 5mM OTT for 5 minutes at 37°C, then washed and 
chased in the presence of fresh medium for a further 10 minutes. The cells then 
were alkylated and lysed at 4°C. LOL receptor was immunoprecipitated with lgG-
C7 and analysed by SOS polyacrylamide gel electrophoresis under non-reducing 
conditions and fluorography. The labels indicate the wild type LOL receptor (wt) 
and the cysteine residue which was substituted in the mutant LOL receptors: 1, 
Cys176Ala; 2, Cys183Ala; 3, Cys188Ala; 4, Cys195Ala; 5, Cys201Ala. Panel A is 
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Figure 6.6 Reduction and post-translational folding of the wild type and the FH 
Afrikaner-1 LOL receptors. 
CHO cells expressing either the wild type LOL receptor (panel A) or the FH 
Afrikaner-1 LOL receptor (panel B) were pulsed with 1 OOµCi/ml 
Tran[35S]methionine for 45 minutes and then treated with the indicated 
concentrations of OTT for 5 minutes at 37°C. Cells were washed and chased in 
the presence of fresh medium for O minutes, 10 minutes or 30 minutes, as 
indicated. The LOL receptor was immunoprecipitated with lgG-C7 and analysed 
by SOS polyacrylamide gel electrophoresis under reducing conditions. 
lmmunoprecipitated protein was detected by fluorography. The positions of the 
mature and the precursor forms of the LOL receptor are indicated. 
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Afrikaner-1 LOL receptor as in the wild type LOL receptor (panel A and 8, lane 2). The 
altered structure of the FH Afrikaner-1 LOL receptor thus did not render the protein 
more unstable to reduction by OTT as compared to the wild type LOL receptor. After 
OTT treatment, the FH Afrikaner-1 LOL receptor refolded with 100% efficiency and 
reformed the lgG-C7 epitope within 10 minutes (Figure 6.68, compare lanes 4, 5 and 
6). After refolding, the FH Afrikaner-1 LOL receptor remained retarded in transport 
from the ER (lane 7). Thus the post-translational folding of the mutant LOL receptor 
was indistinguishable from its folding prior to the addition of OTT. 
When OTT was added during the pulse-period (Figure 6. 7) , translation of the FH 
Afrikaner-1 LDL receptor continued as was shown for the wild type LDL receptor in 
chapter 4 (Figure 4.6). However, under these circumstances, the amount of LDL 
receptor recovered was impaired (Figure 6. 7 A, lanes 1 and 2). After OTT was 
removed, disulfide bonded forms of the FH Afrikaner-1 LOL receptor were detected 
within 1 minute (Figure 6. 78, lane 6). This refolding occurred at a similar rate as was 
seen for the wild type LOL receptor in Figure 4.6. Whereas the mature form of the wild 
type LDL receptor was detected within 30 minutes after removal of OTT, the FH 
Afrikaner-1 LOL receptor was transported slowly (over hours) from the ER (Figure 
6. 7C). Thus after having been treated with OTT, the quality control mechanism of the 
ER was still able to distinguish between folded and malfolded proteins. 
At no point during the chase period was a precursor form of the FH Afrikaner-1 LDL 
receptor detected which had the electrophoretic mobility of the wild type precursor 
under non-reduced conditions (Figure 6. 7C and results not shown). Throughout its 
residence in the ER, the FH Afrikaner-1 precursor maintained the abnormal 
electrophoretic mobility seen 10 minutes after the removal of OTT (Figure 6.7C). Thus, 
after an initial rapid period of folding, the FH Afrikaner-1 LOL receptor remained in an 
abnormal conformation in the ER 
6.3. Discussion 
In this section, cysteine residues were substituted within the 5th binding repeat and the 
protein phenotypes of the mutant LOL receptors were determined. Substitution of any 
of the 6 cysteine residues altered the disulfide bond structure of the LDL receptor 
(assessed by mobility on non-reduced gels) and delayed processing from the ER All 
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of the mutants were unstable and seemed to be processed at different rates. Very low 
levels of mature LDL receptor were expressed at the cell surface. These results 
indicate that all 6 cysteine residues are required for the folding of the 5th binding 
repeat, and are involved in disulfide bonds. The instability of the mutant LDL receptors 
prevented a precise measurement of the processing rates and similarly, the low level of 
mature LDL receptors prevented an assessment of their degradation rates. LDL 
receptor turnover seemed to occur after exit from the ER as the precursors were stable 
in this compartment, over 3 hours. During this period, a slight increase in apparent 
molecular weight of the mutants was noted, which possibly was due to enhanced 
processing of the sugar chains beyond that of the wild type LDL receptor. Mutant 3 
remained at the same molecular weight throughout its residence in the ER and was 
distinguished by being markedly more stable than the other mutants while in the ER. 
The unique phenotype of mutant 3 was important in negating the hypothesis that either 
cysteine residue of a disulfide bond may be substituted with the same effect. 
According to this hypothesis, for the 6 cysteine residues substituted, 3 phenotypes 
might be obtained, each corresponding to the disulfide bond that was disrupted. In this 
manner, it was anticipated that the pattern of disulfide bonding might be determined. 
These arguments have been used to determine the disulfide bonding of the Mr 46 000 
mannose 6-phosphate receptor; clearly such evidence is indirect, but has been termed 
'internally consistent' and is compelling (Wendland et al., 1991 ). A weakness of 
experiments involving amino acid substitutions is that the final effect is a combination 
both of the effect of the loss of the original amino acid and the possible gain of function 
induced by the inserted amino acid. Alanine, with its short side chain, was chosen as 
the substitute for cysteine in order to minimise the potential for undesired interactions. 
Serine is of a similar size to cysteine but was not chosen as it contains a hydroxyl 
group and also may be 0-glycosylated. The cysteine residue substituted in mutant 1, 
Cys176Ala, is involved in two naturally-occurring mutations, FH Shreveport 
(Cys176Phe) and FH El Salvador-1 (Cys176Tyr). These substitutions also slow 
processing from the ER and cause LDL receptor binding activity on the cell surface to 
be reduced to less than 2% of the wild type activity (Hobbs et al., 1992). Apart from the 
unique phenotype for mutant 3, the phenotypes of the other 5 mutants could not be 
distinguished clearly and thus cysteine residues could not be paired for the purposes of 
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Figure 6.7 Post-translational folding of the FH Afrikaner-1 LDL receptor. 
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CHO cells expressing the FH Afrikaner-1 LDL receptor were pulsed for 1 hour 
with 1 OOµCi/ml Tran[ 5S]methionine. OTT (5mM) was included in the pulse-
period of dishes 2-7 (panel A), dishes 3-8 (panel B) and all of the dishes (panel 
C) . Dishes were washed and then chased in fresh medium containing 
cycloheximide for the times indicated. Dishes were cooled to 4°C, alkylated and 
lysed in detergent. LDL receptor was immunoprecipitated with lgG-HL 1 and then 
divided for electrophoresis under reduced (panels A, all lanes, panel B, lane 1) 
and non-reduced conditions (panel B, lanes 2-9). The cells in panel C were 
labelled in a separate experiment to those in panel A and B, and were 
electrophoresed under reduced conditions. As described in Figure 5.1 , the 
positions of the precursor (p, P) and the mature (m, M) LDL receptor are indicated 
under non-reduced (p, m) and reduced (P, M) conditions. 
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The absence of paired phenotypes indicated that at least some of the amino acid 
substitutions had effects other than simply the disruption of a single disulfide bond. 
One possibility is that the unpaired cysteine residue (the partner of the substituted 
cysteine) may have affected the formation of disulfide bonds by the other cysteine 
residues within the 5th repeat. This may have prevented more than one bond from 
forming or have altered the pattern of disulfide bond pairing. 
The compact structure of the mutant LDL receptors indicated that the folding of the 
neighbouring cysteine-rich repeats were unlikely to have been affected by the 
misfolding of the 5th repeat. The overall compact structure of the mutant LDL receptors 
was indicated by their enhanced gel mobility compared to the wild type protein under 
non-reduced conditions. Conventionally, driven by hydrophobic effects, proteins fold 
into compact globular structures which exhibit enhanced gel-mobilities compared to 
their partially-unfolded counterparts. These findings suggest that the wild type disulfide 
bonds prevent the LDL receptor from folding into the most compact structure and 
maintain the 5th repeat in an extended conformation. Hence the substitution of the 
cysteine residues cause the LDL receptor to collapse into a more compact structure. It 
can be speculated that the extended conformation of the 5th binding repeat aids the 
spatial arrangement and the presentation of the charged residues needed for 
lipoprotein binding (see section 1.6). 
Peptides corresponding to the first and the second ligand binding repeats fold to form 
the same disulfide bond pattern, with cysteine 1 and 3, 2 and 5, 4 and 6 pairing in each 
peptide (Bieri et al., 1995a; Bieri et al., 1995b; Daly et al. , 1995). It is probable that the 
other repeats fold to form similar structures. For the first repeat, folding is Ca
2
• -
dependent (the first repeat binds Ca
2
•) and forms a single stable structure with the 
cysteine residues positioned within the core and the charged residues generally 
exposed on the surface (Daly et al., 1995). The structure is tightly folded and is 
resistant to proteases (Bieri et al., 1995a). Folding was verified by the formation of the 
epitope for the conformation-specific antibody, lgG-C7 (van Oriel et al., 1987b ). 
Deletion of Asp26 and Gly27, corresponding to the FH Cape Town-1 mutant LDL 
receptor (Leitersdorf et al., 1988), causes the peptide corresponding to the 1st repeat 
to fold into an equilibrium mixture of four isomers, rather than the single structure of the 
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wild type repeat (personal communication, P. Kroon). Each isomer contains three 
disulfide bonds, but none were recognised by lgG-C7. The mutant LDL receptors 
studied in this chapter were not more heterogeneous than the wild type LDL receptor 
when assessed by non-reduced electrophoresis. This technique was able to detect, 
albeit to a limited degree, the subtle differences in the disulfide bonded structures of 
the LDL receptors with different cysteine substitutions (Figure 6.1 C), which suggests 
that it would have been able to detect LDL receptor isomers. At the time of writing this 
thesis, the mobility of the FH Cape Town-1 LDL receptor had not been determined by 
electrophoresis under non-reduced conditions. It was anticipated that its non-reduced 
mobility would be affected directly by the loss of the two amino acids and could not be 
compared to the wild type LDL receptor. However, a comparison of the heterogeneity 
of the electrophoretic bands of the mutant and the wild type LDL receptor would be of 
interest. 
Other mutagenesis studies have largely ignored cysteine residues and have assumed 
that they were critical for the structure of the binding domain. Esser has reported that 
the replacement of cysteine residues in repeat 1 (residues 6 and 18) did not affect the 
behaviour of the LDL receptor, though in that study COS cells were used, which 
process the wild type LDL receptor slowly compared to CHO cells and are not a 
sensitive assay for LDL receptor processing (Esser et al., 1988). The assumption that 
cysteine residues are critical for protein structure is not necessarily valid, even when 
those cysteines are involved in disulfide bonds. Recently, it was reported that 
substitution of the cysteine residues involved in a disulfide bond in the H2b subunit of 
the asialoglycoprotein receptor did not prevent proper folding of the protein, and 
surprisingly enhanced its transport form the ER (Yuk and Lodish, 1995). 
Mutations within the cytoplasmic tail slow the processing of LDL receptors from the ER, 
which suggests that the cytoplasmic domain possibly could influence the folding of the 
intralumenal domain. These mutations did not retard the electrophoretic mobility of the 
LDL receptor unduly under non-reduced conditions, beyond the change accounted for 
by the truncation of the length of the protein. This indicates that the disulfide bond 
structure of the LDL receptor was not influenced by mutations within the cytoplasmic 
tail. Another possibility is that the cytoplasmic tail mutations impair secretion by 
preventing the assembly of oligomeric structures in the ER Oligomers involving the 
175 
mature LDL receptor have been detected by cross-linking, and require amino acids 812 
to 839 of the cytoplasmic tail to assemble (van Oriel et al., 1987a). In that study, the 
involvement of the precursor LDL receptor in oligomers could not be assessed because 
the blotting system used to identify the components of the oligomers was not 
sufficiently sensitive to detect the precursor LDL receptor. 
The enhanced electrophoretic mobility of the precursor LDL receptor with the FH 
Afrikaner-1 mutation (Asp206Glu) indicated that the disulfide bond structure of its 5th 
binding repeat was abnormal in a manner similar to the cysteine substitutions 
described above. This is the first demonstration that the disulfide bond structure of the 
LDL receptor is altered by a missense mutation which does not involve a cysteine 
residue. The finding that disulfide bonding was altered resolves the enigma posed by 
this extremely conservative substitution involving 2 amino acids (aspartate and 
glutamate) with similar properties. This change does not lead to the loss of a negative 
charge in the conserved serine-aspartate-glutamate triplet thought to be necessary for 
ligand binding to the LDL receptor (Fourie et al., 1992). The subtly difference in the 
length of the side-chain of the substituted amino acid is probably what interferes with 
the formation of disulfide bonds. 
The electrophoretic mobility of the FH Afrikaner-1 was abnormal throughout its 
residence in the ER. It is possible that the precursor undergoes a conformational 
change immediately prior to exit from the ER, which may be critical for escape from the 
quality control apparatus, though this change was not detected. The mature form of the 
FH Afrikaner-1 LDL receptor did not have an altered electrophoretic mobility under 
non-reduced conditions, suggesting that the disulfide bonds were intact. The mature 
FH Afrikaner-1 population exhibits functional heterogeneity, with about 20% of the LDL 
receptors able to bind LDL with a normal affinity (Fourie et al., 1992); these LDL 
receptors must have intact disulfide bonds. The inactive population was not separated 
from this population by non-reduced electrophoresis, either because their disulfide 
bonds were not different, or because the gels were unable to resolve the differences. 
The latter possibility is likely in that the mature forms of the mutants with cysteine 
substitutions were not resolved from the mature form of the wild type LDL receptor. 
Neither the precursor nor the mature forms of the FH Afrikaner-1 LDL receptor were 
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more sensitive to OTT than the wild type LDL receptor, which indicated that the region 
of unfolding that was induced by the mutation, probably was localised (see below). 
The FH Afrikaner-2 mutant is processed slowly from the ER and undergoes rapid 
degradation once it has reached the cell surface (Fourie et al., 1988). Both of these 
phenotypes suggest that the structure of the protein is altered, yet the electrophoretic 
mobility of the protein indicated that the disulfide bonds were intact. Despite the 
electrophoretic mobility assay not being sensitive to small alterations in LDL receptor 
structure (see above), the results indicate that the instability of the FH Afrikaner-2 
mutant does not require extensive unfolding of the LDL receptor. Rather, a localised 
region of unfolding is sufficient to target the protein molecule for a rapid rate of 
degradation. The altered phenotype of a mutant LDL receptor with intact disulfide 
bonds complements the findings of Esser and Russell (Esser and Russell, 1988), who 
substituted free cysteine residues in the EGF precursor homology domain of truncated 
LDL receptors to show that unpaired cysteines were not required for slow processing 
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The aim of this thesis was to study the influence of post-translational events on the 
synthesis of the LDL receptor. Requirements for the folding of the LDL receptor were 
characterised and aspects of the inter-relationship between LDL receptor folding and 
its transport from the ER were determined. A number of novel findings have emerged 
from these studies. Co-translational folding was not essential for normal LDL receptor 
synthesis and disulfide bonds were able to form post-translationally. Folding required 
metabolic energy which implicated a requirement for associated chaperone protein(s). 
Ca2+ was required for LDL receptor folding in a manner that was different to its role in 
ligand binding to the mature LDL receptor. The glycosylation of the LDL receptor did 
not influence the formation of disulfide bonds. Conversely, reduction of the disulfide 
bonds of the LDL receptor did not irreversibly alter its glycosylation. LDL receptor 
transport from the ER was impaired when ATP or Ca2+ was depleted, when disulfide 
bonds were reduced and when cysteine residues were mutated in the 5th binding 
repeat of the ligand binding domain. All of these changes were shown to affect the 
folding of the LDL receptor. These findings clearly show the inter-relationship between 
LDL receptor folding and transport. 
A missense mutation causing the conservative substitution of an aspartate residue by a 
glutamate residue (FH Afrikaner-1) was shown to impair the disulfide bonding of the 
mutant LDL receptor in the ER. By contrast, other missense mutations did not alter the 
formation of disulfide bonds. Similarly, mutations (truncation and missense) in the 
cytoplasmic tail of the LDL receptor retarded processing but did not alter the formation 
of disulfide bonds. The chaperone, calnexin, did not show quantitatively significant 
association with the LDL receptor. Together with other results, this suggested that 
calnexin is not critical for the folding of the wild type LDL receptor. Reduced or mutant 
forms of the LDL receptor were not retained in the ER in a complex with calnexin. 
7.1. Relationship between folding, glycosylation and transport 
The 'bulk' rate of transport from the ER is defined as the transport rate for proteins 
containing neither retention nor transport-enhancing signals (Wieland, 1992). This rate 
has been measured using tripeptides which are too small to contain signals that could 
affect transport. The transport rate of the wild type LDL receptor transport from the ER 
(half-time of processing of about 15 minutes) (Tolleshaug et al. , 1982) is similar to the 
bulk rate, which suggests that the LDL receptor does not contain signals that influence 
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exit from the ER. Similarly, the findings that missense mutations at many different sites 
in the LDL receptor cause retarded processing (Hobbs et al., 1992; Hobbs et al., 1990) 
cannot be consistent with damage to a putative transport signal. By contrast, recent 
evidence indicates that the transport of vesicular stomatitis virus glycoprotein is 
enhanced by its selective concentration into transport vesicles (Balch et al., 1994). 
In general, it is presumed that misfolding causes exposed hydrophobic groups to 
associate with resident ER proteins and retards exit from the ER (Gething and 
Sambrook, 1992). The areas of misfolding probably do not constitute a linear 
sequence of hydrophobic amino acids; rather, they are probably patches assembled 
from hydrophobic residues from adjacent parts of the partially folded protein. In the 
present study, the altered folding of LDL receptors with missense mutations was 
shown. When cysteine residues were mutated in the LDL receptor binding domain, 
misfolding was localised. Despite the disulfide bonds being affected directly, these 
mutants folded into compact structures which would not have been possible if unfolding 
was extensive. In other studies, the finding that missense mutations do not affect the 
binding functions of the neighbouring cysteine-rich repeats (Esser et al., 1988; Russell 
et al. , 1989) also indicates that missense mutations disturb folding only within their 
respective repeat. These areas of misfolding are able to cause the retention of the LDL 
receptor despite most of the protein apparently having folded correctly. 
Surprisingly, while the overall effect of the normal disulfide bonds is to cross-link the 
LDL receptor into a compact, convoluted structure, when the cysteine residues of the 
5th repeat were individually mutated, or the LDL receptor was partially reduced with low 
doses of DTT, the LDL receptor folded into an abnormally compact structure. Normal 
LDL receptor folding thus does not entail the attainment of the most compact structure. 
These findings also suggest that the quality control mechanism in the ER recognises 
conformational features on the mutant (or the partially-reduced) proteins even when 
they are folded into compact structures. In general, protein malfolding causes 
hydrophobic groups to be exposed and recognised by chaperones (Gething and 
Sambrook, 1992; Hartl and Martin, 1995; Hartl et al. , 1994 ). However, these features 
are not easily reconciled with a folded structure more compact than that achieved by 
the wild type protein. 
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Recently, it was reported that a mutant form of the H2b subunit of the 
asialoglycoprotein receptor proteins folds at an enhanced rate compared to the wild 
type protein (Yuk and Lodish, 1995). The mutant protein lacks a disulfide bond, yet it is 
transported more rapidly from the ER than the wild type protein. Possibly, in this 
example, the wild type disulfide bond complicates the folding itinerary by stabilising 
multiple structures, and wild type protein folding is delayed by disulfide bond shuffling. 
It must be remembered that the folding of proteins is not driven by criteria of rapid 
folding (see example above), nor by criteria of efficient folding. In fact, only a small 
fraction of newly-synthesised erythropoietin receptors exit the ER and are competent to 
bind erythropoietin at the cell surface (Hilton et al., 1995). The majority of the newly-
made erythropoietin receptors are retained within the ER (and are degraded). This 
inefficient folding may contribute to regulating the number of active surface receptors 
and, in turn, the response of cells to erythropoietin. Intriguingly, a mutant form of the 
erythropoietin receptor was processed through the secretory pathway more efficiently 
than the wild type receptor, probably due to better folding (Hilton et al., 1995). 
Similarly, the folding of the cystic fibrosis transmembrane conductance regulator 
protein is inefficient, with only about 25% of the newly-synthesised molecules being 
detected as mature forms at the cell surface (Ward and Kopito, 1994 ). These findings 
are different to those for the wild type LDL receptor, where there is quantitative 
conversion from the precursor to the mature form (Tolleshaug et al. , 1982). In this 
thesis, the folding of the wild type LDL receptor was efficient and was coupled to 
transport from the ER. In all instances, malfolding was associated with retarded 
transport from the ER. This malfolding was induced both by mutations (substitution of 
cysteine residues or FH Afrikaner mutant LDL receptors) and by manipulating the 
folding of the wild type LDL receptor (using OTT or by depleting Ca2+ or ATP). 
The involvement of chaperone proteins in LDL receptor folding poses new challenges. 
It has not been determined whether chaper~nes are able to substitute for one another, 
or whether the same chaperones that are necessary for normal folding are the cause of 
the ER-retention of malfolded proteins. By analogy with the assembly of the 
transcription initiation complex, it is possible that chaperones may function as a mixture 
of general and specific protein factors. The definition of what qualifies as a chaperone 
is complicated by the inter-relationship between different processes such as 
glycosylation and folding (Helenius, 1994). Since certain glycosyltranferases 
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distinguish between the state of folding of their substrates, and modulate the activity of 
other proteins, such as calnexin (Helenius, 1994), these distinctions are not so clear. 
Similarly, a chaperone that retains a malfolded protein in the ER and thus targets it for 
degradation, could hardly be considered as aiding protein folding. Ultimately, the 
definition of a chaperone should be expanded to include those functions which are 
essential for 1.) the efficient trans location of proteins into the ER; 2.) protein folding 
and 3.) the assessment of protein competence for transport from the ER. 
7.2. Therapeutic implications 
Despite several human diseases having been identified to result in a phenotype of 
impaired transport from the ER to the cell surface (see Table 1.1 ), and the probability 
that most mutant forms of other surface molecules are similarly affected, the prospects 
for therapeutic intervention are probably limited. Intervention would be appropriate 
where the mutation does not severely impair the function of the protein apart from the 
delay in transport. The FH Afrikaner-1 mutant would be a suitable candidate as there 
is about 20% residual receptor activity (Fourie et al., 1992; Fourie et al., 1988). 
Considerable benefit might also be expected where retention is associated with rapid 
degradation within the ER. It is possible that the shorter retention time in the 
degradation compartment may lead to greater protein stability. Of course, once 
transported from the ER, the protein may exhibit instability in one of the post-ER 
compartments, such as at the cell surface or within the endocytic pathway. The 
common mutant form of the cystic fibrosis transmembrane conductance regulator ( delta 
Tyr508) is transported from the ER at an enhanced rate when the temperature is 
reduced from 37°C to 24-28°C (Denning et al., 1992). Unfortunately, this mutant 
protein, which is functional, is unstable at the cell surface compared to the wild type 
protein (Ward and Kopito, 1994; Lukacs et al., 1993). 
Another scenario where the manipulation of protein folding and transport from the ER 
may be advantageous is in the heterozygous form of familial hypercholesterolaemia. 
Under these circumstances, heterodimers of normal and mutant receptors may form 
oligomeric assemblies and may influence each other's transport. The mutant LDL 
receptors may cause the retention of the wild type LDL receptors and may reduce 
surface receptor activity beyond that caused simply by the loss of the function of the 
mutant allele (Schneider et al., 1983a). However, it is difficult to conceive of a 
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therapeutic strategy suitable for in vivo use that would be selective for the target 
protein (in this case, the LDL receptor). The unregulated transport from the ER of other 
proteins would be expected to cause undesired effects, which have not been 
determined. The assembly of oligomeric proteins, for example cell adhesion molecules 
and immune cell receptors, is dependent on the ordered processing from the ER, and 
would be expected to be disrupted. 
7.3. Future study goals 
A major goal of continued studies in this field is to define the structural basis for the 
phenotype of slowed processing of mutant forms of the LDL receptor. To achieve this 
aim, the structure of the wild type LDL receptor would need to be determined and 
compared with the structure of mutant forms of the protein. Presently, the 
crystallisation of membrane proteins such as the LDL receptor is not possible. In this 
regard, current attempts to express truncated soluble forms of the LDL receptor are of 
great interest (Dower and van der Westhuyzen, unpublished results). It is anticipated 
that it will be possible to crystallise the soluble LDL receptor and hence determine its 
three dimensional structure. 
The folding of peptides corresponding to the different ligand binding repeats of the LDL 
receptor is also of interest (Daly et al., 1995; Bieri et al., 1995b; Bieri et al., 1995a). 
These studies address whether the structures of the different binding repeats are 
equivalent and the manner in which their folding and structures are disrupted by 
mutations. Despite the limitations inherent in studying the folding of peptides rather 
than the intact LDL receptor molecule, these studies they have the potential to address 
whether the repeats fold and behave as modular units. These studies could be 
extended to address the manner in which the arrangement of the binding repeats 
determines the different ligand binding specificities of the members of the LDL receptor 
gene family (Herz and Willnow, 1994). The structural features which underlie the 
ability of a single binding domain to bind disparate ligands could be addressed (Krieger 
and Herz, 1994). Ultimately, these studies could lead to the design of custom receptor 
molecules with binding specificities for defined ligands. 
The identification of candidate chaperones which aid LDL receptor folding/retention is 
another key task. In this regard, the possible role for the chaperone, petidyl-prolyl cis-
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trans isomerase, in LDL receptor folding is of interest. The function of this chaperone 
is possibly important for the compact folding of convoluted structures such as the 
binding domain of the LDL receptor (Schmid, 1993). Conveniently, the requirement for 
this chaperone in protein folding can be determined as it is inhibited by the 
immunosuppressive agent, cyclosporin (Lodish and Kong, 1991 ). 
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